KCA
Search
- Page Path
- HOME > Search
Original Articles
- Gastrointestinal cancer
- A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer
- Ting Liu, Qing Li, Zhen Lin, Chunhua Liu, Wei Pu, Shasha Zeng, Jun Lai, Xuebin Cai, Lisha Zhang, Shuyang Wang, Miao Chen, Wei Cao, Hongfeng Gou, Qing Zhu
- Cancer Res Treat. 2024;56(2):602-615. Published online October 12, 2023
- DOI: https://doi.org/10.4143/crt.2023.726
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Patients with advanced biliary tract cancer (BTC) have a poor survival. We aim to evaluate the efficacy and safety of nab-paclitaxel plus gemcitabine and cisplatin regimen in Chinese advanced BTC patients.
Materials and Methods
Eligible patients with locally advanced or metastatic BTC administrated intravenous 100 mg/m2 nab-paclitaxel, 800 mg/m2 gemcitabine, and 25 mg/m2 cisplatin every 3 weeks. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS) and adverse events, while exploratory endpoint was the association of biomarkers with efficacy.
Results
After the median follow-up of 25.0 months, the median PFS and OS of 34 enrolled patients were 7.1 months (95% confidence interval [CI], 5.4 to 13.7) and 16.4 months (95% CI, 10.9 to 23.6), respectively. The most common treatment-related adverse events at ≥ 3 grade were neutropenia (26.5%) and leukopenia (26.5%). Survival analyses demonstrated that carcinoembryonic antigen (CEA) levels could monitor patients’ survival outcomes. A significant increase in the number of infiltrating CD4+ cells (p=0.008) and a decrease in programmed death-1–positive (PD-1+) cells (p=0.032) were observed in the response patients.
Conclusion
In advanced BTC patients, nab-paclitaxel plus gemcitabine and cisplatin regimen showed therapeutic potential. Potential prognostic factors of CEA levels, number of CD4+ cells and PD-1+ cells may help us maximize the efficacy benefit. -
Citations
Citations to this article as recorded by
- Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer
Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
Cancer Science.2024; 115(7): 2371. CrossRef
- Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer
- 3,569 View
- 157 Download
- 2 Web of Science
- 1 Crossref
- Head and Neck cancer
- A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
- Hye Ryeon Kim, Su Jin Lee, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Han-Sin Jeong, Man Ki Chung, Myung-Ju Ahn
- Cancer Res Treat. 2022;54(3):719-727. Published online November 1, 2021
- DOI: https://doi.org/10.4143/crt.2021.1019
-
Abstract
PDFPubReaderePub
- Purpose
Salivary gland cancers (SGCs) are relatively rare but comprise various histologic subtypes, which complicates design of prospective trials. Systemic chemotherapy plays a limited role in treatment of SGCs, but cisplatin and docetaxel showed efficacy in a previous preclinical study. Here, we conduct a prospective, phase II study to evaluate the efficacy and toxicities of cisplatin plus weekly docetaxel in patients with metastatic or recurrent SGC.
Materials and Methods
We included patients with histologically confirmed SGCs of the following subtypes: mucoepidermoid carcinoma, adenocarcinoma, ductal carcinoma, or adenoid cystic carcinoma. Patients had no prior systemic chemotherapy for metastatic or recurrent tumors and at least one measurable lesion. Patients were treated with docetaxel 35 mg/m2 (D1, 8) and cisplatin 70 mg/m2 (D1) every 21 days.
Results
Forty-one patients were enrolled between April 2014 and October 2020. The median age was 58 years (range, 32 to 73 years). The most common histologic subtype was adenoid cystic carcinoma (63.4%), followed by ductal carcinoma (24.4%). The most common metastatic site was the lung (75.6%). The median treatment cycle was 5.5 (range, 3 to 8), and the objective response rate was 46.3%, with three complete responses. The median duration of response was 6.8 months (interquartile range, 4.0 to 10.2). The progression-free survival and overall survival were 9.4 months (95% confidence interval [CI], 8.4 to 10.5) and 28.2 months (95% CI, 22.7 to 33.6), respectively. There were no treatment-related deaths. The most common grade 3/4 adverse events were neutropenia (4.9%) and fatigue (4.9%).
Conclusion
Cisplatin plus weekly docetaxel is effective and tolerable with manageable toxicity as first-line therapy in patients with metastatic or recurrent SGC. -
Citations
Citations to this article as recorded by- Clinical Course of Parotid Carcinoma with Hepatic and Nodal Metastases: A Case Report
Antonio Doronzo, Giovanni Musci, Gennaro Gadaleta-Caldarola, Maria Chiara Sergi
International Journal of Translational Medicine.2024; 5(1): 3. CrossRef - Systemic and Targeted Therapies in Adenoid Cystic Carcinoma
Alec J. Kacew, Glenn J. Hanna
Current Treatment Options in Oncology.2023; 24(1): 45. CrossRef - Major and minor salivary gland cancers: A multicenter retrospective study
Muhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, Efnan Algın, Burcu Gulbagcı, Ilhan Hacibekiroglu, Jamshid Hamdard, Omer Fatih Olmez, Hadi Akkus, Berna Oksuzoglu, Sema Sezgin Goksu, Shute Ailia Dae, Ahmet Taner Sumbul, Muzaffer Ugraklı, Mustafa Ka
Head & Neck.2023; 45(7): 1643. CrossRef - Prognostic Significance of Primary Tumor Surgery in Adenoid Cystic Carcinoma Patients With Distant Metastases at Diagnosis: A Population-Based Database Analysis in Head and Neck Region
Han Li, Li Zhao, Yixuan Song, Yang Liu, Song Ni, Shaoyan Liu
Ear, Nose & Throat Journal.2023;[Epub] CrossRef - The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?
Robbert Cleymaet, Tijl Vermassen, Renaat Coopman, Hubert Vermeersch, Stijn De Keukeleire, Sylvie Rottey
International Journal of Molecular Sciences.2022; 23(23): 14891. CrossRef
- Clinical Course of Parotid Carcinoma with Hepatic and Nodal Metastases: A Case Report
- 6,912 View
- 192 Download
- 6 Web of Science
- 5 Crossref
- Gastrointestinal Cancer
- Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
- Kyung-Hun Lee, Eui Kyu Chie, Seock-Ah Im, Jee Hyun Kim, Jihyun Kwon, Sae-Won Han, Do-Youn Oh, Jin-Young Jang, Jae-Sung Kim, Tae-You Kim, Yung-Jue Bang, Sun Whe Kim, Sung W. Ha
- Cancer Res Treat. 2021;53(4):1096-1103. Published online December 30, 2020
- DOI: https://doi.org/10.4143/crt.2020.928
-
Abstract
PDFPubReaderePub
- Purpose
Despite curative resection, the 5-year survival for patients with resectable pancreatic cancer is less than 20%. Recurrence occurs both locally and at distant sites and effective multimodality adjuvant treatment is needed.
Materials and Methods
Patients with curatively resected stage IB-IIB pancreatic adenocarcinoma were eligible. Treatment consisted of chemotherapy with gemcitabine 1,000 mg/m2 on days 1 and 8 and cisplatin 60 mg/m2 on day 1 every 3 weeks for two cycles, followed by chemoradiotherapy (50.4 Gy/28 fx) with weekly gemcitabine (300 mg/m2/wk), and then gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks for four cycles. The primary endpoint was 1-year disease-free survival rate. The secondary endpoints were disease-free survival, overall survival, and safety.
Results
Seventy-four patients were enrolled. One-year disease-free survival rate was 57.9%. Median disease-free and overall survival were 15.0 months (95% confidence interval [CI], 11.6 to 18.4) and 33.0 months (95% CI, 21.8 to 44.2), respectively. At the median follow-up of 32 months, 57 patients (77.0%) had recurrence including 11 patients whose recurrence was during the adjuvant treatment. Most of the recurrences were systemic (52 patients). Stage at the time of diagnosis (70.0% in IIA, 51.2% in IIB, p=0.006) were significantly related with 1-year disease-free survival rate. Toxicities were generally tolerable, with 53 events of grade 3 or 4 hematologic toxicity and four patients with febrile neutropenia.
Conclusion
Adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiotherapy with gemcitabine and maintenance gemcitabine showed efficacy and good tolerability in curatively resected pancreatic cancer. -
Citations
Citations to this article as recorded by- NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis
Xiao-Dong Huang, Yong-Wei Chen, Lv Tian, Li Du, Xiao-Chen Cheng, Yu-Xin Lu, Dong-Dong Lin, Feng-Jun Xiao
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef - Efficacy of Cisplatin-Containing Chemotherapy Regimens in Patients of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis
Obaid Ur Rehman, Eeshal Fatima, Zain Ali Nadeem, Arish Azeem, Jatin Motwani, Habiba Imran, Hadia Mehboob, Alishba Khan, Omer Usman
Journal of Gastrointestinal Cancer.2024; 55(2): 559. CrossRef - OTUB1/NDUFS2 axis promotes pancreatic tumorigenesis through protecting against mitochondrial cell death
Xiao-Dong Huang, Li Du, Xiao-Chen Cheng, Yu-Xin Lu, Qiao-Wei Liu, Yi-Wu Wang, Ya-Jin Liao, Dong-Dong Lin, Feng-Jun Xiao
Cell Death Discovery.2024;[Epub] CrossRef - Impact of obesity on pathological complete remission in early stage breast cancer patients after neoadjuvant chemotherapy: a retrospective study from a German University breast center
Johannes Felix Englisch, Alexander Englisch, Dominik Dannehl, Kenneth Eissler, Christian Martin Tegeler, Sabine Matovina, Léa Louise Volmer, Diethelm Wallwiener, Sara Y. Brucker, Andreas Hartkopf, Tobias Engler
Archives of Gynecology and Obstetrics.2024;[Epub] CrossRef - A Photothermal Therapy Study Based on Electrospinning Nanofibers Blended and Coated with Polydopamine Nanoparticles
Chunhong Sui, Yijia Luo, Xiao Xiao, Jiaxue Liu, Xiaotong Shao, Yingxue Xue, Cheng Wang, Wenliang Li
ChemistrySelect.2023;[Epub] CrossRef - Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
Da Eun Lee, Hyeon Woong Kang, So Yi Kim, Myeong Jin Kim, Jae Woong Jeong, Woosol Chris Hong, Sungsoon Fang, Hyung Sun Kim, Yun Sun Lee, Hyo Jung Kim, Joon Seong Park
Frontiers in Pharmacology.2022;[Epub] CrossRef - CircLMTK2 Silencing Attenuates Gemcitabine Resistance in Pancreatic Cancer by Sponging miR-485-5p and to Target PAK1
Yeting Lu, Shuping Zhou, Gong Cheng, Yi Ruan, Yuan Tian, Kaiji Lv, Shuo Han, Xinhua Zhou, Xiangya Ding
Journal of Oncology.2022; 2022: 1. CrossRef - Effects of Radiotherapy and Chemotherapy on Postoperative Prognosis of Patients Undergoing Radical Surgery for Pancreatic Cancer—Based on SEER Database Analysis
媛媛 苏
Advances in Clinical Medicine.2022; 12(10): 9540. CrossRef - Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients
Alice Usai, Gregorio Di Franco, Margherita Piccardi, Perla Cateni, Luca Emanuele Pollina, Caterina Vivaldi, Enrico Vasile, Niccola Funel, Matteo Palmeri, Luciana Dente, Alfredo Falcone, Dimitri Giunchi, Alessandro Massolo, Vittoria Raffa, Luca Morelli
Cancers.2021; 13(16): 4131. CrossRef - Hypoxia-Induced ZWINT Mediates Pancreatic Cancer Proliferation by Interacting With p53/p21
Peng Chen, Zhiwei He, Jie Wang, Jian Xu, Xueyi Jiang, Yankun Chen, Xinyuan Liu, Jianxin Jiang
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
- NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis
- 6,646 View
- 149 Download
- 10 Crossref
- Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
- Jaewon Hyung, Bumjun Kim, Changhoon Yoo, Kyo-pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo
- Cancer Res Treat. 2019;51(3):901-909. Published online October 4, 2018
- DOI: https://doi.org/10.4143/crt.2018.326
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Gemcitabine plus cisplatin (GemCis) is the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC). In ABC-02 study, the BTC patients received up to 6-8 cycles of 3-weekly GemCis; however, those without progression often receive more than 6-8 cycles. The clinical benefit of maintenance treatment in patients without progression is uncertain.
Materials and Methods
Advanced BTC patients treated with GemCis between April 2010 and February 2015 at Asan Medical Center, Seoul, Korea, were retrospectively analysed. The patients without progression after 6-8 cycles were stratified according to further treatment i.e., with or without further cycles of GemCis (maintenance vs. observation groups). The primary endpoint was overall survival (OS) and progression-free survival (PFS).
Results
Among the 740 BTC patients in the initial screen, 231 cases (31.2%) were eligible for analysis (111 in the observation group, 120 in the maintenance group). The median OS from the GemCis initiation was 20.5 months (95% confidence interval [CI], 15.4 to 25.6) and 22.4 months (95% CI, 17.0 to 27.8) in the observation and maintenance groups, respectively (p=0.162). The median PFS was 10.4 months (95% CI, 7.0 to 13.8) and 13.2 months (95% CI, 11.3 to 15.2), respectively (p=0.320).
Conclusions
GemCis maintenance is not associated with an improved survival outcome. -
Citations
Citations to this article as recorded by- Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy
A. Lamarca, J. Adeva, I. Ales Díaz, R. Alvarez Gallego, A.J. Muñoz Martín, T. Macarulla Mercade
ESMO Gastrointestinal Oncology.2025; 7: 100116. CrossRef - Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
Gael S. Roth, Loic Verlingue, Matthieu Sarabi, Jean-Frédéric Blanc, Emmanuel Boleslawski, Karim Boudjema, Anne-Laure Bretagne-Bignon, Marine Camus-Duboc, Romain Coriat, Gilles Créhange, Thierry De Baere, Christelle de la Fouchardière, Clarisse Dromain, Ju
European Journal of Cancer.2024; 202: 114000. CrossRef - Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Do-Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li-Tzong Chen, Masayuki Kitano, Choong-kun Lee, Jin Won Kim, Ming-Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen-Shi Chen, Piotr Potemski, Howard A Burris,
The Lancet Gastroenterology & Hepatology.2024; 9(8): 694. CrossRef - Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial
Anant Ramaswamy, Prabhat Bhargava, Sujay Srinivas, Akhil Kapoor, Bal Krishna Mishra, Anuj Gupta, Sarika Mandavkar, Sadhana Kannan, Deepali Chaugule, Rajshree Patil, Manali Parulekar, Chaitali Nashikkar, Suman Kumar Ankathi, Rajiv Kumar Kaushal, Deepali Na
Journal of Clinical Oncology.2024; 42(27): 3218. CrossRef - Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine
Dillum Patel, Alison L. Dickson, Greice M. Zickuhr, In Hwa Um, Oliver J. Read, Clarissa M. Czekster, Peter Mullen, David J. Harrison, Jennifer Bré
Translational Oncology.2024; 50: 102114. CrossRef - Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis
Bi-Cheng Wang, Bo-Hua Kuang, Guo-He Lin, Chen Fu
Frontiers in Immunology.2024;[Epub] CrossRef - Rational development of combination therapies for biliary tract cancers
James J. Harding, Danny N. Khalil, Luca Fabris, Ghassan K. Abou-Alfa
Journal of Hepatology.2023; 78(1): 217. CrossRef - Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
Cindy Neuzillet, Pascal Artru, Eric Assenat, Julien Edeline, Xavier Adhoute, Jean-Christophe Sabourin, Anthony Turpin, Romain Coriat, David Malka
Targeted Oncology.2023; 18(1): 51. CrossRef - Prolonged survival with first-line chemotherapy in advanced extrahepatic cholangiocarcinoma
Mascarenhas Chrystle, D'souza Sanyo
BMJ Case Reports.2023; 16(3): e249681. CrossRef - Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy
Valerie Gunchick, Rachel L McDevitt, Elizabeth Choi, Katherine Winslow, Mark M Zalupski, Vaibhav Sahai
The Oncologist.2023; 28(6): 531. CrossRef - A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada
Ravi Ramjeesingh, Prosanto Chaudhury, Vincent C. Tam, David Roberge, Howard J. Lim, Jennifer J. Knox, Jamil Asselah, Sarah Doucette, Nirlep Chhiber, Rachel Goodwin
Current Oncology.2023; 30(8): 7132. CrossRef - A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
Targeted Oncology.2023; 18(6): 837. CrossRef - Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement
Lorenza Rimassa, Giovanni Brandi, Monica Niger, Nicola Normanno, Davide Melisi
Critical Reviews in Oncology/Hematology.2023; 192: 104146. CrossRef - Mutational signatures and processes in hepatobiliary cancers
Ekaterina Zhuravleva, Colm J. O’Rourke, Jesper B. Andersen
Nature Reviews Gastroenterology & Hepatology.2022; 19(6): 367. CrossRef - Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
Chan Su Park, Min Je Sung, So Jeong Kim, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park
Cancers.2022; 14(17): 4323. CrossRef - Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective
Vincent C. Tam, Ravi Ramjeesingh, Ronald Burkes, Eric M. Yoshida, Sarah Doucette, Howard J. Lim
Current Oncology.2022; 29(10): 7072. CrossRef - Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukher
Cancer Research and Treatment.2021; 53(2): 457. CrossRef - PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
Zhihong Wang, Tianmei Zeng, Yong Li, Ding Zhang, Zhengang Yuan, Mengli Huang, Yuan Yang, Weiping Zhou
Frontiers in Immunology.2021;[Epub] CrossRef - Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo
Cancer Research and Treatment.2020; 52(2): 594. CrossRef - Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
Ah-Rong Nam, Mei-Hua Jin, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Do-Youn Oh, Yung-Jue Bang
Cancer Research and Treatment.2020; 52(3): 945. CrossRef - Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports
Andrea Nicolini, Paola Ferrari, Riccardo Morganti, Angelo Carpi
International Journal of Molecular Sciences.2019; 20(23): 5986. CrossRef
- Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy
- 10,345 View
- 340 Download
- 20 Web of Science
- 21 Crossref
- Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer
- Ah-Rong Nam, Ji-Won Kim, Ji Eun Park, Ju-Hee Bang, Mei Hua Jin, Do-Youn Oh, Yung-Jue Bang
- Cancer Res Treat. 2019;51(3):886-900. Published online October 1, 2018
- DOI: https://doi.org/10.4143/crt.2018.375
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Jab1 is a coactivator of c-Jun that enhances the transcriptional function of c-Jun. Jab1 is frequently overexpressed in various cancers and is associatedwith poor prognosis of cancer patients. Thus, Jab1 could be a potential therapeutic target in cancer. However, the role of Jab1 in biliary tract cancer (BTC) has not been studied.
Materials and Methods
We performed in vitro and in vivo experiments to evaluate the therapeutic potential ofJab1 inhibition in BTC.
Results
Among 8 BTC cell lines, many showed higher Jab1 expression levels. In addition, Jab1 silencing by siRNA increased p27 expression levels. SNU478 and HuCCT-1 cells exhibited profound Jab1 knockdown and increased p27 expression by Jab1-specific siRNA transfection. Jab1 silencing induced anti-proliferative and anti-migratory effects and resulted in G1 cell cycle arrest in SNU478 and HuCCT-1 cells. In addition, Jab1 silencing potentiated the anti-proliferative and anti-migratory effects of cisplatin by increasing DNA damage. Interestingly,Jab1 knockdown increased PTEN protein half-life, resulting in increased PTEN expression. In the HuCCT-1 mouse xenograft model, stable knockdown of Jab1 by shRNA also showed anti-proliferative effects in vivo, with decreased Ki-67 expression and AKT phosphorylation and increased Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling and p27 expression.
Conclusion
Jab1 knockdown demonstrated anti-proliferative and anti-migratory effects in BTC cells by increasing DNA damage and stabilizing PTEN, resulting in G1 cell cycle arrest. In addition, Jab1 silencing potentiated the anti-proliferative effects of cisplatin. Our data suggest that Jab1 may be a potential therapeutic target in BTC that is worthy of further investigations. -
Citations
Citations to this article as recorded by- COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma
Jiahui Liu, Dexing Han, Junfeng Xuan, Jinye Xie, Weijia Wang, Quan Zhou, Kang Chen
Aging.2024; 16(6): 5264. CrossRef - Pan-cancer analyses of Jab1/COPS5 reveal oncogenic role and clinical outcome in human cancer
Liping Wang, Xiaojiao Zeng, Gui Yang, Guohong Liu, Yunbao Pan
Heliyon.2022; 8(12): e12553. CrossRef - Jab1/Cops5: a promising target for cancer diagnosis and therapy
Chunjue Yuan, Dong Wang, Guohong Liu, Yunbao Pan
International Journal of Clinical Oncology.2021; 26(7): 1159. CrossRef
- COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma
- 8,536 View
- 225 Download
- 6 Web of Science
- 3 Crossref
- A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
- Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
- Cancer Res Treat. 2019;51(2):718-726. Published online September 3, 2018
- DOI: https://doi.org/10.4143/crt.2018.324
-
Abstract
PDFPubReaderePub
- Purpose
The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
Materials and Methods
We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles.
Results
A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms.
Conclusion
The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin. -
Citations
Citations to this article as recorded by-
Osimertinib with Chemotherapy in
EGFR
-Mutated NSCLC
New England Journal of Medicine.2024; 390(5): 478. CrossRef - Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao
Frontiers in Oncology.2024;[Epub] CrossRef - Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 87. CrossRef - Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, Yu-Feng Wei
Frontiers in Oncology.2023;[Epub] CrossRef - Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali
JAMA Oncology.2022; 8(6): 879. CrossRef - Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang
Oncology Letters.2022;[Epub] CrossRef - Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Lung Cancer.2021; 152: 15. CrossRef - Exploring the role of epidermal growth factor receptor variant III in meningeal tumors
Rashmi Rana, Vaishnavi Rathi, Kirti Chauhan, Kriti Jain, Satnam Singh Chhabra, Rajesh Acharya, Samir Kumar Kalra, Anshul Gupta, Sunila Jain, Nirmal Kumar Ganguly, Dharmendra Kumar Yadav, Timir Tripathi
PLOS ONE.2021; 16(9): e0255133. CrossRef - Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung
Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Lung Cancer.2021; 162: 169. CrossRef - Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef - Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma
Wang Chun Kwok, David Chi Leung Lam, Ka Yan Chiang, James Chung Man Ho, Mary Sau Man Ip, Terence Chi Chun Tam
Journal of Chemotherapy.2020; 32(8): 429. CrossRef
-
Osimertinib with Chemotherapy in
EGFR
-Mutated NSCLC
- 10,053 View
- 349 Download
- 11 Web of Science
- 11 Crossref
- Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
- Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo
- Cancer Res Treat. 2019;51(1):119-127. Published online March 12, 2018
- DOI: https://doi.org/10.4143/crt.2018.019
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
This randomized phase III study was designed to compare the efficacy and safety of irinote-can plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC).
Materials and Methods
Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m2 intravenously on days 1 and 8+cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m2 intravenously on days 1, 2, 3+cisplatin 70 mg/m2 intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival.
Results
A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP.
Conclusion
The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC. -
Citations
Citations to this article as recorded by- Effect of Trilaciclib Administered Before Chemotherapy in Patients With Extensive-Stage Small-Cell Lung Cancer: A Pooled Analysis of Four Randomized Studies
Ying Liu, Lin Wu, Dingzhi Huang, Qiming Wang, Chen Yang, Li Zhou, Shuguang Sun, Xiaomei Jiang, Ying Cheng
Cancer Treatment and Research Communications.2025; : 100869. CrossRef - Factors associated with posttraumatic stress and anxiety among the parents of babies admitted to neonatal care: a systematic review
Reem Malouf, Sian Harrison, Victoria Pilkington, Charles Opondo, Chris Gale, Alan Stein, Linda S. Franck, Fiona Alderdice
BMC Pregnancy and Childbirth.2024;[Epub] CrossRef - Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort
Hassan Abdelilah Tafenzi, Farah Choulli, Edwin Kelly Haag, Anass Baladi, Ismail Essaadi, Rhizlane Belbaraka
Translational Oncology.2024; 47: 102015. CrossRef - Clinical Benefits of new Systemic Therapy for Small‐Cell Lung Cancer Over Two Decades: A Cross‐Sectional Study
Yuejing Chen, Honghong Liu, Shaohua Bai, Xuejiao Han, Fei Jin, Bo Cui
The Clinical Respiratory Journal.2024;[Epub] CrossRef - Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis
Paul O. Odeniran, Paradise Madlala, Nompumelelo P. Mkhwanazi, Mahmoud E. S. Soliman
Cancers.2024; 16(22): 3802. CrossRef - Efficacy and toxicity profile of first‐line treatment for extensive‐stage small cell lung cancer: A Bayesian network meta‐analysis
Guo Lin, Zhuoran Yao, Kai Kang, Hui Wang, Ren Luo, You Lu
Cancer Medicine.2023; 12(9): 10230. CrossRef - Therapeutic strategy analysis of patients with advanced stage high‐grade neuroendocrine cervical cancer: A real‐world multicenter study
Yuanyuan Zhang, Yi Huang, Suiyu Luo, Lin Li, Hongying Yang, Ziyi Wang, Yongmei Peng, Manni Huang, Jusheng An, Xi Yang, Jing Wang, Chunmei Li, Lingying Wu
International Journal of Gynecology & Obstetrics.2022; 158(3): 722. CrossRef - Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer
Christine M. Cramer‐van der Welle, Franz M. N. H. Schramel, Bas J. M. Peters, John W. G. van Putten, Olaf H. Klungel, Harry J. M. Groen, Ewoudt M. W. van de Garde
Pharmacoepidemiology and Drug Safety.2021; 30(4): 445. CrossRef - Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database
Jung Soo Lee, Seoree Kim, Soo-Yoon Sung, Yeo Hyung Kim, Hyun Woo Lee, Ji Hyung Hong, Yoon Ho Ko
Frontiers in Oncology.2021;[Epub] CrossRef - Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi, Hironori Sagara
Current Oncology.2021; 28(2): 1094. CrossRef - Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
Seo Ree Kim, Ji Hyung Hong, Soo-Yoon Sung, Yeo Hyung Kim, Sang Hoon Chun, Hyun Woo Lee, Jung Soo Lee, Yoon Ho Ko
BMC Cancer.2021;[Epub] CrossRef - Clinical significance of the cachexia index in patients with small cell lung cancer
Se-Il Go, Mi Jung Park, Gyeong-Won Lee
BMC Cancer.2021;[Epub] CrossRef - Sevens Cases of Neuroendocrine Carcinoma of the Nasal and Paranasal Sinuses
Ichiro Sekine, Kan Kishibe, Miki Takahara, Hiroaki Katada, Tatsuya Hayashi, Yasuaki Harabuchi
Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology).2021; 60(2): 169. CrossRef - Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
Millie Das, Sukhmani K. Padda, Jared Weiss, Taofeek K. Owonikoko
Advances in Therapy.2021; 38(11): 5431. CrossRef - Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Current Oncology.2021; 28(6): 4894. CrossRef - Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive‐stage disease small cell lung cancer: Results from a randomized controlled trial
Gyeong‐Won Lee, Se‐Il Go, Dong‐Wan Kim, Hoon‐Gu Kim, Joo‐Hang Kim, Ho Jung An, Joung Soon Jang, Bong‐Seog Kim, Seokyung Hahn, Dae Seog Heo
Thoracic Cancer.2020; 11(1): 62. CrossRef - IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
Mi-Sook Lee, Kyungsoo Jung, Ji-Young Song, Min-Jung Sung, Sung-Bin Ahn, Boram Lee, Doo-Yi Oh, Yoon-La Choi
Molecular Therapy - Oncolytics.2020; 16: 188. CrossRef - Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study
Panpan Zhang, Jie Li, Jian Li, Xiaotian Zhang, Jun Zhou, Xicheng Wang, Zhi Peng, Lin Shen, Ming Lu
Cancer.2020; 126(S9): 2086. CrossRef - Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
Hao Chen, Nobuyuki Horita, Kentaro Ito, Hideyuki Nagakura, Yu Hara, Nobuaki Kobayash, Masaki Yamamoto, Makoto Kudo, Takeshi Kaneko
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen
Feiwen Liu, Shaozhang Zhou, Liping Tan, Huiqin Jiang, Yucong Huang
Cancer Management and Research.2020; Volume 12: 10341. CrossRef- Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
Ting Zhou, Zhonghan Zhang, Fan Luo, Yuanyuan Zhao, Xue Hou, Tingting Liu, Kai Wang, Hongyun Zhao, Yan Huang, Li Zhang
JAMA Network Open.2020; 3(10): e2015748. CrossRef - Thérapie ciblée et immunothérapie du cancer bronchique à petites cellules
J.-L. Pujol, C. Goze, C. Pujol, B. Roch
Revue des Maladies Respiratoires Actualités.2019; 11(3): 315. CrossRef - Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
Fei Xu, Xiaoli Ren, Yuan Chen, Qianxia Li, Ruichao Li, Yu Chen, Shu Xia
BMC Cancer.2018;[Epub] CrossRef - Traitement médical du cancer bronchique à petites cellules : peut-on sortir de l’aire du cisplatine–étoposide ?
Jean-Louis Pujol, Benoît Roch, Camille N. Pujol, Catherine Goze
Bulletin du Cancer.2018;[Epub] CrossRef
- Effect of Trilaciclib Administered Before Chemotherapy in Patients With Extensive-Stage Small-Cell Lung Cancer: A Pooled Analysis of Four Randomized Studies
- 12,689 View
- 517 Download
- 29 Web of Science
- 24 Crossref
- S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
- Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha
- Cancer Res Treat. 2019;51(1):1-11. Published online February 5, 2018
- DOI: https://doi.org/10.4143/crt.2018.028
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients.
Materials and Methods
Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m2 /day on days 1-14 plus docetaxel 35 mg/m2 on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m2 /day on days 1-14 plus cisplatin 60 mg/m2 on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.
Results
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment.
Conclusion
Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer. -
Citations
Citations to this article as recorded by- Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
Frontiers in Pharmacology.2024;[Epub] CrossRef - A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer
Lili Liu, Li Sun, Ning Zhang, Cheng-gong Liao, Haichuan Su, Jie Min, Yang Song, Xue Yang, Xiaofeng Huang, Dongxu Chen, Yu Chen, Hong-wei Zhang, Helong Zhang
International Journal of Hyperthermia.2022; 39(1): 239. CrossRef - Comment on “post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial”
Qiang Hu, Yuanshui Sun
Clinical Nutrition.2021; 40(3): 1438. CrossRef - THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
A. A. Bobryshev, M. M. Davudov, M. N. Narimanov, S. B. Polycarpova, V. Y. Kirsanov, V. N. Blindar
Siberian journal of oncology.2021; 20(1): 133. CrossRef - Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
Surgical Oncology.2021; 38: 101599. CrossRef - Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
Chih-Chieh Yen, Yan-Shen Shan, Ying-Jui Chao, Ting-Kai Liao, I-Shu Chen, Hsuan-Yi Huang, I-Ting Liu, Chia-Jui Yen
BMC Cancer.2021;[Epub] CrossRef - Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
Ina Valeria Zurlo, Michele Basso, Antonia Strippoli, Maria Alessandra Calegari, Armando Orlandi, Alessandra Cassano, Mariantonietta Di Salvatore, Giovanna Garufi, Emilio Bria, Giampaolo Tortora, Carlo Barone, Carmelo Pozzo
Cancers.2020; 12(7): 1749. CrossRef - A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer
Long Ge, Liangying Hou, Qingxia Yang, Yiting Wu, Xiue Shi, Jiang Li, Kehu Yang
Medicine.2019; 98(7): e14478. CrossRef - Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(4): 530. CrossRef - COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Frontiers in Oncology.2019;[Epub] CrossRef - Cutting-edge evidence of adjuvant treatments for gastric cancer
Dai Shimizu, Mitsuro Kanda, Yasuhiro Kodera, Junichi Sakamoto
Expert Review of Gastroenterology & Hepatology.2018; 12(11): 1109. CrossRef
- Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
- 13,024 View
- 591 Download
- 22 Web of Science
- 11 Crossref
- Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
- Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok
- Cancer Res Treat. 2018;50(3):691-700. Published online July 6, 2017
- DOI: https://doi.org/10.4143/crt.2017.280
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials.
Materials and Methods
This analysis evaluated previously treated and untreated patients in two randomized, openlabel phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and “as-treated” populations for efficacy and safety endpoints, respectively.
Results
In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade)with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity.
Conclusion
These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC. -
Citations
Citations to this article as recorded by- Inhalable iron redox cycling powered nanoreactor for amplified ferroptosis-apoptosis synergetic therapy of lung cancer
Linjing Wu, Wenhao Wang, Mengqin Guo, Fangqin Fu, Wenhua Wang, Tszching Sung, Meihong Zhang, Ziqiao Zhong, Chuanbin Wu, Xin Pan, Zhengwei Huang
Nano Research.2024; 17(6): 5435. CrossRef - Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
Akhil Kapoor, Vanita Noronha, Vijay Patil, Nandini Menon, Ravindra Nandhana, Amit Kumar, Abhishek Mahajan, Amit Janu, Rajiv Kumar, Kumar Prabhash
South Asian Journal of Cancer.2023; 12(02): 179. CrossRef - Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
Byoung Chul Cho, Dong-Wan Kim, Ullas Batra, Keunchil Park, Sang-We Kim, Cheng-Ta Yang, Pei-Jye Voon, Virote Sriuranpong, K. Govind Babu, Khalid Amin, Yingbo Wang, Paramita Sen, Khemaies Slimane, Sarayut Geater
Cancer Research and Treatment.2023; 55(1): 83. CrossRef - Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
Xiangming Zhang, Kai Ni, Huijun Chen
OncoTargets and Therapy.2023; Volume 16: 87. CrossRef - A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang
Cancer Medicine.2023; 12(15): 15983. CrossRef - Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review
Fabien Moinard-Butot, Simon Nannini, Cathie Fischbach, Safa Abdallahoui, Martin Demarchi, Thierry Petit, Laura Bender, Roland Schott
Cancers.2023; 15(20): 4940. CrossRef - Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy
Ziyu Zhao, Wenhao Wang, Guanlin Wang, Zhengwei Huang, Liping Zhou, Li Lin, Yueling Ou, Wanzhen Huang, Xuejuan Zhang, Chuanbin Wu, Liang Tao, Qin Wang
Journal of Nanobiotechnology.2023;[Epub] CrossRef - Performance of Japanese patients in registrational studies
Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Japanese Journal of Clinical Oncology.2022; 52(1): 53. CrossRef - Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Laird B Cameron, Nadia Hitchen, Elias Chandran, Tessa Morris, Renée Manser, Benjamin J Solomon, Vanessa Jordan
Cochrane Database of Systematic Reviews.2022;[Epub] CrossRef - Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
Kai Chen, Yingnan Si, Jia-Shiung Guan, Zhuoxin Zhou, Seulhee Kim, Taehyun Kim, Liang Shan, Christopher D. Willey, Lufang Zhou, Xiaoguang Liu
Biomedicines.2022; 10(1): 130. CrossRef - The application of radiomics in predicting gene mutations in cancer
Yana Qi, Tingting Zhao, Mingyong Han
European Radiology.2022; 32(6): 4014. CrossRef - Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D. Ross Camidge, Karin Berghoff, Soetkin Vlassak, Paul K. Paik
Clinical Lung Cancer.2022; 23(3): 195. CrossRef - Role ofSTK11inALK‑positive non‑small cell lung cancer (Review)
Wen Zhou, Lu-Da Yan, Zhi-Qiong Yu, Na Li, Yong-Hua Yang, Meng Wang, Yuan-Yuan Chen, Meng-Xia Mao, Xiao-Chun Peng, Jun Cai
Oncology Letters.2022;[Epub] CrossRef - Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Myung J. Ahn, Hye R. Kim, James C.H. Yang, Ji-Yu Han, Jacky Yu-Chung. Li, Maximilian J. Hochmair, Gee-Chen Chang, Angelo Delmonte, Ki H. Lee, Rosario G. Campelo, Cesare Gridelli, Alexander I. Spira, Raffaele Califano, Frank Griesinger, Sharmistha Ghosh, E
Clinical Lung Cancer.2022; 23(8): 720. CrossRef - Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
Dan Han, Kewei Zhao, Qin Yang, Liling Zhang, Shihong Fei
Frontiers in Oncology.2022;[Epub] CrossRef - Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
Mei-ting Chen, Xiao-hong Fu, He Huang, Zhao Wang, Xiao-jie Fang, Yu-Yi Yao, Quan-Guang Ren, Ze-geng Chen, Tong-yu Lin
Leukemia & Lymphoma.2021; 62(3): 571. CrossRef - Breakthrough in targeted therapy for non-small cell lung cancer
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Biomedicine & Pharmacotherapy.2021; 133: 111079. CrossRef - Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
Daniel S.W. Tan, Sarayut Geater, Chong-Jen Yu, Chun-Ming Tsai, Te-Chun Hsia, Jun Chen, Meng-Chih Lin, You Lu, Virote Sriuranpong, Cheng-Ta Yang, Paramita Sen, Fabrice Branle, Michael Shi, Yi-Long Wu
JTO Clinical and Research Reports.2021; 2(3): 100131. CrossRef - Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group
Wenbin Li, Jing Zhang, Zhijie Wang, Lin Li, Jie Ma, Xiaoyang Zhou, Jie Wang, Zhiyong Liang, Jianming Ying
Journal of the National Cancer Center.2021; 1(4): 123. CrossRef - Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study
Fenge Jiang, Congcong Wang, Ping Yang, Ping Sun, Jiannan Liu
World Journal of Surgical Oncology.2021;[Epub] CrossRef - Genetic Analysis of Pediatric Pancreatoblastoma
Zhengzheng Wang, Xiaoting Li, Qingjun Li, Jinxue Zhou
Pancreas.2021; 50(10): 1445. CrossRef - Treatment of advanced non-small-cell lung cancer
Kumar Prabhash, Amish Vora, Sewanti Limaye, Tarini Prasad Sahoo, Ullas Batra, Shekhar Patil, Vijay M. Patil, Vanita Noronha, Bharat Bhosale, Nirmal Vivek Raut, Narayanankutty Warrier, Bharat Vaswani, Govind Babu, Adwaita Gore, Nitesh Rohatgi, Shailesh Bon
Cancer Research, Statistics, and Treatment.2021; 4(2): 279. CrossRef - Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi
The Lancet Respiratory Medicine.2020; 8(1): 45. CrossRef - Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients
Lan Song, Zhenchen Zhu, Li Mao, Xiuli Li, Wei Han, Huayang Du, Huanwen Wu, Wei Song, Zhengyu Jin
Frontiers in Oncology.2020;[Epub] CrossRef - Renal complication of crizotinib: Crizotinib-associated complex renal cyst
Warissara Jutidamrongphan, Pimporn Puttawibul
The ASEAN Journal of Radiology.2020; : 44. CrossRef - A Unique Case of a High-Grade Neuroepithelial Tumor With EML4-ALK Fusion in a Five-Month-Old
Oliver D Mrowczynski, Russell Payne, Cunfeng Pu, Robert Greiner, Elias Rizk
Cureus.2020;[Epub] CrossRef - Histomorphologic features of lung adenocarcinomas exhibiting ALK gene rearrangement
Daniel S. Grosser, Haiying Zhang
Baylor University Medical Center Proceedings.2019; 32(2): 206. CrossRef - ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib
Ye Qiu, Bixun Li, Yihong Zhang, Xiaoyun Guo, Chunzhi Xiang, Congshui Wang, Yang Lu, Shuang Ren, Juan Zhao
Medicine.2019; 98(11): e14826. CrossRef - Emerging therapies for non-small cell lung cancer
Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
Journal of Hematology & Oncology.2019;[Epub] CrossRef - De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
Jing-Wen Li, Shu-Hui Cao, Jian-Lin Xu, Hua Zhong
Cancer Biology & Therapy.2019; 20(9): 1183. CrossRef - Incidence and risk of fatigue in cancer patients treated with MET inhibitors
Hongxuan Tong, Yutian Zhu, Yihua Liu
Medicine.2019; 98(22): e15522. CrossRef - Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
Xing Chang, Zi Liu, Shuai Man, Annie Roys, Zengqiang Li, Daiying Zuo, Yingliang Wu
RSC Advances.2019; 9(31): 17921. CrossRef - Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
Shih‐Hao Huang, Allen Chung‐Cheng Huang, Chin‐Chou Wang, Wen‐Chen Chang, Chien‐Ying Liu, Stelios Pavlidis, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
Thoracic Cancer.2019; 10(12): 2274. CrossRef - Erastin/sorafenib induces cisplatin‑resistant non‑small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway
Yu Li, Hengyi Yan, Xiaoman Xu, Hongbo Liu, Cen Wu, Li Zhao
Oncology Letters.2019;[Epub] CrossRef - Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1
Yan Yang, Caiyu Jiang, Yang Yang, Lu Guo, Jiang Huang, Xingren Liu, Chi Wu, Jun Zou
Biochemical and Biophysical Research Communications.2018; 497(4): 1003. CrossRef - Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices
Claudio Martín, Andrés F. Cardona, Zyanya Lucia Zatarain-Barrón, Alejandro Ruiz-Patiño, Omar Castillo, George Oblitas, Luis Corrales, Lorena Lupinacci, María Angelina Pérez, Leonardo Rojas, Lisde González, Luis Chirinos, Carlos Ortíz, Mauricio Lema, Carlo
Oncology.2018; 94(5): 297. CrossRef - CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Stella Baliou, Maria Adamaki, Anthony Kyriakopoulos, Demetrios Spandidos, Michalis Panagiotidis, Ioannis Christodoulou, Vassilis Zoumpourlis
International Journal of Oncology.2018;[Epub] CrossRef
- Inhalable iron redox cycling powered nanoreactor for amplified ferroptosis-apoptosis synergetic therapy of lung cancer
- 15,934 View
- 706 Download
- 43 Web of Science
- 37 Crossref
- Ferroptosis: A Novel Anti-tumor Action for Cisplatin
- Jipeng Guo, Bingfei Xu, Qi Han, Hongxia Zhou, Yun Xia, Chongwen Gong, Xiaofang Dai, Zhenyu Li, Gang Wu
- Cancer Res Treat. 2018;50(2):445-460. Published online May 10, 2017
- DOI: https://doi.org/10.4143/crt.2016.572
-
Abstract
PDFPubReaderePub
- Purpose
Ferroptosis is a new mode of regulated cell death, which is completely distinct from other cell death modes based on morphological, biochemical, and genetic criteria. This study evaluated the therapeutic role of ferroptosis in classic chemotherapy drugs, including the underlying mechanism.
Materials and Methods
Cell viabilitywas detected by using the methylthiazoltetrazlium dye uptake method. RNAiwas used to knockout iron-responsive element binding protein 2, and polymerase chain reaction, western blot was used to evaluate the efficiency. Intracellular reduced glutathione level and glutathione peroxidases activitywere determined by related assay kit. Intracellularreactive oxygen species levelswere determined by flowcytometry. Electron microscopywas used to observe ultrastructure changes in cell.
Results
Among five chemotherapeutic drugs screened in this study, cisplatin was found to be an inducer for both ferroptosis and apoptosis in A549 and HCT116 cells. The depletion of reduced glutathione caused by cisplatin and the inactivation of glutathione peroxidase played the vital role in the underlying mechanism. Besides, combination therapy of cisplatin and erastin showed significant synergistic effect on their anti-tumor activity.
Conclusion
Ferroptosis had great potential to become a new approach in anti-tumor therapies and make up for some classic drugs, which open up a new way for their utility in clinic. -
Citations
Citations to this article as recorded by- Illuminating cisplatin-induced ferroptosis in non-small-cell lung cancer with biothiol-activatable fluorescent/photoacoustic bimodal probes
Li Xu, Hongwen Liu, Yi Kong, Lingyun Li, Jia Li, Kang Li, Shuzhi Liang, Bolin Chen
Journal of Materials Chemistry B.2025; 13(1): 239. CrossRef - EMC2 suppresses ferroptosis via regulating TFRC in nasopharyngeal carcinoma
Xianghui Chen, Xiaoyan Wang, Yuxia Zou, Yan Wang, Tingting Duan, Zijie Zhou, Yi Huang, Qing Ye
Translational Oncology.2025; 52: 102251. CrossRef - Research progress on gene mutations and drug resistance in leukemia
Xiangyu Ma, Jiamin Xu, Yanan Wang, Joshua S. Fleishman, Hao Bing, Boran Yu, Yanming Li, Letao Bo, Shaolong Zhang, Zhe-Sheng Chen, Libo Zhao
Drug Resistance Updates.2025; 79: 101195. CrossRef - Reconnoitering the role of Lipid Metabolites in Ferroptosis
Manikandan Vani Raju, Meenakshi Kaniyur Chandrasekaran, Rathi Muthaiyan Ahalliya, Gopalakrishnan Velliyur Kanniappan
Advances in Redox Research.2025; 14: 100117. CrossRef - DLBCL cells with ferroptosis morphology can be detected with a deep convolutional neural network
Pyry Kotkaranta, Mikko Chan, Tero Vuolio, Ilkka Miinalainen, Hanne Kuitunen, Taina Turpeenniemi-Hujanen, Hanna-Riikka Teppo, Outi Kuittinen, Milla E.L. Kuusisto
Biomedicine & Pharmacotherapy.2025; 182: 117785. CrossRef - Synergistic antitumor efficacy of gemcitabine and cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via Sp1-SAT1-polyamine metabolism pathway
Wanhui Wei, Yuanyuan Lu, Qian Hu, Jinwen Yin, Youwei Wang, Heng Zhang, Qiu Zhao, Lan Liu
Cellular Oncology.2024; 47(1): 321. CrossRef - Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy
Shutong Li, Aoxue Wang, Yongya Wu, Shengyuan He, Wen Shuai, Min Zhao, Yumeng Zhu, Xiuying Hu, Yubin Luo, Guan Wang
Immunological Reviews.2024; 321(1): 300. CrossRef - Impact of TP53‐induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma
Katsuya Toshida, Shinji Itoh, Norifumi Iseda, Takuma Izumi, Shohei Yoshiya, Takeo Toshima, Mizuki Ninomiya, Takeshi Iwasaki, Yoshinao Oda, Tomoharu Yoshizumi
Cancer Science.2024; 115(1): 170. CrossRef - Verteporfin Exerts Anticancer Effects and Reverses Resistance to Paclitaxel via Inducing Ferroptosis in Esophageal Squamous Cell Cancer Cells
Xue-Wei Wang, Zi-Yi Yang, Ting Li, Xin-Ran Zhao, Xiao-Zhong Li, Xiao-Xia Wang
Molecular Biotechnology.2024; 66(9): 2558. CrossRef - Heteronemin promotes iron-dependent cell death in pancreatic cancer
Gizem Kaftan, Mümin Alper Erdoğan, Mohamed El-Shazly, Mei-Chin Lu, Shou-Ping Shih, Hung-Yu Lin, Luciano Saso, Güliz Armagan
Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(3): 1865. CrossRef - Prognostic significance of a 3-gene ferroptosis-related signature in lung cancer via LASSO analysis and cellular functions of UBE2Z
Bin Xie, Qiong Chen, Ziyu Dai, Chen Jiang, Jingyi Sun, Anqi Guan, Xi Chen
Computational Biology and Chemistry.2024; 113: 108192. CrossRef - Yi-qi-hua-yu-jie-du decoction induces ferroptosis in cisplatin-resistant gastric cancer via the AKT/GSK3β/NRF2/GPX4 axis
Wenjie Huang, Fang Wen, Peipei Yang, Ye Li, Qiurong Li, Peng Shu
Phytomedicine.2024; 123: 155220. CrossRef - Mitochondrial dysfunction decreases cisplatin sensitivity in gastric cancer cells through upregulation of integrated stress response and mitokine GDF15
Sheng‐Fan Wang, Yuh‐Lih Chang, Ting‐Yu Liu, Kuo‐Hung Huang, Wen‐Liang Fang, Anna Fen‐Yau Li, Tien‐Shun Yeh, Giun‐Yi Hung, Hsin‐Chen Lee
The FEBS Journal.2024; 291(6): 1131. CrossRef - Current and Potential Roles of Ferroptosis in Bladder Cancer
Wen-xin An, Radheshyam Gupta, Kun Zhai, Ya-ru Wang, Wan-hai Xu, Yan Cui
Current Medical Science.2024; 44(1): 51. CrossRef - BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1
Yizhi Cao, Xuelong Wang, Yang Liu, Pengyi Liu, Jiejie Qin, Youwei Zhu, Shuyu Zhai, Yongsheng Jiang, Yihao Liu, Lijie Han, Jiaxin Luo, Ronghao Zhang, Minmin Shi, Liwen Wang, Xiaomei Tang, Meilin Xue, Jia Liu, Weishen Wang, Chenlei Wen, Xiaxing Deng, Chengh
Advanced Science.2024;[Epub] CrossRef - Ferroptosis and its modulators: A raising target for cancer and Alzheimer’s disease
Gourav Singh, Prashant Kesharwani, Gireesh Kumar Singh, Saroj Kumar, Anjaneyulu Putta, Gyan Modi
Bioorganic & Medicinal Chemistry.2024; 98: 117564. CrossRef - The application of nanoparticles based on ferroptosis in cancer therapy
Yifei Li, Chen Wei, Jianqin Yan, Fashun Li, Bohan Chen, Yong Sun, Kui Luo, Bin He, Yan Liang
Journal of Materials Chemistry B.2024; 12(2): 413. CrossRef - Stability-Enhanced Cisplatin Gold Nanoparticles as Therapeutic Anticancer Agents
Tae Joon Cho, Vytas Reipa, Justin M. Gorham, John M. Pettibone, Alessandro Tona, Aaron Johnston-Peck, Jingyu Liu, Bryant C. Nelson, Vincent A. Hackley
ACS Applied Nano Materials.2024; 7(1): 836. CrossRef - Mechanism of ferroptosis in breast cancer and research progress of natural compounds regulating ferroptosis
Anqi Ge, Qi He, Da Zhao, Yuwei Li, Junpeng Chen, Ying Deng, Wang Xiang, Hongqiao Fan, Shiting Wu, Yan Li, Lifang Liu, Yue Wang
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef - Iron accumulation and lipid peroxidation: implication of ferroptosis in hepatocellular carcinoma
Xiaodong Li, Fanguang Meng, Hankang Wang, Liwei Sun, Shulin Chang, Guijie Li, Feng Chen
Frontiers in Endocrinology.2024;[Epub] CrossRef - Crosstalk between ferroptosis and cuproptosis: From mechanism to potential clinical application
Na Liu, Minbin Chen
Biomedicine & Pharmacotherapy.2024; 171: 116115. CrossRef - A risk model based on 10 ferroptosis regulators and markers established by LASSO-regularized linear Cox regression has a good prognostic value for ovarian cancer patients
Tingchuan Xiong, Yinghong Wang, Changjun Zhu
Diagnostic Pathology.2024;[Epub] CrossRef - The role of ferroptosis in cardio-oncology
Kai Hou, Lin Liu, Zhi-Hui Fang, Wei-Xing Zong, Daqiang Sun, Zhigang Guo, Lu Cao
Archives of Toxicology.2024; 98(3): 709. CrossRef - Exploring the Use of Intracellular Chelation and Non-Iron Metals to Program Ferroptosis for Anticancer Application
Oscar Claudio-Ares, Jeileen Luciano-Rodríguez, Yolmarie L. Del Valle-González, Selene L. Schiavone-Chamorro, Alex J. Pastor, Javier O. Rivera-Reyes, Carmen L. Metzler, Lizandra M. Domínguez-Orona, Brenda Lee Vargas-Pérez, Rachid Skouta, Arthur D. Tinoco
Inorganics.2024; 12(1): 26. CrossRef - Ferroptosis: a dual-edged sword in tumour growth
Xiangye Zhao, Xiaoning Li, Yinghui Xu
Frontiers in Pharmacology.2024;[Epub] CrossRef - Propionate promotes ferroptosis and apoptosis through mitophagy and ACSL4-mediated ferroptosis elicits anti-leukemia immunity
Yihong Wei, Wancheng Liu, Ruiqing Wang, Yuhong Chen, Jinting Liu, Xiaodong Guo, Can Can, Xinyu Yang, Dongmei Wang, Xiang Hu, Daoxin Ma
Free Radical Biology and Medicine.2024; 213: 36. CrossRef - Programmed cell death in tumor immunity: mechanistic insights and clinical implications
Man Wang, Fei Yu, Yuan Zhang, Peifeng Li
Frontiers in Immunology.2024;[Epub] CrossRef - Extracellular vesicle-mediated ferroptosis, pyroptosis, and necroptosis: potential clinical applications in cancer therapy
Yi-Chi Yang, Qian Jiang, Ke-Ping Yang, Lingzhi Wang, Gautam Sethi, Zhaowu Ma
Cell Death Discovery.2024;[Epub] CrossRef - Modulating ferroptosis sensitivity: environmental and cellular targets within the tumor microenvironment
Yuze Hua, Sen Yang, Yalu Zhang, Jiayi Li, Mengyi Wang, Palashate Yeerkenbieke, Quan Liao, Qiaofei Liu
Journal of Experimental & Clinical Cancer Research.2024;[Epub] CrossRef - Chemo-photothermal nanoplatform with diselenide as the key for ferroptosis in colorectal cancer
Kaili Deng, Hailong Tian, Tingting Zhang, Yajie Gao, Edouard C. Nice, Canhua Huang, Na Xie, Guoliang Ye, Yuping Zhou
Journal of Controlled Release.2024; 366: 684. CrossRef - Ferroptosis in head and neck squamous cell carcinoma: from pathogenesis to treatment
Jing Yang, Zhaowei Gu
Frontiers in Pharmacology.2024;[Epub] CrossRef - Lysine acetyltransferase KAT2A modulates ferroptosis during colorectal cancer development
Zhenye Xu, Xiaoyan Wang, Ping Yu, Yong Zhang, Liang Huang, Enqiang Mao, Yi Han
Scandinavian Journal of Gastroenterology.2024; 59(4): 437. CrossRef - Recent Progress in Ferroptosis Induced Tumor Cell Death by Anti‐tumor Metallic complexes
Yong‐Chang Zhou, Tian‐Kun Zhao, Si‐Man Tao, Peng Wang, Yi‐Chen Guan, Ke‐Pei Yang, Sheng‐Qiang Chen, Xiu‐Ying Pu
Chemistry – An Asian Journal.2024;[Epub] CrossRef - Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer
Tong-Mei Shi, Xiao-Fei Chen, Huihui Ti
Journal of Medicinal Chemistry.2024; 67(4): 2238. CrossRef - Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration
Jiayan Wei, Jinsong Wang, Xinyi Chen, Li Zhang, Min Peng
PeerJ.2024; 12: e16819. CrossRef - Edaravone-loaded poly(amino acid) nanogel inhibits ferroptosis for neuroprotection in cerebral ischemia injury
Yunhan Zhang, Zhulin Zou, Shuang Liu, Fangfang Chen, Minglu Li, Haoyang Zou, Haiyan Liu, Jianxun Ding
Asian Journal of Pharmaceutical Sciences.2024; 19(2): 100886. CrossRef - A Pt(II) complex bearing N-heterocycle ring induced ferroptotic cell death in ovarian cancer
Xiaomin Shen, Yue Peng, Haixia Zhou, Xiaoxia Ye, Zhong Han, Xiangchao Shi
Journal of Inorganic Biochemistry.2024; 253: 112502. CrossRef - A Smooth Muscle Cell-Based Ferroptosis Model to Evaluate Iron-Chelating Molecules for Cardiovascular Disease Treatment
Sarah El Hajj, Laetitia Canabady-Rochelle, Isabelle Fries-Raeth, Caroline Gaucher
Current Issues in Molecular Biology.2024; 46(2): 1348. CrossRef - DTTZ suppresses ferroptosis and reverses mitochondrial dysfunction in normal tissues affected by chemotherapy
Yuwei Yang, Yuanfang Chen, Haikang Tang, Ziqi Zhang, Xiaoliang Zhou, Wenqing Xu
Biomedicine & Pharmacotherapy.2024; 172: 116227. CrossRef - Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer
Jun Zhao, Jijie Shen, Liang Mao, Tianli Yang, Jingyu Liu, Sun Hongbin
Oncogene.2024; 43(27): 2104. CrossRef - Iron Oxide Nanoparticles Carrying microRNA-124 Promote Ferroptosis in Treatment of Prostate Cancer
Min Liu, Chuanbing Xu, Huichao Dong, Dongshen Jia, Dongfang Hao, Ruozen Rong, Yao Peng
Journal of Biomedical Nanotechnology.2024; 20(2): 224. CrossRef - Targeting LGR4–Wnt activates ferroptosis and reverses drug resistance in colorectal cancer
Nature Cancer.2024; 5(4): 542. CrossRef - Recent research progress based on ferroptosis-related signaling pathways and the tumor microenvironment on it effects
Shijing Yu, Lingwu Tong, Jiangwen Shen, Chenglei Li, Yongshan Hu, Keke Feng, Jingwei Shao
European Journal of Medicinal Chemistry.2024; 269: 116290. CrossRef - TRAIL predisposes non-small cell lung cancer to ferroptosis by regulating ASK-1/JNK1 pathway
Xiaofang Liu, Huiqian Deng, Mi Huang, Wei Zhou, Yilin Yang
Discover Oncology.2024;[Epub] CrossRef - G protein-coupled estrogen receptor activates PI3K/AKT/mTOR signaling to suppress ferroptosis via SREBP1/SCD1-mediated lipogenesis
Jiaping Chen, Rong Zhao, Yangwei Wang, Han Xiao, Wei Lin, Mingxin Diao, Shiwen He, Peiyuan Mei, Yongde Liao
Molecular Medicine.2024;[Epub] CrossRef - Cisplatin Nephrotoxicity Is Critically Mediated by the Availability of BECLIN1
Tillmann Bork, Camila Hernando-Erhard, Wei Liang, Zhejia Tian, Kosuke Yamahara, Tobias B. Huber
International Journal of Molecular Sciences.2024; 25(5): 2560. CrossRef - Ailanthone induces autophagy and ferroptosis in non‑small cell lung cancer Lewis cells
Hongbin Yang, Xiaotong Zhang, Yanjie Lu, Xin Wang, Zhengxin Zhang, Hailan Xu, Fan Li, Qianhui Chen, Yiying Bai, Xinyu Bai, Li Zhang, Lei Liu
Molecular and Clinical Oncology.2024;[Epub] CrossRef - Ferroptosis in lung cancer: dual role, multi-level regulation, and new therapeutic strategies
Yunbin Li, Xiaosong Li, Jian Li
Frontiers in Oncology.2024;[Epub] CrossRef - Curcumin activates the JNK signaling pathway to promote ferroptosis in colon cancer cells
Wei Xin, Yong Zhang
Chemical Biology & Drug Design.2024;[Epub] CrossRef - Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Qian Zhou, Yu Meng, Daishi Li, Lei Yao, Jiayuan Le, Yihuang Liu, Yuming Sun, Furong Zeng, Xiang Chen, Guangtong Deng
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef - AURKA knockdown inhibits esophageal squamous cell carcinoma progression through ferroptosis
Yuan Mi, Liying Chen, Cong Wang, Yuxin Miao, Chuntao Song, Jie Su, Lei Wang
Heliyon.2024; 10(7): e28365. CrossRef - Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects
Jing Zeng, Xianghong Zhang, Zhengjun Lin, Yu Zhang, Jing Yang, Pengcheng Dou, Tang Liu
Experimental Hematology & Oncology.2024;[Epub] CrossRef - Emerging mechanisms of ferroptosis and its implications in lung cancer
Qian Li, Qibin Song, Huadong Pei, Yali Chen
Chinese Medical Journal.2024; 137(7): 818. CrossRef - Role of ferroptosis and ferroptosis-related long non'coding RNA in breast cancer
Shasha Xiang, Wen Yan, Xing Ren, Jianbo Feng, Xuyu Zu
Cellular & Molecular Biology Letters.2024;[Epub] CrossRef - Meningioma achieves malignancy and erastin-induced ferroptosis resistance through FOXM1-AURKA-NRF2 axis
Yangfan Ye, Lei Xu, Liuchao Zhang, Pengzhan Zhao, Wanzhi Cai, Guoqiang Fu, Tian Wang, Zeqiang Tao, Wenqian Shi, Wei Gu, Jingming Hu, Guangyao Yuan, Yutian Wei, Ke Xu, Zhongyuan Bao, Honglu Chao, Ning Liu, Lin Zhao, Yiming Tu, Jing Ji
Redox Biology.2024; 72: 103137. CrossRef - Esculin induces endoplasmic reticulum stress and drives apoptosis and ferroptosis in colorectal cancer via PERK regulating eIF2α/CHOP and Nrf2/HO-1 cascades
Xiaoke Ji, Zongpin Chen, Weifan Lin, Qifang Wu, Yu Wu, Yan Hong, Haibin Tong, Changxiong Wang, Ya Zhang
Journal of Ethnopharmacology.2024; 328: 118139. CrossRef - A multi-mode Rhein-based nano-platform synergizing ferrotherapy/chemotherapy-induced immunotherapy for enhanced tumor therapy
Xiaokang Zhu, Li Xie, Jinming Tian, Yang Jiang, Erqun Song, Yang Song
Acta Biomaterialia.2024; 180: 383. CrossRef - Synergistic eradicating impact of 5-fluouracil with FeO nanoparticles-diethyldithiocarbamate in colon cancer spheroids
Marwa M Abu-Serie
Nanomedicine.2024; 19(11): 979. CrossRef - Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M. Huffman, Zsofia Sztupinszki, Clare X. Morris, David Chen, Judit Börcsök, Miklos Diossy, Viktoria Tisza, Sandor Spisak, Pornlada Likasitwatanakul, Orsolya Rusz, Istvan Csabai, Michael Cecchini, Yasmine Baca, Andrew E
npj Precision Oncology.2024;[Epub] CrossRef - Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology
Muhammad Hossein Ashoub, Razieh Razavi, Kamran Heydaryan, Masoud Salavati-Niasari, Mahnaz Amiri
European Journal of Medical Research.2024;[Epub] CrossRef - LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis
Nan Cao, Fangmei Zhang, Jiang Yin, Jianlei Zhang, Xiqing Bian, Guopei Zheng, Nan Li, Ying Lin, Liyun Luo
Oncogene.2024; 43(22): 1714. CrossRef - Endometrial stem cells alleviate cisplatin-induced ferroptosis of granulosa cells by regulating Nrf2 expression
Rumeng Pan, Rongli Wang, Feiyan Cheng, Lihui Wang, Zhiwei Cui, Jing She, Xinyuan Yang
Reproductive Biology and Endocrinology.2024;[Epub] CrossRef - Deciphering Ferroptosis: From Molecular Pathways to Machine Learning-Guided Therapeutic Innovation
Megha Mete, Amiya Ojha, Priyanka Dhar, Deeplina Das
Molecular Biotechnology.2024;[Epub] CrossRef - FSP1-mediated ferroptosis in cancer: from mechanisms to therapeutic applications
Ran Gao, Jinge Wang, Jingjing Huang, Tong Wang, Lingfeng Guo, Wenlu Liu, Jialu Guan, Desen Liang, Qinghui Meng, Huayang Pan
Apoptosis.2024; 29(7-8): 1019. CrossRef - Recent advancements in nanomaterial-mediated ferroptosis-induced cancer therapy: Importance of molecular dynamics and novel strategies
Namdev Dhas, Ritu Kudarha, Ruchi Tiwari, Gaurav Tiwari, Neha Garg, Praveen Kumar, Sanjay Kulkarni, Jahnavi Kulkarni, Soji Soman, Aswathi R. Hegde, Jayvadan Patel, Atul Garkal, Anam Sami, Deepanjan Datta, Viola Colaco, Tejal Mehta, Lalitkumar Vora, Sriniva
Life Sciences.2024; 346: 122629. CrossRef - Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers
Pham Hong Anh Cao, Abishai Dominic, Fabiola Ester Lujan, Sanjanaa Senthilkumar, Pratip K. Bhattacharya, Daniel E. Frigo, Elavarasan Subramani
Nature Reviews Urology.2024; 21(10): 615. CrossRef - Disruption of lipid metabolism to induce ferroptosis using multifunctional fibrate-Pt(iv) prodrugs for cancer treatment
Peng Sun, Jia-Qian Wang, Qiang Xie, Xuan-Lin Ren, Xin Qiao, Jing-Yuan Xu
Inorganic Chemistry Frontiers.2024; 11(10): 2914. CrossRef - Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2
Feng Liu, Ling Tang, Huai Liu, Yanzhu Chen, Tengfei Xiao, Wangning Gu, Hongmin Yang, Hui Wang, Pan Chen
Cell Death & Disease.2024;[Epub] CrossRef - Ferroptosis-related lncRNA NRAV affects the prognosis of hepatocellular carcinoma via the miR-375-3P/SLC7A11 axis
Ke Zong, Caifeng Lin, Kai Luo, Yilei Deng, Hongfei Wang, Jianfei Hu, Shi Chen, Renfeng Li
BMC Cancer.2024;[Epub] CrossRef - Oleanolic Acid Acetate Alleviates Cisplatin-Induced Nephrotoxicity via Inhibition of Apoptosis and Necroptosis In Vitro and In Vivo
Bori Lee, Yeon-Yong Kim, Seungwon Jeong, Seung Woong Lee, Seung-Jae Lee, Mun-Chual Rho, Sang-Hyun Kim, Soyoung Lee
Toxics.2024; 12(4): 301. CrossRef - Ferroptosis is an effective strategy for cancer therapy
Afrasyab Khan, Yu Huo, Yilei Guo, Juanjuan Shi, Yongzhong Hou
Medical Oncology.2024;[Epub] CrossRef - Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer
Xin Jin, Wenke Jin, Linlin Tong, Jia Zhao, Lan Zhang, Na Lin
Acta Pharmaceutica Sinica B.2024; 14(7): 2815. CrossRef - Polyphyllin I induces rapid ferroptosis in acute myeloid leukemia through simultaneous targeting PI3K/SREBP-1/SCD1 axis and triggering of lipid peroxidation
Xinyu Zhou, Duanna Zhang, Jieting Lei, Jixia Ren, Bo Yang, Zhixing Cao, Chuanjie Guo, Yuzhi Li
Journal of Natural Medicines.2024; 78(3): 618. CrossRef - Ferroptotic therapy in cancer: benefits, side effects, and risks
Jiandong Diao, Yuanyuan Jia, Enyong Dai, Jiao Liu, Rui Kang, Daolin Tang, Leng Han, Yingjie Zhong, Lingjun Meng
Molecular Cancer.2024;[Epub] CrossRef - Ferroptosis in antitumor therapy: Unraveling regulatory mechanisms and immunogenic potential
Ting Zhang, Xiaoping Zeng, Erming Zeng, Hongmei Wang
International Immunopharmacology.2024; 134: 112203. CrossRef - Tumor-repopulating cells evade ferroptosis via PCK2-dependent phospholipid remodeling
Zhe Li, Zhi-min Xu, Wei-peng Chen, Xiao-jing Du, Chun-xian Ou, Zi-kang Luo, Rong Wang, Chu-qing Zhang, Chao-dong Ge, Meng Han, Fudi Wang, Rong-Rong He, Wan-yang Sun, Jun Ma, Xiao-yu Liang, Zhuo-wei Liu
Nature Chemical Biology.2024; 20(10): 1341. CrossRef - Network pharmacology and molecular docking technology for exploring the effect and mechanism of high-dose vitamin c on ferroptosis of tumor cells: A review
Jinxiu Qu, Shuai Lu, Bing Wang, Shiwan Wang, Zhenpeng Yang, Huazhen Tang, Jia He, Yuan Zhao, Xin Wang, Xiaozhu Liu, Benqiang Rao
Medicine.2024; 103(20): e38189. CrossRef - A ferroptosis-related signature predicts the clinical diagnosis and prognosis, and associates with the immune microenvironment of lung cancer
Hua Zhou, Xiaoting Zhou, Runying Zhu, Zhongquan Zhao, Kang Yang, Zhenghai Shen, Hongwen Sun
Discover Oncology.2024;[Epub] CrossRef - CDKN2A inhibited ferroptosis through activating JAK2/STAT3 pathway to modulate cisplatin resistance in cervical squamous cell carcinoma
Xiang Yong, Yanling Zhang, Heng Tang, Huaiyuan Hu, Rui Song, Qiang Wu
Anti-Cancer Drugs.2024; 35(8): 698. CrossRef - Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance
Celine Kapper, Peter Oppelt, Barbara Arbeithuber, Ayberk Alp Gyunesh, Ivona Vilusic, Patrick Stelzl, Marlene Rezk-Füreder
Life Sciences.2024; 349: 122720. CrossRef - Cysteine substitutants emerge in lung cancer proteomes during arginine restriction
Dennis J. Hsu, Sohail F. Tavazoie
Molecular Cell.2024; 84(10): 1819. CrossRef - The role of ferroptosis in radiotherapy and combination therapy for head and neck squamous cell carcinoma (Review)
Yu Feng, Xiulei Li, Bingwu Yang, Maocai Li, Yongya Du, Jing Wang, Siyu Liu, Lili Gong, Lianqing Li, Lei Gao
Oncology Reports.2024;[Epub] CrossRef - Ferroptosis and cuproptosis: Metal-dependent cell death pathways activated in response to classical chemotherapy – Significance for cancer treatment?
M. Kciuk, A. Gielecińska, Ż. Kałuzińska-Kołat, E.B. Yahya, R. Kontek
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2024; 1879(4): 189124. CrossRef - Curcumin suppresses colorectal cancer by induction of ferroptosis via regulation of p53 and solute carrier family 7 member 11/glutathione/glutathione peroxidase 4 signaling axis
Tianqi Ming, Jiarong Lei, Yuhui Peng, Minmin Wang, Yuanjing Liang, Shun Tang, Qiu Tao, Muqing Wang, Xiaomeng Tang, Ziyu He, Xiaohong Liu, Haibo Xu
Phytotherapy Research.2024; 38(8): 3954. CrossRef - Ferroptosis: A double-edged sword
Shengmei Wang, Qiuyan Guo, Lili Zhou, Xinhua Xia
Cell Death Discovery.2024;[Epub] CrossRef - Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions
Jiaan Lu, Ru He, Yang Liu, Jinghan Zhang, Heng Xu, Tianchi Zhang, Li Chen, Guanhu Yang, Jun Zhang, Jie Liu, Hao Chi
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef - Unveiling ferroptosis as a promising therapeutic avenue for colorectal cancer and colitis treatment
Aaron T. Kao, Christian V. Cabanlong, Kendra Padilla, Xiang Xue
Acta Pharmaceutica Sinica B.2024; 14(9): 3785. CrossRef - The Role of Nrf2 in the Regulation of Mitochondrial Function and Ferroptosis in Pancreatic Cancer
Dinara Baiskhanova, Heiner Schäfer
Antioxidants.2024; 13(6): 696. CrossRef - Ferroptosis: principles and significance in health and disease
Fangquan Chen, Rui Kang, Daolin Tang, Jiao Liu
Journal of Hematology & Oncology.2024;[Epub] CrossRef - Micro-PIXE reveals cisplatin uptake followed by Fe accumulation in U87 cells
Henrique Fonteles, T. S. Klippel, Julia Marcolin, Deiverti Bauer, Daphne Torgo, Laura Boose, Karine Begnini, Eduardo Filippi-Chiela, Guido Lenz, Johnny Ferraz Dias, Pedro Luis Grande
Journal of Analytical Atomic Spectrometry.2024; 39(8): 2087. CrossRef - Retinoic acid receptor alpha inhibits ferroptosis by promoting thioredoxin and protein phosphatase 1F in lung adenocarcinoma
Yunyi Bian, Guangyao Shan, Jiaqi Liang, Zhengyang Hu, Qihai Sui, Haochun Shi, Qun Wang, Guoshu Bi, Cheng Zhan
Communications Biology.2024;[Epub] CrossRef - TRIM33 enhances the ubiquitination of TFRC to enhance the susceptibility of liver cancer cells to ferroptosis
Wenjing Ji, Weibin Zhang, Xin Zhang, Yue Ke
Cellular Signalling.2024; 121: 111268. CrossRef - Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation
Yu Cao, Chang Lu, Narasimha M. Beeraka, Sergey Efetov, Mikhail Enikeev, Yu Fu, Xinyi Yang, Basappa Basappa, Mingze He, Zhi Li
Frontiers in Immunology.2024;[Epub] CrossRef - The metabolites from traditional Chinese medicine targeting ferroptosis for cancer therapy
Yu Tang, Ying Zhuang, Chuanxiang Zhao, Shuangshuang Gu, Junya Zhang, Shiqi Bi, Ming Wang, Lei Bao, Mei Li, Wei Zhang, Liqun Zhu
Frontiers in Pharmacology.2024;[Epub] CrossRef - Ferroptosis-inducing compounds synergize with docetaxel to overcome chemoresistance in docetaxel-resistant non-small cell lung cancer cells
Wei Huang, Yi Guo, Yazhi Qian, Xiaoang Liu, Gaoxiang Li, Jun Wang, Xiaozhou Yang, Mo Wu, Ying Fan, Haojun Luo, Yuzhu Chen, Liangren Zhang, Nan Yang, Zhenming Liu, Yanyong Liu
European Journal of Medicinal Chemistry.2024; 276: 116670. CrossRef - The role of hydrogen sulfide regulation of ferroptosis in different diseases
Jingwen Lian, Yuhang Chen, Yanting Zhang, Shiyun Guo, Honggang Wang
Apoptosis.2024; 29(9-10): 1377. CrossRef - Glutathione-Dependent Pathways in Cancer Cells
Elena Kalinina
International Journal of Molecular Sciences.2024; 25(15): 8423. CrossRef - Potential therapies for HCC involving targeting the ferroptosis pathway
Denghui Li
American Journal of Cancer Research.2024; 14(4): 1446. CrossRef - Loss of Lipocalin2 confers cisplatin vulnerability through modulating NF-ĸB mediated ferroptosis via ferroportin
Meibao Feng
American Journal of Cancer Research.2024; 14(5): 2088. CrossRef - Ropivacaine prompts ferroptosis to enhance the cisplatin-sensitivity of human colorectal cancer through SIRT1/Nrf2 signaling pathway
Lian Zeng, WenBo Zhao, Tiantian Han, Fangfang Qing, Zhongshi He, Qiang Zhao, Ailin Luo, Pengchao Hu, Xudong Ding, Zhen Zhang
Chemico-Biological Interactions.2024; 400: 111163. CrossRef - Dihydroisotanshinone I regulates ferroptosis via PI3K/AKT pathway to enhance cisplatin sensitivity in lung adenocarcinoma
Feng-Jiao Li, Li-Chen Gao, Hui-Zhi Long, Zi-Wei Zhou, Hong-Yu Luo, Shuo-Guo Xu, Shang-Ming Dai, Jin-Da Hu
Journal of Pharmacy and Pharmacology.2024;[Epub] CrossRef - Ferroptosis: Molecular perspective, cellular influence, cancer manifestation, and therapeutic potentials
Pawan Kumar Pandey, Saurabh Bhorkade, Shikha Jha, Brojendra Nath Saren, Kaushik Kuche, Sanyog Jain
Journal of Drug Delivery Science and Technology.2024; 100: 105998. CrossRef - Cell Death and Survival Mechanisms in Cholangiocarcinogenesis
Luana D'Artista, Marco Seehawer
The American Journal of Pathology.2024;[Epub] CrossRef - The interplay of transition metals in ferroptosis and pyroptosis
Frantisek Vana, Zoltan Szabo, Michal Masarik, Monika Kratochvilova
Cell Division.2024;[Epub] CrossRef - SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors
Yingshu Cui, Yi Li, Yuanyuan Xu, Xinxin Liu, Xiaofeng Kang, Junwen Zhu, Shan Long, Yuchen Han, Chunyuan Xue, Zhijia Sun, Yimeng Du, Jia Hu, Lu Pan, Feifan Zhou, Xiaojie Xu, Xiaosong Li
Redox Biology.2024; 76: 103304. CrossRef - Ellagic acid ameliorates arsenic-induced neuronal ferroptosis and cognitive impairment via Nrf2/GPX4 signaling pathway
Xiyue Yang, Fang Chu, Zhe Jiao, Hao Yu, Wenjing Yang, Yang Li, Chunqing Lu, Hao Ma, Sheng Wang, Zhipeng Liu, Shaoxiao Qin, Hongna Sun
Ecotoxicology and Environmental Safety.2024; 283: 116833. CrossRef - Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S. Fleishman, Sihang Cheng, Weixue Wang, Fan Wu, Yumin Wang, Yu Wang
Molecular Cancer.2024;[Epub] CrossRef - Targeting ferroptosis as a potential prevention and treatment strategy for aging-related diseases
Taiwei Jiao, Yiman Chen, Haiyan Sun, Lina Yang
Pharmacological Research.2024; 208: 107370. CrossRef - A new therapeutic strategy for luminal A-breast cancer treatment: vulpinic acid as an anti-neoplastic agent induces ferroptosis and apoptosis mechanisms
Ayşe Hale Alkan, Mine Ensoy, Demet Cansaran-Duman
Medical Oncology.2024;[Epub] CrossRef - FOXO1‐NCOA4 Axis Contributes to Cisplatin‐Induced Cochlea Spiral Ganglion Neuron Ferroptosis via Ferritinophagy
Xue Wang, Lei Xu, Yu Meng, Fang Chen, Jinzhu Zhuang, Man Wang, Weibin An, Yuechen Han, Bo Chu, Renjie Chai, Wenwen Liu, Haibo Wang
Advanced Science.2024;[Epub] CrossRef - Targeting Ferroptosis with Small Molecule Atranorin (ATR) as a Novel Therapeutic Strategy and Providing New Insight into the Treatment of Breast Cancer
Mine Ensoy, Demet Cansaran-Duman
Pharmaceuticals.2024; 17(10): 1380. CrossRef - Asiatic acid induces lung cancer toxicity by triggering SRC-mediated ferroptosis
Huizhen Li, Guixuan Fang, Wen Tian, Yinglin Liao, Jing Xiang, Yingying Hu, Lianxiang Luo
Toxicology and Applied Pharmacology.2024; 492: 117097. CrossRef - UBR5 mediates colorectal cancer chemoresistance by attenuating ferroptosis via Lys 11 ubiquitin-dependent stabilization of Smad3-SLC7A11 signaling
Mei Song, Shuting Huang, Xiaoxue Wu, Ziyi Zhao, Xiaoting Liu, Chong Wu, Mengru Wang, Jialing Gao, Zunfu Ke, Xiaojing Ma, Weiling He
Redox Biology.2024; 76: 103349. CrossRef - Regulating ferroptosis by non-coding RNAs in hepatocellular carcinoma
Lijie Sun, Hongfei Cao, Yanzhe Wang, Hongquan Wang
Biology Direct.2024;[Epub] CrossRef - Emerging Therapeutic Approaches Targeting Ferroptosis in Cancer:
Focus on Immunotherapy and Nanotechnology
Zongchao Yu, Zhongcheng Mo, Yuan Qiu, Hengzhe Lu, Biao Zheng, Longfei Liu
Current Pharmaceutical Biotechnology.2024; 25(15): 2012. CrossRef - Inorganic Nanomedicine—Mediated Ferroptosis: A Synergistic Approach to Combined Cancer Therapies and Immunotherapy
Adityanarayan Mohapatra, Ayeskanta Mohanty, In-Kyu Park
Cancers.2024; 16(18): 3210. CrossRef - Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis
Yunyi Bian, Guangyao Shan, Guoshu Bi, Jiaqi Liang, Zhengyang Hu, Qihai Sui, Haochun Shi, Zhaolin Zheng, Guangyu Yao, Qun Wang, Hong Fan, Cheng Zhan
Redox Biology.2024; 77: 103361. CrossRef - Research progress on ferroptosis in colorectal cancer
Yuan Li, Yao Bi, Wenjing Li, Yingshi Piao, Junjie Piao, Tong Wang, Xiangshan Ren
Frontiers in Immunology.2024;[Epub] CrossRef - A Pan-Cancer Analysis of Ferroptosis-Related Gene Arachidonic Acid 15-Lipoxygenase-1 (ALOX15): Its Prognostic and Immunotherapeutic Values
Hua Yang
Cytology and Genetics.2024; 58(5): 456. CrossRef - Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma
Jiasi Zhang, Yuxi Liu, Liping Zuo, Fengjuan Fan, Han Yan, Fei Zhao, Junying Li, Chi Ma, Qun Li, Aoshuang Xu, Jian Xu, Bo Zhang, Yu Hu, Chunyan Sun
Blood Advances.2024; 8(19): 5022. CrossRef - Mechanosensitive fluorescence lifetime probes for investigating the dynamic mechanism of ferroptosis
Xing Liang, Yuping Zhao, Jun Yan, Qian Zhang, Tony D. James, Weiying Lin
Proceedings of the National Academy of Sciences.2024;[Epub] CrossRef - Mechanisms of ferroptosis and targeted therapeutic approaches in urological malignancies
Wenjie Ma, Xiaotian Jiang, Ruipeng Jia, Yang Li
Cell Death Discovery.2024;[Epub] CrossRef - The melatonin-FTO-ATF4 signaling pathway protects granulosa cells from cisplatin-induced chemotherapeutic toxicity by suppressing ferroptosis
Rongli Wang, Jing Geng
Journal of Assisted Reproduction and Genetics.2024;[Epub] CrossRef - Therapeutic efficacy of ferroptosis in the treatment of colorectal cancer (Review)
Zhao Guo, Haoyan Zhuang, Xuewen Shi
Oncology Letters.2024;[Epub] CrossRef - The Potential Role of Non-coding RNAs in Regulating Ferroptosis in Cancer: Mechanisms and Application Prospects
Ming-Yuan Cao, Zhen-Dong Zhang, Xin-Rui Hou, Xiao-Ping Wang
Anti-Cancer Agents in Medicinal Chemistry.2024; 24(16): 1182. CrossRef - A herbal pair of Scutellaria barbata D. Don and Scleromitrion diffusum (Willd.) R.J. Wang induced ferroptosis in ovarian cancer A2780 cells via inducing heme catabolism and ferritinophagy
Zhen Wang, Min Liu, Guang-xing Li, Liu Zhang, Kai-yue Ding, Si-qi Li, Bing-qing Gao, Peng Chen, Hyok-Chol Choe, Lun-yue Xia, Yu-tong Yang, Yi Liu, Xue Sui, Jun-nan Ma, Lin Zhang
Journal of Integrative Medicine.2024; 22(6): 665. CrossRef - Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies
Elsayed A. Elmorsy, Sameh Saber, Rabab S. Hamad, Mustafa Ahmed Abdel-Reheim, Attalla F. El-kott, Mohammed A. AlShehri, Kareem Morsy, Salama A. Salama, Mahmoud E. Youssef
European Journal of Pharmaceutical Sciences.2024; 203: 106939. CrossRef - Natural product mitigation of ferroptosis in platinum-based chemotherapy toxicity: targeting the underpinning oxidative signaling pathways
Ademola C Famurewa, Nupura Manish Prabhune, Sudharshan Prabhu
Journal of Pharmacy and Pharmacology.2024;[Epub] CrossRef - Critical role of non-coding RNA-mediated ferroptosis in urologic malignancies
Wei Li, Liying Zheng, Peiyue Luo, Tao Chen, Jun Zou, Qi Chen, Le Cheng, Lifeng Gan, Fangtao Zhang, Biao Qian
Frontiers in Immunology.2024;[Epub] CrossRef - Targeting ferroptosis with polymerized platinum (IV) prodrugs nanoparticles with everolimus for enhancing therapeutic efficacy on cholangiocarcinoma
Yang Chen, Jia Huang, Hanchen Zhang, Fuzhen Hu, Zheng Cao, Zhiying Yang, Haiqin Song, Rong Liu
Nano Today.2024; 59: 102531. CrossRef - Targeted Positron Emission Tomography-Tracked Biomimetic Codelivery Synergistically Amplifies Ferroptosis and Pyroptosis for Inducing Lung Cancer Regression and Anti-PD-L1 Immunotherapy Efficacy
Jinyu Zhu, Wenyuan Zhou, Yuan Yao, Xin Zhou, Xiaokun Ma, Baohui Zhang, Zhi Yang, Bufu Tang, Hua Zhu, Nan Li
ACS Nano.2024; 18(45): 31401. CrossRef - Genetic profile of ferroptosis in non-small cell lung carcinoma and pharmaceutical options for ferroptosis induction
Rohil Jawed, Huma Bhatti, Adnan khan
Clinical and Translational Oncology.2024;[Epub] CrossRef - Quantitative determination and subcellular mapping of Pt-based drugs in single breast tumour cells via laser ablation-ICP-mass spectrometry
Legna Colina-Vegas, Thibaut Van Acker, Wilmer Villarreal, Olivier De Wever, Alzir Azevedo Batista, Joaquim Araújo Nóbrega, Frank Vanhaecke
Dalton Transactions.2024; 53(47): 18880. CrossRef - STUB1 suppresses paclitaxel resistance in ovarian cancer through mediating HOXB3 ubiquitination to inhibit PARK7 expression
Laigang Zhao, HanLin Yang, Yuanmei Wang, Shuang Yang, Qisi Jiang, Jun Tan, Xing Zhao, Dan Zi
Communications Biology.2024;[Epub] CrossRef - Ferroptosis in Cancer: Epigenetic Control and Therapeutic Opportunities
Roberta Veglia Tranchese, Sabrina Battista, Laura Cerchia, Monica Fedele
Biomolecules.2024; 14(11): 1443. CrossRef - LncRNA MALAT1 promotes Erastin-induced ferroptosis in the HBV-infected diffuse large B-cell lymphoma
Xiaofei Bai, Jianguo Li, Xuecong Guo, Yinghui Huang, Xu Xu, Ailing Tan, Yisha Jia, Qiaoyi Sun, Xudong Guo, Jie Chen, Jiuhong Kang
Cell Death & Disease.2024;[Epub] CrossRef - MDM4 inhibits ferroptosis in p53 mutant colon cancer via regulating TRIM21/GPX4 expression
Jie Liu, Xujin Wei, Yixuan Xie, Yuxiang Yan, Sihui Xue, Xiangyu Wang, Han Chen, Qilong Pan, Sisi Yan, Xiaoling Zheng, Qingling Huang
Cell Death & Disease.2024;[Epub] CrossRef - RETRACTED ARTICLE: CKS2 induces autophagy-mediated glutathione metabolic reprogramming to facilitate ferroptosis resistance in colon cancer
Leilei Yang, Chengfeng Fang, Jiaju Han, Yufeng Ren, Zaiping Yang, Lingyan Shen, Dinghai Luo, Ruili Zhang, Yan Chen, Shenkang Zhou
Molecular Medicine.2024;[Epub] CrossRef - Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
Ruchi Saxena, Craig M. Welsh, You-Wen He
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef - Ferroptosis: mechanisms and therapeutic targets
Qian Zhou, Yu Meng, Jiayuan Le, Yuming Sun, Yating Dian, Lei Yao, Yixiao Xiong, Furong Zeng, Xiang Chen, Guangtong Deng
MedComm.2024;[Epub] CrossRef - Mechanism of ferroptosis resistance in cancer cells
Yuan Wang, Guifang Yu, Xin Chen
Cancer Drug Resistance.2024;[Epub] CrossRef - Clinicopathological characteristics of invasive stratified mucinous carcinoma of the cervix and the expression and clinical significance of SLC7A11, SLC3A2 and PD-L1
Changyu Lu, Wei Zhu, Xiahui Han, Xiuzhen Du, Hui Zhang, Qin Yao, Ting Liu, Ce Zhang
Frontiers in Oncology.2024;[Epub] CrossRef - Infection of Helicobacter pylori contributes to the progression of gastric cancer through ferroptosis
Yun Liu, Renjie Miao, Jinxuan Xia, Yong Zhou, Jun Yao, Shihe Shao
Cell Death Discovery.2024;[Epub] CrossRef - Synergistic effects of dihydroartemisinin and cisplatin on inducing ferroptosis in gastric cancer through GPX4 inhibition
Huina Wang, Chanchan Lu, Haihua Zhou, Xiaojun Zhao, Chuanjiang Huang, Zhiyi Cheng, Guiyuan Liu, Xiaolan You
Gastric Cancer.2024;[Epub] CrossRef - Non‑coding RNA‑mediated epigenetic modification of ferroptosis in non‑small cell lung cancer (Review)
Yumin Wang, Joshua Fleishman, Yulin Li, Yuwei Cao, Haidong Wei, Zhe Zhang, Jichao Chen, Mingchao Ding
International Journal of Oncology.2024;[Epub] CrossRef - Overexpressed transferrin receptor implied poor prognosis and relapse in gastrointestinal stromal tumors
Chun Zhuang, Xiaoqi Li, Linxi Yang, Xinli Ma, Yanying Shen, Chen Huang, Tao Pan, Jianzhi Cui, Bo Ni, Ming Wang
Frontiers in Oncology.2023;[Epub] CrossRef - Nitroimidazoles Part 10. Synthesis, crystal structure, molecular docking, and anticancer evaluation of 4-nitroimidazole derivatives combined with piperazine moiety
Yaseen A. Al-Soud, Sadeekah O. W. Saber, Amneh Shtaiwi, Sondos O. Alsawakhneh, Kafa’ A. S. Alhelal, Qusay F. A. Salman, Luay Abu-Qatouseh, Monther A. Khanfar, Raed A. Al-Qawasmeh
Zeitschrift für Naturforschung C.2023; 78(3-4): 93. CrossRef - The role of ferroptosis in prostate cancer: a novel therapeutic strategy
Yue Wang, Yifan Ma, Kui Jiang
Prostate Cancer and Prostatic Diseases.2023; 26(1): 25. CrossRef - Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways
Nasrin Ghassemi-Barghi, Zeynab Ehsanfar, Omid Mohammadrezakhani, Sorour Ashari, Shamim Ghiabi, Zahra Bayrami
Inflammation.2023; 46(1): 342. CrossRef - Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy
Amir Ajoolabady, Daolin Tang, Guido Kroemer, Jun Ren
British Journal of Cancer.2023; 128(2): 190. CrossRef - Metal complexes induced ferroptosis for anticancer therapy
Shumeng Li, Hao Yuan, Yuncong Chen, Zijian Guo
Fundamental Research.2023; 3(4): 525. CrossRef - Arenobufagin causes ferroptosis in human gastric cancer cells by increasing rev-erbα expression
Ke Chen, Angling Li, Jian Wang, Dongchang Li, Xiaoshan Wang, Chengwei Liu, Zhengguang Wang
Journal of Traditional and Complementary Medicine.2023; 13(1): 72. CrossRef - Research trends in ferroptosis since the origin of the concept: A bibliometric analysis
Huimin Deng, Juan Wei, Keting Min, Hao Yang, Sheng Wang, Zhuoran Xiao, Meiyun Liu, Li Zheng, Huanping Zhou, Yuanli Chen, Wanli Zhu, Quanfu Li, Xin Lv
Clinical and Experimental Pharmacology and Physiology.2023; 50(2): 149. CrossRef - Targeting lipid metabolism for ferroptotic cancer therapy
Minhua Luo, Jiajing Yan, Xinyu Hu, Haolong Li, Hongsheng Li, Quentin Liu, Yibing Chen, Zhengzhi Zou
Apoptosis.2023; 28(1-2): 81. CrossRef - Metal-free polymer nano-photosensitizer actuates ferroptosis in starved cancer
Dapeng Chen, Chen Liang, Xinyu Qu, Tian Zhang, Xiaozhou Mou, Yu Cai, Wenjun Wang, Jinjun Shao, Xiaochen Dong
Biomaterials.2023; 292: 121944. CrossRef - Targeting ferroptosis: Paving new roads for drug design and discovery
Yilin Gu, Yizhe Li, Jiaxing Wang, Lele Zhang, Jifa Zhang, Yuxi Wang
European Journal of Medicinal Chemistry.2023; 247: 115015. CrossRef - Ferroptosis: a potential therapeutic target for Alzheimer’s disease
Lan Yang, Jianfei Nao
Reviews in the Neurosciences.2023; 34(5): 573. CrossRef - Mechanism and application of ferroptosis in colorectal cancer
Liu Yang, Yewei Zhang, Yingyi Zhang, Zhe Fan
Biomedicine & Pharmacotherapy.2023; 158: 114102. CrossRef - Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Yumin Wang, Xiaorui Wu, Zhao Ren, Yulin Li, Wailong Zou, Jichao Chen, Hongquan Wang
Drug Resistance Updates.2023; 66: 100916. CrossRef - Amplified Fenton-Based Oxidative Stress Utilizing Ultraviolet Upconversion Luminescence-Fueled Nanoreactors for Apoptosis-Strengthened Ferroptosis Anticancer Therapy
Nguyen Thi Nguyen, Juho Kim, Xuan Thien Le, Woo Tak Lee, Eun Seong Lee, Kyung Taek Oh, Han-Gon Choi, Yu Seok Youn
ACS Nano.2023; 17(1): 382. CrossRef - NaErF4-Based Nanocarrier for Enhanced Ferroptosis Therapy of Cancer
Jin-Yang Liu, Na Liu, Yue Wu, Xiao-Min Ning, Wen-Chao Zhang, Jing Qian
ACS Applied Nano Materials.2023; 6(1): 270. CrossRef - Liposomes embedded with PEGylated iron oxide nanoparticles enable ferroptosis and combination therapy in cancer
Yang Liu, Xuebo Quan, Jie Li, Jiawei Huo, Xing Li, Zhongpu Zhao, Shumu Li, Jing Wan, Jiao Li, Shuai Liu, Tao Wang, Xing Zhang, Bo Guan, Rui Wen, Zhenwen Zhao, Chunru Wang, Chunli Bai
National Science Review.2023;[Epub] CrossRef - Review and Chemoinformatic Analysis of Ferroptosis Modulators with a Focus on Natural Plant Products
Višnja Stepanić, Marta Kučerová-Chlupáčová
Molecules.2023; 28(2): 475. CrossRef - Mechanism of ferroptosis in traditional chinese medicine for clinical treatment: A review
Jiajiao Liu, Guanyin Jiang, Pengfei He, Xing Du, Zhenming Hu, Fuxiang Li
Frontiers in Pharmacology.2023;[Epub] CrossRef - Glutathione metabolism rewiring protects renal tubule cells against cisplatin-induced apoptosis and ferroptosis
Xing-Qiang Dong, Li-Kai Chu, Xu Cao, Qian-Wei Xiong, Yi-Ming Mao, Ching-Hsien Chen, Yun-Li Bi, Jun Liu, Xiang-Ming Yan
Redox Report.2023;[Epub] CrossRef - Review of ferroptosis in colorectal cancer: Friends or foes?
Zheng Wu, Ze-Xuan Fang, Yan-Yu Hou, Bing-Xuan Wu, Yu Deng, Hua-Tao Wu, Jing Liu
World Journal of Gastroenterology.2023; 29(3): 469. CrossRef - Ferroptosis as a therapeutic target for inflammation-related intestinal diseases
Xiaoli Zhang, Yiming Ma, Guoqing Lv, Hongying Wang
Frontiers in Pharmacology.2023;[Epub] CrossRef - Crosstalk between microwave ablation and ferroptosis: The next hot topic?
Lu Yu, Min Cheng, Jie Liu, Xin Ye, Zhigang Wei, Jiamei Xu, Qi Xie, Jing Liang
Frontiers in Oncology.2023;[Epub] CrossRef - Progress in the study of ferroptosis in cancer treatment: State-of-the-Art
Dong Wang
Chemico-Biological Interactions.2023; 371: 110348. CrossRef - RNA methylation and cellular response to oxidative stress-promoting anticancer agents
Marco Ponzetti, Nadia Rucci, Stefano Falone
Cell Cycle.2023; 22(8): 870. CrossRef - Open pocket and tighten holes: Inhalable lung cancer-targeted nanocomposite for enhanced ferroptosis-apoptosis synergetic therapy
Wenhua Wang, Wenhao Wang, Shiwei Jin, Fangqin Fu, Zhengwei Huang, Ying Huang, Chuanbin Wu, Xin Pan
Chemical Engineering Journal.2023; 458: 141487. CrossRef - Iron as a therapeutic target in chronic liver disease
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki
World Journal of Gastroenterology.2023; 29(4): 616. CrossRef - Ferroptosis in colorectal cancer: a future target?
Hong Yan, Ronan Talty, Oladimeji Aladelokun, Marcus Bosenberg, Caroline H. Johnson
British Journal of Cancer.2023; 128(8): 1439. CrossRef - Targeting critical pathways in ferroptosis and enhancing antitumor therapy of Platinum drugs for colorectal cancer
Gang Wang, Jun-Jie Wang, Zhu Zhi-Min, Xiao-Na Xu, Feng Shi, Xing-Li Fu
Science Progress.2023;[Epub] CrossRef - Solute Carrier Family 7 Member 11 (SLC7A11) is a Potential Prognostic Biomarker in Uterine Corpus Endometrial Carcinoma
Xiangming Fang, Ting Zhang, Zhitao Chen
International Journal of General Medicine.2023; Volume 16: 481. CrossRef - Overexpression of PRDX2 in Adipose-Derived Mesenchymal Stem Cells Enhances the Therapeutic Effect in a Neurogenic Erectile Dysfunction Rat Model by Inhibiting Ferroptosis
Peng Chen, Zehong Chen, Jiancheng Zhai, Wende Yang, Hongbo Wei, Víctor M. Mendoza-Núñez
Oxidative Medicine and Cellular Longevity.2023; 2023: 1. CrossRef - Ferroptosis: challenges and opportunities for nanomaterials in cancer therapy
Qiaolin Liu, Yuliang Zhao, Huige Zhou, Chunying Chen
Regenerative Biomaterials.2023;[Epub] CrossRef - miR-29a-5p modulates ferroptosis by targeting ferritin heavy chain FTH1 in prostate cancer
Guang Yang, Qi Pan, Yang Lu, Junlong Zhu, Xin Gou
Biochemical and Biophysical Research Communications.2023; 652: 6. CrossRef - Reactive Oxygen Species and Ferroptosis at the Nexus of Inflammation and Colon Cancer
Wesley Huang, Noora Aabed, Yatrik M. Shah
Antioxidants & Redox Signaling.2023; 39(7-9): 551. CrossRef - Cell death, therapeutics, and the immune response in cancer
Kay Hänggi, Brian Ruffell
Trends in Cancer.2023; 9(5): 381. CrossRef - Ferroptosis-related metabolic mechanism and nanoparticulate anticancer drug delivery systems based on ferroptosis
Danni Yan, Zhenghong Wu, Xiaole Qi
Saudi Pharmaceutical Journal.2023; 31(4): 554. CrossRef - Molecular Mechanisms of Nemorosone-Induced Ferroptosis in Cancer Cells
Roberto Fernández-Acosta, Behrouz Hassannia, Jurgen Caroen, Bartosz Wiernicki, Daniel Alvarez-Alminaque, Bruno Verstraeten, Johan Van der Eycken, Peter Vandenabeele, Tom Vanden Berghe, Gilberto L. Pardo-Andreu
Cells.2023; 12(5): 735. CrossRef - Ferroptosis As Ultimate Target of Cancer Therapy
Yashiro Motooka, Shinya Toyokuni
Antioxidants & Redox Signaling.2023; 39(1-3): 206. CrossRef - Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer
Federica Maccarinelli, Daniela Coltrini, Silvia Mussi, Mattia Bugatti, Marta Turati, Paola Chiodelli, Arianna Giacomini, Floriana De Cillis, Nadia Cattane, Annamaria Cattaneo, Alessia Ligresti, Michela Asperti, Maura Poli, William Vermi, Marco Presta, Rob
Cell Death Discovery.2023;[Epub] CrossRef - Identification of cuproptosis hub genes contributing to the immune microenvironment in ulcerative colitis using bioinformatic analysis and experimental verification
Cejun Yang, Wendi Wang, Sang Li, Zhengkang Qiao, Xiaoqian Ma, Min Yang, Juan Zhang, Lu Cao, Shanhu Yao, Zhe Yang, Wei Wang
Frontiers in Immunology.2023;[Epub] CrossRef - The unfolding story of dying tumor cells during cancer treatment
Sijia He, Qian Huang, Jin Cheng
Frontiers in Immunology.2023;[Epub] CrossRef - Engineered exosomes from different sources for cancer-targeted therapy
Menghui Zhang, Shengyun Hu, Lin Liu, Pengyuan Dang, Yang Liu, Zhenqiang Sun, Bingbing Qiao, Chengzeng Wang
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef - Development and validation of a combined hypoxia and ferroptosis prognostic signature for breast cancer
Jianxin Zhong, Xi Shen, Junjie Zhou, Heping Yu, Birong Wang, Jianbin Sun, Jing Wang, Feng Liu
Frontiers in Oncology.2023;[Epub] CrossRef - Mechanism of ferroptosis in a rat model of premature ovarian insufficiency induced by cisplatin
Rong Du, Xi Cheng, Jingjing Ji, Yang Lu, Yuanyuan Xie, Weina Wang, Yanhua Xu, Yuquan Zhang
Scientific Reports.2023;[Epub] CrossRef - An anticancer Ti(IV) complex increases mitochondrial reactive oxygen species levels in relation with hypoxia and endoplasmic-reticulum stress: A distinct non DNA-related mechanism
Zohar Shpilt, Naomi Melamed-Book, Edit Y. Tshuva
Journal of Inorganic Biochemistry.2023; 243: 112197. CrossRef - Ferroptosis: Mechanism and potential applications in cervical cancer
Xiangyu Chang, Jinwei Miao
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef - Ferroptosis in gastrointestinal cancer: from mechanisms to implications
Ruoxi Zhang, Rui Kang, Daolin Tang
Cancer Letters.2023; 561: 216147. CrossRef - Ferroptosis Detection: From Approaches to Applications
Fantian Zeng, Sureya Nijiati, Longguang Tang, Jinmin Ye, Zijian Zhou, Xiaoyuan Chen
Angewandte Chemie International Edition.2023;[Epub] CrossRef - Ferroptosis Detection: From Approaches to Applications
Fantian Zeng, Sureya Nijiati, Longguang Tang, Jinmin Ye, Zijian Zhou, Xiaoyuan Chen
Angewandte Chemie.2023;[Epub] CrossRef - The Regulation Role of Ferroptosis Mechanism of Anti-Cancer Drugs
and Noncoding RNAs
Mine Ensoy, Zehra Sena Bumin, Huda Abdirizak Jama, Demet Cansaran-Duman
Current Medicinal Chemistry.2023; 30(14): 1638. CrossRef - Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment
Jingjuan Zhu, Xiao Xu, Man Jiang, Fangfang Yang, Yingying Mei, Xiaochun Zhang
Frontiers in Oncology.2023;[Epub] CrossRef - Ferroptosis in lung cancer: a novel pathway regulating cell death and a promising target for drug therapy
Nan Xing, Qinyun Du, Sa Guo, Gelin Xiang, Yi Zhang, Xianli Meng, Li Xiang, Shaohui Wang
Cell Death Discovery.2023;[Epub] CrossRef - Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling
Solveigh C. Koeberle, Anna P. Kipp, Hermann Stuppner, Andreas Koeberle
Medicinal Research Reviews.2023; 43(3): 614. CrossRef - Implication of Ferroptosis in Cholangiocarcinoma: A Potential Future Target?
Mingyu Yang, Meng Li, Zhuozhen Lyu, Zhen Yang
Cancer Management and Research.2023; Volume 15: 335. CrossRef - A review of nemorosone: Chemistry and biological properties
Osmany Cuesta-Rubio, Lianet Monzote, Roberto Fernández-Acosta, Gilberto Lázaro Pardo-Andreu, Luca Rastrelli
Phytochemistry.2023; 210: 113674. CrossRef - Ferroptosis landscape in prostate cancer from molecular and metabolic perspective
Jiaming Liang, Yihao Liao, Pu Wang, Kun Yang, Youzhi Wang, Keke Wang, Boqiang Zhong, Diansheng Zhou, Qian Cao, Junbo Li, Yang Zhao, Ning Jiang
Cell Death Discovery.2023;[Epub] CrossRef - Gallium maltolate shows synergism with cisplatin and activates nucleolar stress and ferroptosis in human breast carcinoma cells
Chieh-Hsin Chen, Yi-Ming Huang, Louis Grillet, Yu-Chen Hsieh, Ya-Wen Yang, Kai-Yin Lo
Cellular Oncology.2023; 46(4): 1127. CrossRef - Ferroptosis regulates key signaling pathways in gastrointestinal tumors: Underlying mechanisms and therapeutic strategies
Ravichandiran Rabitha, Sethuraman Shivani, Yahya Showket, Ganapasam Sudhandiran
World Journal of Gastroenterology.2023; 29(16): 2433. CrossRef - Ginsenoside Rh3 induces pyroptosis and ferroptosis through the Stat3/p53/NRF2 axis in colorectal cancer cells
Yingchao Wu, Dajin Pi, Shuyao Zhou, Zhongjia Yi, Yangyang Dong, Wuhong Wang, Huan Ye, Yiliu Chen, Qian Zuo, Mingzi Ouyang
Acta Biochimica et Biophysica Sinica.2023; 55(4): 587. CrossRef - Modulation of Ferroptosis by microRNAs in Human Cancer
Irena Velkova, Martina Pasino, Zumama Khalid, Paola Menichini, Emanuele Martorana, Alberto Izzotti, Alessandra Pulliero
Journal of Personalized Medicine.2023; 13(5): 719. CrossRef - Role of Escin in breast cancer therapy: potential mechanism for inducing ferroptosis and synergistic antitumor activity with cisplatin
Chenyuan Li, Ziqi He, Feng Yao, Shichong Liao, Kai Sun, Shengrong Sun, Zhiyu Li, Zhong Wang
Apoptosis.2023; 28(7-8): 1154. CrossRef - PCBP1 protects bladder cancer cells from mitochondria injury and ferroptosis by inducing LACTB mRNA degradation
Yang Luo, Yunli Zhang, Shiyu Pang, Jingxian Min, Tao Wang, Dali Wu, Chun Lin, Zebin Xiao, Qi Xiang, Qing Li, Lili Ma
Molecular Carcinogenesis.2023; 62(7): 907. CrossRef - Recent Advances of Platinum‐Based Anticancer Complexes in Combinational Multimodal Therapy
Tianyuan Zhong, Jie Yu, Yong Pan, Ning Zhang, Yanxin Qi, Yubin Huang
Advanced Healthcare Materials.2023;[Epub] CrossRef - SIRT3-mediated autophagy contributes to ferroptosis-induced anticancer by inducing the formation of BECN1-SLC7A11 complex
Ping Huang, Han Zhao, Xiafang Pan, Jinying Li, Wentian Pan, Hua Dai, Jia Wang, Chunhua Xia, Fanglan Liu
Biochemical Pharmacology.2023; 213: 115592. CrossRef - AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells
Kaitlyn M. Cahuzac, Abigail Lubin, Kaitlyn Bosch, Nicole Stokes, Sarah Mense Shoenfeld, Royce Zhou, Haddy Lemon, John Asara, Ramon E. Parsons
Cell Reports.2023; 42(5): 112536. CrossRef - CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer
Xiaoqian Zhang, Xiaocui Zheng, Xiang Ying, Weiwei Xie, Yujia Yin, Xipeng Wang
Journal of Translational Medicine.2023;[Epub] CrossRef - Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin
Ryosuke Takahashi, Koki Kamizaki, Keitaro Yamanaka, Yoshito Terai, Yasuhiro Minami
Oncology Reports.2023;[Epub] CrossRef - Exosomal miR-17–92 derived from human mesenchymal stem cells promotes wound healing by enhancing angiogenesis and inhibiting endothelial cell ferroptosis
Wenbo Nie, Xuemiao Huang, Lijing Zhao, Taiwei Wang, Dan Zhang, Tianxin Xu, Lin Du, Yuxiang Li, Weiyuan Zhang, Fengjun Xiao, Lisheng Wang
Tissue and Cell.2023; 83: 102124. CrossRef - Progress in the Mechanism of the Effect of Fe3O4 Nanomaterials on Ferroptosis in Tumor Cells
Yaxuan Wang, Xiao Wu, Xiaoying Bao, Xianbo Mou
Molecules.2023; 28(11): 4562. CrossRef - Donafenib and GSK‐J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression
Chenyang Zheng, Bo Zhang, Yunyun Li, Kejia Liu, Wei Wei, Shuhang Liang, Hongrui Guo, Kun Ma, Yao Liu, Jiabei Wang, Lianxin Liu
Advanced Science.2023;[Epub] CrossRef - Schizochytrium sp. Extracted Lipids Prevent Alopecia by Enhancing Antioxidation and Inhibiting Ferroptosis of Dermal Papilla Cells
Zuye Zeng, Boyu Wang, Muhammad Ibrar, Ming Ying, Shuangfei Li, Xuewei Yang
Antioxidants.2023; 12(7): 1332. CrossRef - Interaction mechanisms between autophagy and ferroptosis: Potential role in colorectal cancer
Xin-Ya Zeng, Xin-Ze Qiu, Jiang-Ni Wu, Sheng-Mei Liang, Jie-An Huang, Shi-Quan Liu
World Journal of Gastrointestinal Oncology.2023; 15(7): 1135. CrossRef - A Novel Bromophenol Compound from Leathesia nana Inhibits Breast Cancer in a Direct Tumor Killing and Immunotherapy Manner
Ruochen Sun, Mi Zhang, Bufan Li, Shan Jiang, Wanpeng Yu, Lina Yang, Yantao Han, Zhangfeng Zhong, Wenwen Zhao
Molecules.2023; 28(14): 5349. CrossRef - “Double-Edged Sword” Effect of Reactive Oxygen Species (ROS) in Tumor Development and Carcinogenesis
W Zhao, P Zhuang, Y Chen, Y Wu, M Zhong, Y Lun
Physiological Research.2023;[Epub] CrossRef - Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy
Xiaogang Zheng, Xiaodong Jin, Fei Ye, Xiongxiong Liu, Boyi Yu, Zheng Li, Ting Zhao, Weiqiang Chen, Xinguo Liu, Cuixia Di, Qiang Li
Experimental Hematology & Oncology.2023;[Epub] CrossRef - Integrated single-cell and bulk RNA sequencing analysis identifies a prognostic signature related to ferroptosis dependence in colorectal cancer
Xiaochen Xu, Xinwen Zhang, Qiumei Lin, Yuling Qin, Yihao Liu, Weizhong Tang
Scientific Reports.2023;[Epub] CrossRef - Targeting Heat Shock Protein 27 and Fatty Acid Oxidation Augments Cisplatin Treatment in Cisplatin-Resistant Ovarian Cancer Cell Lines
James Patrick Heiserman, Zenab Minhas, Elahe Nikpayam, Dong-Joo Cheon
International Journal of Molecular Sciences.2023; 24(16): 12638. CrossRef - A planning strategy may reduce the risk of heart diseases and radiation pneumonia: Avoiding the specific heart substructures
AiHui Feng, YanHua Duan, ZhangRu Yang, Yan Shao, Hao Wang, Hua Chen, HengLe Gu, Ying Huang, ZhenJiong Shen, Xufei Wang, ZhiYong Xu
Journal of Applied Clinical Medical Physics.2023;[Epub] CrossRef - Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance
Yuqing Ren, Xiangrong Mao, Hui Xu, Qin Dang, Siyuan Weng, Yuyuan Zhang, Shuang Chen, Shutong Liu, Yuhao Ba, Zhaokai Zhou, Xinwei Han, Zaoqu Liu, Guojun Zhang
Cellular and Molecular Life Sciences.2023;[Epub] CrossRef - Sinularin Exerts Anti-cancer Effects by Inducing Oxidative Stress-mediated Ferroptosis,
Apoptosis, and Autophagy in Prostate Cancer Cells
ZhengPing Wu, MengQiao Su, HanWu Chen, XuZhou Chen, Chung-Yi Chen, LiJie An, ZiChen Shao, XiaoYu Liu, Yi Lin, Ai-Jun OuYang, Chi-Ming Liu
Anti-Cancer Agents in Medicinal Chemistry.2023; 23(12): 1457. CrossRef - NRF2, a Superstar of Ferroptosis
Ruihan Yan, Bingyi Lin, Wenwei Jin, Ling Tang, Shuming Hu, Rong Cai
Antioxidants.2023; 12(9): 1739. CrossRef - SOCS1 acts as a ferroptosis driver to inhibit the progression and chemotherapy resistance of triple-negative breast cancer
Yiding Wang, Xiaoling Pang, Yuexin Liu, Guiling Mu, Qian Wang
Carcinogenesis.2023; 44(8-9): 708. CrossRef - Ferroptosis, autophagy, tumor and immunity
Yuyan Xie, Yang Zhou, Jiale Wang, Lijuan Du, Yuanyuan Ren, Fang Liu
Heliyon.2023; 9(9): e19799. CrossRef - Ferroptosis regulation by methylation in cancer
Mengqiu Hao, Yixin Jiang, Yang Zhang, Xuyang Yang, Junhong Han
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(6): 188972. CrossRef - FOXA2 Suppression by TRIM36 Exerts Anti‐Tumor Role in Colorectal Cancer Via Inducing NRF2/GPX4‐Regulated Ferroptosis
Xin Liu, Chunli Yan, Chunxiao Chang, Fansong Meng, Wenjie Shen, Song Wang, Yi Zhang
Advanced Science.2023;[Epub] CrossRef - Creation of a Rat Takotsubo Syndrome Model and Utilization of Machine Learning Algorithms for Screening Diagnostic Biomarkers
Hongyu Huai, Junliang Li, Xiangjie Zhang, Qiang Xu, Huan Lan
Journal of Inflammation Research.2023; Volume 16: 4833. CrossRef - Analysis of a new therapeutic target and construction of a prognostic model for breast cancer based on ferroptosis genes
Qi Li, Hengchen Liu, Yun Jin, Yuanquan Yu, Yihang Wang, Di Wu, Yinghao Guo, Longfu Xi, Dan Ye, Yanzhi Pan, Xiaoxiao Zhang, Jiangtao Li
Computers in Biology and Medicine.2023; 165: 107370. CrossRef - Ferroptosis as a promising therapeutic strategy for melanoma
Na Ta, Xiaodong Jiang, Yongchun Zhang, Hongquan Wang
Frontiers in Pharmacology.2023;[Epub] CrossRef - The crosstalk between ferroptosis and anti‐tumor immunity in the tumor microenvironment: molecular mechanisms and therapeutic controversy
Yichen Zheng, Lingqi Sun, Jiamin Guo, Ji Ma
Cancer Communications.2023; 43(10): 1071. CrossRef - Impact of ferroptosis on preeclampsia: A review
Yuping Shan, Chengcheng Guan, Jingli Wang, Weihong Qi, Aiping Chen, Shiguo Liu
Biomedicine & Pharmacotherapy.2023; 167: 115466. CrossRef - Endogenous molecule-targeted fluorescent probes for ferroptosis visualization: Current progress and future prospects
Wen-Jie Shu, Zhengzhi Cao, Yuxing Yan, Zhuang Cai, Fu Wang
Coordination Chemistry Reviews.2023; 496: 215432. CrossRef - Selenium intake and multiple health-related outcomes: an umbrella review of meta-analyses
Puze Wang, Bo Chen, Yin Huang, Jin Li, Dehong Cao, Zeyu Chen, Jinze Li, Biao Ran, Jiahao Yang, Ruyi Wang, Qiang Wei, Qiang Dong, Liangren Liu
Frontiers in Nutrition.2023;[Epub] CrossRef - Recent advances of ferroptosis in tumor: From biological function to clinical application
Shunfeng Hu, Yurou Chu, Xiangxiang Zhou, Xin Wang
Biomedicine & Pharmacotherapy.2023; 166: 115419. CrossRef - Regulation of m6A modification on ferroptosis and its potential significance in radiosensitization
Xun Chen, Lejia Zhang, Yi He, Siyuan Huang, Shangwu Chen, Wei Zhao, Dongsheng Yu
Cell Death Discovery.2023;[Epub] CrossRef - Anaplastic thyroid cancer cells reduce CD71 levels to increase iron overload tolerance
Simona D’Aprile, Simona Denaro, Anna Maria Pavone, Sebastiano Giallongo, Cesarina Giallongo, Alfio Distefano, Lucia Salvatorelli, Filippo Torrisi, Raffaella Giuffrida, Stefano Forte, Daniele Tibullo, Giovanni Li Volti, Gaetano Magro, Nunzio Vicario, Rosal
Journal of Translational Medicine.2023;[Epub] CrossRef - The recent advancements of ferroptosis in the diagnosis, treatment and prognosis of ovarian cancer
Biqing Chen, Liping Zhao, Rulin Yang, Tianmin Xu
Frontiers in Genetics.2023;[Epub] CrossRef - Implanted, Wireless, Self‐Powered Photodynamic Therapeutic Tablet Synergizes with Ferroptosis Inducer for Effective Cancer Treatment
Pingjin Zou, Rui Lin, Zengyi Fang, Junyang Chen, Hongye Guan, Jie Yin, Zhiheng Chang, Lili Xing, Jinyi Lang, Xinyu Xue, Meihua Chen
Advanced Science.2023;[Epub] CrossRef - Variation of Plasma Damage-Associated Molecular Patterns in Patients with Advanced Solid Tumors after Standard of Care Systemic Treatment
Vicente Valentí, Laia Capdevila, Isabel Ruiz, Javier Ramos, Joan Badía, Susana Blázquez, Óscar Villuendas, Cristina Pérez, Laura Fernández-Sender, Mónica Córdoba, Carlos Alonso-Villaverde
Cancer Investigation.2023; 41(10): 821. CrossRef - Engineered exosomes-based theranostic strategy for tumor metastasis and recurrence
Min Deng, Shuang Wu, Peizheng Huang, Yun Liu, Chong Li, Ji Zheng
Asian Journal of Pharmaceutical Sciences.2023; 18(6): 100870. CrossRef - Molecular Mechanisms of Ferroptosis and Its Role in Viral Pathogenesis
Riwei Huang, Jiang Wu, Yaodan Ma, Kai Kang
Viruses.2023; 15(12): 2373. CrossRef - Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Abdullah A. Osman, Emre Arslan, Mason Bartels, Chieko Michikawa, Antje Lindemann, Katarzyna Tomczak, Wangjie Yu, Vlad Sandulache, Wencai Ma, Li Shen, Jing Wang, Anand K. Singh, Mitchell J. Frederick, Nakia D. Spencer, Jeffery Kovacs, Timothy Heffernan, Wi
Clinical Cancer Research.2023; 29(7): 1344. CrossRef - Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases
Yumin Wang, Jing Hu, Shuang Wu, Joshua S. Fleishman, Yulin Li, Yinshi Xu, Wailong Zou, Jinhua Wang, Yukuan Feng, Jichao Chen, Hongquan Wang
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef - Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy
Rui Fu, Borui Zhao, Min Chen, Xiaolong Fu, Qian Zhang, Yange Cui, Xin Hu, Wei Zhou
Medical Oncology.2023;[Epub] CrossRef - ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape
Tianyao Liu, Xinyan Xu, Jiazheng Li, Ming Bai, Wenjie Zhu, Yanqing Liu, Siyang Liu, Zihan Zhao, Tianhang Li, Ning Jiang, Yuhao Bai, Qingyang Jin, Yulin Zhang, Yufeng Zheng, Shengkai Zhou, Shoubin Zhan, Ying Sun, Gaoli Liang, Yang Luo, Xi Chen, Hongqian Gu
Cell Death & Disease.2023;[Epub] CrossRef - NeuroD1-GPX4 signaling leads to ferroptosis resistance in hepatocellular carcinoma
Ping Huang, Wei Duan, Cao Ruan, Lingxian Wang, Rendy Hosea, Zheng Wu, Jianting Zeng, Shourong Wu, Vivi Kasim, Carmen Priolo
PLOS Genetics.2023; 19(12): e1011098. CrossRef - Ferroptosis: An emerging therapeutic opportunity for cancer
Liyuan Wang, Xiaoguang Chen, Chunhong Yan
Genes & Diseases.2022; 9(2): 334. CrossRef - Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy
Nasim Ebrahimi, Samaneh Adelian, Siavash Shakerian, Maral Afshinpour, Siavash Rahimian Chaleshtori, Nadi Rostami, Fatemeh Rezaei-Tazangi, Sheida Beiranvand, Michael R. Hamblin, Amir Reza Aref
Cytokine & Growth Factor Reviews.2022; 64: 33. CrossRef - Programmed cell death in aortic aneurysm and dissection: A potential therapeutic target
Abhijit Chakraborty, Yang Li, Chen Zhang, Yanming Li, Scott A. LeMaire, Ying H. Shen
Journal of Molecular and Cellular Cardiology.2022; 163: 67. CrossRef - Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression
Shiyao Sui, Shouping Xu, Da Pang
Pharmacology & Therapeutics.2022; 232: 107992. CrossRef - GALNT14 Regulates Ferroptosis and Apoptosis of Ovarian Cancer Through the EGFR/mTOR Pathway
Hua-wen Li, Mu-biao Liu, Xue Jiang, Ting Song, Shu-xian Feng, Jing-ya Wu, Peng-fei Deng, Xiao-yu Wang
Future Oncology.2022; 18(2): 149. CrossRef - Research progress on the occurrence and therapeutic mechanism of ferroptosis in NSCLC
Yifan Zhang, Ruixue Guo, Jia Li, Liangming Zhu
Naunyn-Schmiedeberg's Archives of Pharmacology.2022; 395(1): 1. CrossRef - A novel mechanism linking ferroptosis and endoplasmic reticulum stress via the circPtpn14/miR-351-5p/5-LOX signaling in melatonin-mediated treatment of traumatic brain injury
Chenrui Wu, Mengran Du, Renqiang Yu, Yuqi Cheng, Biying Wu, Jiayuanyuan Fu, Weilin Tan, Qiang Zhou, Ehab Balawi, Z.B. Liao
Free Radical Biology and Medicine.2022; 178: 271. CrossRef - The Role of Ferroptosis Signature in Overall Survival and Chemotherapy of Pancreatic Adenocarcinoma
Wanhui Wei, Qian Hu, Wenjie Li, Mengting Li, Shouquan Dong, Yanan Peng, Jingwen Yin, Yuanyuan Lu, Lan Liu, Qiu Zhao
DNA and Cell Biology.2022; 41(2): 116. CrossRef - The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer
Yingying Hu, Nan Guo, Ting Yang, Jianghong Yan, Wenjun Wang, Xiang Li, Julio J. Ochoa
Oxidative Medicine and Cellular Longevity.2022; 2022: 1. CrossRef - Induction and application of ferroptosis in cancer therapy
Qing Nie, Yue Hu, Xiao Yu, Xiao Li, Xuedong Fang
Cancer Cell International.2022;[Epub] CrossRef - Molecular regulatory mechanism of ferroptosis and its role in gastrointestinal oncology: Progress and updates
Fan Yang, Si-Yu Sun, Sheng Wang, Jin-Tao Guo, Xiang Liu, Nan Ge, Guo-Xin Wang
World Journal of Gastrointestinal Oncology.2022; 14(1): 1. CrossRef - Can Polyphenols Inhibit Ferroptosis?
Marija Lesjak, Nataša Simin, Surjit K. S. Srai
Antioxidants.2022; 11(1): 150. CrossRef - Nickel oxide nanoparticles induce apoptosis and ferroptosis in airway epithelial cells via ATF3
Fengfan Liu, Xiang Cheng, Shuang Wu, Bei Hu, Chen Yang, Shufen Deng, Qiwen Shi
Environmental Toxicology.2022; 37(5): 1093. CrossRef - Emerging Mechanisms and Disease Implications of Ferroptosis: Potential Applications of Natural Products
Chun Ge, Sujie Zhang, Huiwen Mu, Shaojun Zheng, Zhaoyi Tan, Xintong Huang, Chen Xu, Jianjun Zou, Yubing Zhu, Dong Feng, Jiye Aa
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef - Identification of Five Ferroptosis-Related LncRNAs as Novel Prognosis and Diagnosis Signatures for Renal Cancer
Xiangjun Shu, Zaiqi Zhang, Zhi-Yong Yao, Xiao-Liang Xing
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef - Modulations of ferroptosis in lung cancer therapy
Robert Walters, Shaker A. Mousa
Expert Opinion on Therapeutic Targets.2022; 26(2): 133. CrossRef - Epigenetic landscape of drug responses revealed through large-scale ChIP-seq data analyses
Zhaonan Zou, Michio Iwata, Yoshihiro Yamanishi, Shinya Oki
BMC Bioinformatics.2022;[Epub] CrossRef - Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer
Jingchao Liu, Zhipeng Zhang, Wei Zhang, Lingfeng Meng, Jiawen Wang, Zhengtong Lv, Haoran Xia, Meng Wu, Yaoguang Zhang, Jianye Wang
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef - Ferroptosis and metabolic dysfunction‐associated fatty liver disease: Is there a link?
Gong Feng, Christopher D. Byrne, Giovanni Targher, Fudi Wang, Ming‐Hua Zheng
Liver International.2022; 42(7): 1496. CrossRef - Ferroptosis: A Trusted Ally in Combating Drug Resistance in Cancer
Erva Ozkan, Filiz Bakar-Ates
Current Medicinal Chemistry.2022; 29(1): 41. CrossRef - Targeting Regulated Cell Death with Pharmacological Small Molecules: An Update on Autophagy-Dependent Cell Death, Ferroptosis, and Necroptosis in Cancer
Junhao Wu, Jing Ye, Qiang Xie, Bo Liu, Ming Liu
Journal of Medicinal Chemistry.2022; 65(4): 2989. CrossRef - Albumin-Based Therapeutics Capable of Glutathione Consumption and Hydrogen Peroxide Generation for Synergetic Chemodynamic and Chemotherapy of Cancer
Guangbao Yang, Dongdong Wang, Soo Zeng Fiona Phua, Anivind Kaur Bindra, Cheng Qian, Rui Zhang, Liang Cheng, Guofeng Liu, Hongwei Wu, Zhuang Liu, Yanli Zhao
ACS Nano.2022; 16(2): 2319. CrossRef - A Ferroptosis-Related lncRNA Model to Enhance the Predicted Value of Cervical Cancer
Zhaojing Jiang, Jingyu Li, Wenqing Feng, Yujie Sun, Junguo Bu, Fu Wang
Journal of Oncology.2022; 2022: 1. CrossRef - Ferroptosis in cancer and cancer immunotherapy
Lei Zhao, Xiaoxue Zhou, Feng Xie, Lei Zhang, Haiyan Yan, Jun Huang, Chong Zhang, Fangfang Zhou, Jun Chen, Long Zhang
Cancer Communications.2022; 42(2): 88. CrossRef - Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo
Leye He, Hao Chen, Qinqin Qi, Nan Wu, Ying Wang, Mengxia Chen, Qian Feng, Buyuan Dong, Rong Jin, Lei Jiang
European Journal of Pharmacology.2022; 920: 174823. CrossRef - Vulnerability of Triple-Negative Breast Cancer to Saponin Formosanin C-Induced Ferroptosis
Hsin-Chih Chen, Han-Hsuan Tang, Wei-Hsiang Hsu, Shan-Ying Wu, Wen-Hsing Cheng, Bao-Yuan Wang, Chun-Li Su
Antioxidants.2022; 11(2): 298. CrossRef - Ferroptosis in Cancer Immunotherapy—Implications for Hepatocellular Carcinoma
Johanna Kusnick, Alix Bruneau, Frank Tacke, Linda Hammerich
Immuno.2022; 2(1): 185. CrossRef - Cyclophosphamide Induces the Ferroptosis of Tumor Cells Through Heme Oxygenase-1
Hezhan Shi, Bo Hou, Huifeng Li, Hui Zhou, Bin Du
Frontiers in Pharmacology.2022;[Epub] CrossRef - Insights Into Ferroptosis, a Novel Target for the Therapy of Cancer
Hong-Tao Wang, Jie Ju, Shao-Cong Wang, Yu-Hui Zhang, Cui-Yun Liu, Tao Wang, Xue Yu, Fei Wang, Xue-Ru Cheng, Kun Wang, Zhao-Yang Chen
Frontiers in Oncology.2022;[Epub] CrossRef - The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis
Yiting Wei, Shilong Duan, Fanyong Gong, Qiang Li
Biochemical and Biophysical Research Communications.2022; 603: 153. CrossRef - Ferroptosis in hematological malignancies and its potential network with abnormal tumor metabolism
Jiasi Zhang, Yuxi Liu, Qun Li, Aoshuang Xu, Yu Hu, Chunyan Sun
Biomedicine & Pharmacotherapy.2022; 148: 112747. CrossRef - Metabolic regulation of ferroptosis in the tumor microenvironment
Nneka E. Mbah, Costas A. Lyssiotis
Journal of Biological Chemistry.2022; 298(3): 101617. CrossRef - The Role of Ferroptosis in the Treatment and Drug Resistance of Hepatocellular Carcinoma
Siqi Zhao, Wubin Zheng, Chao Yu, Gaoxin Xu, Xinyi Zhang, Chao Pan, Yongheng Feng, Kunxing Yang, Jin Zhou, Yong Ma
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef - Potential Role of APEX1 During Ferroptosis
Nan Guo, Yan Chen, Yuhong Zhang, Yonghao Deng, Fancai Zeng, Xiang Li
Frontiers in Oncology.2022;[Epub] CrossRef - Scutellaria barbata Inhibits Hepatocellular Carcinoma Tumorigenicity by Inducing Ferroptosis of Hepatocellular Carcinoma Cells
Yue Li, Jiongshan Zhang, Kun Zhang, Yan Chen, Wei Wang, Hongjie Chen, Zengcheng Zou, Yongwei Li, Min Dai
Frontiers in Oncology.2022;[Epub] CrossRef - One Ferroptosis-Related Gene-Pair Signature Serves as an Original Prognostic Biomarker in Lung Adenocarcinoma
Lei Li, Buhai Wang
Frontiers in Genetics.2022;[Epub] CrossRef - Ferroptosis, a new target for treatment of renal injury and fibrosis in a 5/6 nephrectomy-induced CKD rat model
Jingyu Wang, Yaqing Wang, Yi Liu, Xintian Cai, Xin Huang, Wenjing Fu, Lei Wang, Lihua Qiu, Junying Li, Li Sun
Cell Death Discovery.2022;[Epub] CrossRef - Targeting ferroptosis as a vulnerability in cancer
Guang Lei, Li Zhuang, Boyi Gan
Nature Reviews Cancer.2022; 22(7): 381. CrossRef - AXL inhibition improves BRAF-targeted treatment in melanoma
Marta Nyakas, Karianne Giller Fleten, Mads Haugland Haugen, Nikolai Engedal, Christina Sveen, Inger Nina Farstad, Vivi Ann Flørenes, Lina Prasmickaite, Gunhild Mari Mælandsmo, Kotryna Seip
Scientific Reports.2022;[Epub] CrossRef - Role of Induced Programmed Cell Death in the Chemopreventive Potential of Apigenin
Jung Yoon Jang, Bokyung Sung, Nam Deuk Kim
International Journal of Molecular Sciences.2022; 23(7): 3757. CrossRef - Boosting ferroptosis via abplatin(iv) for treatment of platinum-resistant recurrent ovarian cancer
Wenwen Wang, Jing Cai, Jiayi Wen, Xinyi Li, Yingjie Yu, Lingpu Zhang, Qing Han, Zheng Wei, Yujia Ma, Feiquan Ying, Xiaohan Xu, Wenhan Li, Qiang Yang, Si Sun, Xiaoqi He, Liqiong Cai, Haihua Xiao, Zehua Wang
Nano Today.2022; 44: 101459. CrossRef - A GSH-depleted platinum(IV) prodrug triggers ferroptotic cell death in breast cancer
Dachuan Qi, Lei Xing, Lijun Shen, Wenshuang Sun, Cheng Cai, Chunhua Xue, Xuwei Song, Hua Yu, Hulin Jiang, Chengjun Li, Qingri Jin, Zhiqi Zhang
Chinese Chemical Letters.2022; 33(10): 4595. CrossRef - miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways
Guoshu Bi, Jiaqi Liang, Mengnan Zhao, Huan Zhang, Xing Jin, Tao Lu, Yuansheng Zheng, Yunyi Bian, Zhencong Chen, Yiwei Huang, Valeria Besskaya, Cheng Zhan, Qun Wang, Lijie Tan
Molecular Therapy - Nucleic Acids.2022; 28: 366. CrossRef - Non-coding RNAs and ferroptosis: potential implications for cancer therapy
Amar Balihodzic, Felix Prinz, Michael A. Dengler, George A. Calin, Philipp J. Jost, Martin Pichler
Cell Death & Differentiation.2022; 29(6): 1094. CrossRef - SLC7A11, a Potential Therapeutic Target Through Induced Ferroptosis in Colon Adenocarcinoma
Xin Cheng, Yadong Wang, Liangchao Liu, Chenggang Lv, Can Liu, Jingyun Xu
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef - Molecular mechanisms of reactive oxygen species in regulated cell deaths: Impact of ferroptosis in cancer therapy
Morteza Golbashirzadeh, Hamid Reza Heidari, Ahmad Yari Khosroushahi
Gene Reports.2022; 27: 101614. CrossRef - Exosomes and ferroptosis: roles in tumour regulation and new cancer therapies
Yixin Shi, Bingrun Qiu, Linyang Huang, Jie Lin, Yiling Li, Yiting Ze, Chenglong Huang, Yang Yao
PeerJ.2022; 10: e13238. CrossRef - Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells
Lu Han, Lei Li, Geng Wu
Molecular and Cellular Probes.2022; 64: 101821. CrossRef - Cullin-9/p53 mediates HNRNPC degradation to inhibit erastin-induced ferroptosis and is blocked by MDM2 inhibition in colorectal cancer
Lv Yang, Tang WenTao, Zhang ZhiYuan, Lin Qi, Luo YuXiang, Zheng Peng, Li Ke, Jia XiaoNa, Pang YuZhi, Ji MeiLing, Feng QingYang, He GuoDong, Wang YueXiang, Xu JianMin
Oncogene.2022; 41(23): 3210. CrossRef - Excessive selenium affects neural development and locomotor behavior of zebrafish embryos
Guang Zhao, Jun Hu, Meng Gao, Yuejie Zhu, Yijiang Hong
Ecotoxicology and Environmental Safety.2022; 238: 113611. CrossRef - Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin(IV) Prodrugs for Safer Synergistic Chemotherapy
Tushar Date, Kaushik Kuche, Dasharath Chaudhari, Rohan Ghadi, Deepak Kumar Sahel, Deepak Chitkara, Sanyog Jain
ACS Biomaterials Science & Engineering.2022; 8(6): 2349. CrossRef - Prospective Application of Ferroptosis in Hypoxic Cells for Tumor Radiotherapy
Jing Su, Qin Zhao, Zhuangzhuang Zheng, Huanhuan Wang, Chenbin Bian, Lingbin Meng, Ying Xin, Xin Jiang
Antioxidants.2022; 11(5): 921. CrossRef - Solasonine Causes Redox Imbalance and Mitochondrial Oxidative Stress of Ferroptosis in Lung Adenocarcinoma
Yao-Ying Zeng, Ying-Bin Luo, Xu-Dong Ju, Bo Zhang, Ya-Jing Cui, Yan-Bin Pan, Jian-Hui Tian, Wen-Jing Teng, Jianchun Wu, Yan Li
Frontiers in Oncology.2022;[Epub] CrossRef - Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges
Zhenyu Nie, Mei Chen, Yuanhui Gao, Denggao Huang, Hui Cao, Yanling Peng, Na Guo, Fei Wang, Shufang Zhang
Frontiers in Pharmacology.2022;[Epub] CrossRef - Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy
Le Zhang, Ningning Hou, Bing Chen, Chengxia Kan, Fang Han, Jingwen Zhang, Xiaodong Sun
Frontiers in Pharmacology.2022;[Epub] CrossRef - Pharmacological Targeting of Ferroptosis in Cancer Treatment
Mehdi Rabiee Valashedi, Amirsadegh Nikoo, Nima Najafi-Ghalehlou, Kazuo Tomita, Yoshikazu Kuwahara, Tomoaki Sato, Amaneh Mohammadi Roushandeh, Mehryar Habibi Roudkenar
Current Cancer Drug Targets.2022; 22(2): 108. CrossRef - Flavonoid 4,4′-dimethoxychalcone induced ferroptosis in cancer cells by synergistically activating Keap1/Nrf2/HMOX1 pathway and inhibiting FECH
Changmei Yang, Tianxiang Wang, Yujiao Zhao, Xianbin Meng, Wenxi Ding, Qingtao Wang, Chongdong Liu, Haiteng Deng
Free Radical Biology and Medicine.2022; 188: 14. CrossRef - Crosstalk between ferroptosis and stress—Implications in cancer therapeutic responses
Cheng Zhang, Jiao‐jiao Yu, Chen Yang, Shuang Shang, Xiao‐xi Lv, Bing Cui, Fang Hua
Cancer Innovation.2022; 1(1): 92. CrossRef - Molecular mechanisms of ferroptosis and its role in prostate cancer therapy
Shaokun Wang, Wei Wei, Ning Ma, Yongliang Qu, Qiuju Liu
Critical Reviews in Oncology/Hematology.2022; 176: 103732. CrossRef - The power of heteronemin in cancers
Kuan Wang, Yi-Fong Chen, Yu-Chen S. H. Yang, Haw-Ming Huang, Sheng-Yang Lee, Ya-Jung Shih, Zi-Lin Li, Jacqueline Whang-Peng, Hung-Yun Lin, Paul J. Davis
Journal of Biomedical Science.2022;[Epub] CrossRef - CRISPR/Cas9-mediated knockout of Lcn2 in human breast cancer cell line MDA-MB-231 ameliorates erastin-mediated ferroptosis and increases cisplatin vulnerability
Mehdi Rabiee Valashedi, Amaneh Mohammadi Roushandeh, Kazuo Tomita, Yoshikazu Kuwahara, Zahra Pourmohammadi-Bejarpasi, Pouya Safarzadeh Kozani, Tomoaki Sato, Mehryar Habibi Roudkenar
Life Sciences.2022; 304: 120704. CrossRef - Ana Hatları ile Ferroptozis
Arzu GEZER, Ebru KARADAĞ SARI
Turkish Veterinary Journal.2022; 4(1): 24. CrossRef - Microwave assisted extraction, characterization of a polysaccharide from Salvia miltiorrhiza Bunge and its antioxidant effects via ferroptosis-mediated activation of the Nrf2/HO-1 pathway
Huanhuan Meng, Jianjun Wu, Li Shen, Guangwei Chen, Liang Jin, Mengxia Yan, Haitong Wan, Yu He
International Journal of Biological Macromolecules.2022; 215: 398. CrossRef - Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Weitong Gao, Xueying Wang, Yang Zhou, Xueqian Wang, Yan Yu
Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef - Predicting prognosis and clinical features of the tumor microenvironment based on ferroptosis score in patients with breast cancer
Lianli Yin, Yinghua Tang
Scientific Reports.2022;[Epub] CrossRef - Multifaceted Roles of Ferroptosis in Lung Diseases
Yi Li, Ying Yang, Yongfeng Yang
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef - Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma
Yiming Zhang, Rong He, Xuan Lei, Lianghao Mao, Zhengyu Yin, Xinyu Zhong, Wenbing Cao, Qiping Zheng, Dapeng Li
Frontiers in Oncology.2022;[Epub] CrossRef - Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity
Bartosz Wiernicki, Sophia Maschalidi, Jonathan Pinney, Sandy Adjemian, Tom Vanden Berghe, Kodi S. Ravichandran, Peter Vandenabeele
Nature Communications.2022;[Epub] CrossRef - Induction of Ferroptosis by Ophiopogonin-B Through Regulating the Gene Signature AURKA in NSCLC
Liqiu Li, Qian Gao, Jin Wang, Ling Gu, Zhihui Li, Shiping Zhang, Cheng Hu, Menglin He, Yulin Wang, Zixuan Wang, Yongxiang Yi, Jin Fu, Xiongfei Zhang, Fei Ge, Meijuan Chen, Xu Zhang
Frontiers in Oncology.2022;[Epub] CrossRef - Combination regimen of granulocyte colony-stimulating factor and recombinant human thrombopoietin improves the curative effect on elderly patients with leukemia through inducing pyroptosis and ferroptosis of leukemia cells
Xiaobin Wang, Xiaoyu Liu, Huihan Wang
Cancer Gene Therapy.2022; 29(11): 1742. CrossRef - Role of Heme Oxygenase in Gastrointestinal Epithelial Cells
Reiko Akagi
Antioxidants.2022; 11(7): 1323. CrossRef - Capsaicin induces ferroptosis of NSCLC by regulating SLC7A11/GPX4 signaling in vitro
Xiao-Yan Liu, Dong-Guang Wei, Rong-Shan Li
Scientific Reports.2022;[Epub] CrossRef - Targeting Ferroptosis Pathways: A Novel Strategy for Cancer Therapy
Devangkumar Maru, Akhil Hothi, Chintan Bagariya, Anmol Kumar
Current Cancer Drug Targets.2022; 22(3): 234. CrossRef - Amorphous ferric oxide-coating selenium core–shell nanoparticles: a self-preservation Pt(iv) platform for multi-modal cancer therapies through hydrogen peroxide depletion-mediated anti-angiogenesis, apoptosis and ferroptosis
Zhaowei Xu, Qingdong Li, Caiyun Zhang, Peng Wang, Xiaotong Xu, Lang Ran, Li Zhang, Geng Tian, Guilong Zhang
Nanoscale.2022; 14(32): 11600. CrossRef - ARPC1A is regulated by STAT3 to inhibit ferroptosis and promote prostate cancer progression
Junpeng Ji, Huibing Li, Wenjun Wang, Bo Yuan, Tianyu Shen
Human Cell.2022; 35(5): 1591. CrossRef - Iron as spirit of life to share under monopoly
Shinya Toyokuni, Yingyi Kong, Hao Zheng, Yuki Maeda, Yashiro Motooka, Shinya Akatsuka
Journal of Clinical Biochemistry and Nutrition.2022; 71(2): 78. CrossRef - Multi-platform-based characterization of ferroptosis in human colorectal cancer
Yafang Zhong, Wei Zhang, Haiyan Yu, Liewen Lin, Xucan Gao, Jingquan He, Dandan Li, Yumei Chen, Zhipeng Zeng, Yong Xu, Donge Tang, Yong Dai
iScience.2022; 25(8): 104750. CrossRef - Knockdown of RRM1 in tumor cells promotes radio-/chemotherapy induced ferroptosis by regulating p53 ubiquitination and p21-GPX4 signaling axis
Yang Gao, Bin Chen, Ruru Wang, An Xu, Lijun Wu, Huayi Lu, Guoping Zhao
Cell Death Discovery.2022;[Epub] CrossRef - Revisiting “BAP1ness” in Malignant Pleural Mesothelioma
Haitang Yang, Feng Yao, Ren-Wang Peng
Journal of Thoracic Oncology.2022; 17(8): e67. CrossRef - Focus on ferroptosis regulation: Exploring novel mechanisms and applications of ferroptosis regulator
Tian-Liang Ma, Jing-Xian Chen, Peng Zhu, Chao-Bin Zhang, Yong Zhou, Jia-Xi Duan
Life Sciences.2022; 307: 120868. CrossRef - The crosstalk effect between ferrous and other ions metabolism in ferroptosis for therapy of cancer
Kun Ke, Li Li, Chao Lu, Qicong Zhu, Yuanyu Wang, Yiping Mou, Huiju Wang, Weiwei Jin
Frontiers in Oncology.2022;[Epub] CrossRef - Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Fu Peng, Minru Liao, Rui Qin, Shiou Zhu, Cheng Peng, Leilei Fu, Yi Chen, Bo Han
Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef - Frontiers of ferroptosis research: An analysis from the top 100 most influential articles in the field
Kunming Cheng, Qiang Guo, Zefeng Shen, Weiguang Yang, Yan Zhou, Zaijie Sun, Xiuhua Yao, Haiyang Wu
Frontiers in Oncology.2022;[Epub] CrossRef - Ferroptosis and Its Multifaceted Role in Cancer: Mechanisms and Therapeutic Approach
Heshu Chen, Chenyu Wang, Zemin Liu, Xinmiao He, Wenjie Tang, Liuqin He, Yanzhong Feng, Di Liu, Yulong Yin, Tiejun Li
Antioxidants.2022; 11(8): 1504. CrossRef - Targeting Ferroptosis in Colorectal Cancer
Xiaojie Liang, Zhihuan You, Xinhao Chen, Jun Li
Metabolites.2022; 12(8): 745. CrossRef - Inhibition of the PIN1-NRF2/GPX4 axis imparts sensitivity to cisplatin in cervical cancer cells
Zheng Zhang, Qiangsheng Hu, Shuang Ye, Libing Xiang
Acta Biochimica et Biophysica Sinica.2022;[Epub] CrossRef - Adipocyte‐Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal Cancer
Qiumo Zhang, Ting Deng, Hongdian Zhang, Duo Zuo, Qihang Zhu, Ming Bai, Rui Liu, Tao Ning, Le Zhang, Zhentao Yu, Haiyang Zhang, Yi Ba
Advanced Science.2022;[Epub] CrossRef - The role of ferroptosis in esophageal cancer
Zimin Wang, Sikai Wu, Chengchu Zhu, Jianfei Shen
Cancer Cell International.2022;[Epub] CrossRef - Ferroptosis-Related Long Noncoding RNAs Have Excellent Predictive Ability for Multiomic Characteristics of Bladder Cancer
Jingchao Liu, Jingyi Cui, Shuangyi Zhao, Meng Wu, Jiawen Wang, Yaoguang Zhang, Bin Jin, Jianye Wang, Lianxiang Luo
Oxidative Medicine and Cellular Longevity.2022; 2022: 1. CrossRef - Neratinib inhibits proliferation and promotes apoptosis of acute myeloid leukemia cells by activating autophagy‐dependent ferroptosis
Hongxia Ma, Yang Liu, Zhen Miao, Shijia Cheng, Yunan Zhu, Yifan Wu, Xinxin Fan, Jing Yang, Xingang Li, Liyin Guo
Drug Development Research.2022; 83(7): 1641. CrossRef - System Xc−/GSH/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy
Feng-Jiao Li, Hui-Zhi Long, Zi-Wei Zhou, Hong-Yu Luo, Shuo-Guo Xu, Li-Chen Gao
Frontiers in Pharmacology.2022;[Epub] CrossRef - The Ferroptosis Molecular Subtype Reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer
Xiao Xu, Na Zhou, Hongwei Lan, Fangfang Yang, Bowen Dong, Xiaochun Zhang
International Journal of Molecular Sciences.2022; 23(17): 9767. CrossRef - The Role of Programmed Necrosis in Colorectal Cancer
Yu-Qiang Yu, Reyes Gamez-Belmonte, Jay V. Patankar, Eva Liebing, Christoph Becker
Cancers.2022; 14(17): 4295. CrossRef - Human umbilical cord mesenchymal stem cells ameliorate erectile dysfunction in rats with diabetes mellitus through the attenuation of ferroptosis
Huan Feng, Qi Liu, Zhiyao Deng, Hao Li, Huajie Zhang, Jingyu Song, Xiaming Liu, Jihong Liu, Bo Wen, Tao Wang
Stem Cell Research & Therapy.2022;[Epub] CrossRef - Long non-coding RNA OGFRP1 regulates cell proliferation and ferroptosis by miR-299-3p/SLC38A1 axis in lung cancer
Liang Liu, Shengtian Su, Dan Ye, Zhigao Yu, Wenjing Lu, Xiaoju Li
Anti-Cancer Drugs.2022;[Epub] CrossRef - Ferroptosis: A mixed blessing for infectious diseases
Leyao Xiao, Huanshao Huang, Shuhao Fan, Biying Zheng, Jianguo Wu, Junai Zhang, Jiang Pi, Jun-Fa Xu
Frontiers in Pharmacology.2022;[Epub] CrossRef - More than a duologue: In-depth insights into epitranscriptomics and ferroptosis
Justin Chak Ting Cheung, Guangzheng Deng, Nathalie Wong, Yujuan Dong, Simon Siu Man Ng
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef - PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer
Dongya Shen, Jia Luo, Ling Chen, Wenjuan Ma, Xiaoyuan Mao, Yu Zhang, Juyan Zheng, Yang Wang, Jielin Wan, Shiyu Wang, Jing Ouyang, Hanying Yi, Dongbo Liu, Weihua Huang, Wei Zhang, Zhaoqian Liu, Howard L. McLeod, Yijing He
Cancer Letters.2022; 550: 215919. CrossRef - Mechanisms and inhibitors of ferroptosis in psoriasis
Qiao Zhou, Lijing Yang, Ting Li, Kaiwen Wang, Xiaobo Huang, Jingfen Shi, Yi Wang
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef - The pyroptosis-related gene signature predicts prognosis and indicates the immune microenvironment status of chronic lymphocytic leukemia
Yeqin Sha, Rui Jiang, Yi Miao, Shuchao Qin, Wei Wu, Yi Xia, Li Wang, Lei Fan, Hui Jin, Wei Xu, Jianyong Li, Huayuan Zhu
Frontiers in Immunology.2022;[Epub] CrossRef - C-phycocyanin alleviated cisplatin-induced oxidative stress and inflammation via gut microbiota—metabolites axis in mice
Yubing Zhang, Lili Li, Song Qin, Jingyi Yuan, Xiaonan Xie, Fan Wang, Shanliang Hu, Yuetao Yi, Min Chen
Frontiers in Nutrition.2022;[Epub] CrossRef - KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma
Hua He, Lu Liang, Jingjing Huang, Shiyao Jiang, Yueying Liu, Xiaoyan Sun, Yi Li, Li Cong, Yiqun Jiang
Frontiers in Pharmacology.2022;[Epub] CrossRef - Ferroptosis-based nano delivery systems targeted therapy for colorectal cancer: Insights and future perspectives
Chu Qiao, Haiying Wang, Qiutong Guan, Minjie Wei, Zhenhua Li
Asian Journal of Pharmaceutical Sciences.2022; 17(5): 613. CrossRef - The Relationship Between Ferroptosis and Diseases
Jinchang Lv, Biao Hou, Jiangang Song, Yunhua Xu, Songlin Xie
Journal of Multidisciplinary Healthcare.2022; Volume 15: 2261. CrossRef - Diclofenac Sensitizes Signet Ring Cell Gastric Carcinoma Cells to Cisplatin by Activating Autophagy and Inhibition of Survival Signal Pathways
Nang Lae Lae Phoo, Amonnat Sukhamwang, Pornngarm Dejkriengkraikul, Supachai Yodkeeree
International Journal of Molecular Sciences.2022; 23(20): 12066. CrossRef - Aberrant expression of microRNA-4443 (miR-4443) in human diseases
Yunan Mao, Jinze Shen, Yuchen Wu, Ruan Wenjing, Feng Zhu, Shiwei Duan
Bioengineered.2022; 13(6): 14770. CrossRef - The differential usage of molecular machinery in brain cancer patients with iron-enriched glioma environments
Lucke-Wold Brandon, Diaz Michael Joseph, Song Joanna, Batchu Sai, Root Kevin, Patel Karan, Taneja Kamil
Journal of Surgery and Surgical Research.2022; 8(3): 030. CrossRef - Ferroptosis-related small-molecule compounds in cancer therapy: Strategies and applications
Linzhou Yin, Pengyu Liu, Yue Jin, Zunxi Ning, Yiren Yang, Huiyuan Gao
European Journal of Medicinal Chemistry.2022; 244: 114861. CrossRef - Integrative analysis of enrichment and prognostic value of ferroptosis-related genes and pathways in multiple myeloma
Qi Su, Qi Li, Weimin Zhang, Bingzong Li, Wenzhuo Zhuang
Carcinogenesis.2022; 43(11): 1050. CrossRef - Regulation mechanism of ferroptosis and its research progress in tumor immunotherapy
Jing Xu, Xiaolin Lin, Ting Han, Qingqing Zhou, Yang Su, Shuqing Jiang, Xiuying Xiao, Tengfei Liu
Frontiers in Molecular Biosciences.2022;[Epub] CrossRef - Ferroptosis in tumor immunity and therapy
Chuandong Gong, Qiankun Ji, Miaojing Wu, Zewei Tu, Kunjian Lei, Min Luo, Junzhe Liu, Li Lin, Kuangxun Li, Jingying Li, Kai Huang, Xingen Zhu
Journal of Cellular and Molecular Medicine.2022; 26(22): 5565. CrossRef - Ethoxyquin is a Competent Radical-Trapping Antioxidant for Preventing Ferroptosis in Doxorubicin Cardiotoxicity
Tomonori Tadokoro, Masataka Ikeda, Ko Abe, Tomomi Ide, Hiroko Deguchi Miyamoto, Shun Furusawa, Kosei Ishimaru, Masatsugu Watanabe, Akihito Ishikita, Shouji Matsushima, Tomoko Koumura, Ken-ichi Yamada, Hirotaka Imai, Hiroyuki Tsutsui
Journal of Cardiovascular Pharmacology.2022; 80(5): 690. CrossRef - Inhibition of AEBP1 predisposes cisplatin-resistant oral cancer cells to ferroptosis
Qianwen Zhou, Xiaoqi Wang, Yingxue Zhang, Lie Wang, Zhijun Chen
BMC Oral Health.2022;[Epub] CrossRef - Ferroptosis: A new insight for treatment of acute kidney injury
Shiyang Li, Rui Wang, Yixue Wang, Yong Liu, Yingjin Qiao, Peipei Li, Jingfang Chen, Shaokang Pan, Qi Feng, Zhangsuo Liu, Dongwei Liu
Frontiers in Pharmacology.2022;[Epub] CrossRef - The Impacts of Iron Overload and Ferroptosis on Intestinal Mucosal Homeostasis and Inflammation
Caiyun Huo, Guiping Li, Yanxin Hu, Huiling Sun
International Journal of Molecular Sciences.2022; 23(22): 14195. CrossRef - Erastin enhances metastatic potential of ferroptosis-resistant ovarian cancer cells by M2 polarization through STAT3/IL-8 axis
Wei Cang, Anyue Wu, Liying Gu, Wenjing Wang, Qi Tian, Zhong Zheng, Lihua Qiu
International Immunopharmacology.2022; 113: 109422. CrossRef - A novel ferroptosis‑related gene signature for overall survival prediction and immune infiltration in patients with breast cancer
Yan Zhang, Yiran Liang, Yajie Wang, Fangzhou Ye, Xiaoli Kong, Qifeng Yang
International Journal of Oncology.2022;[Epub] CrossRef - Comprehensive microRNA analysis across genome-edited colorectal cancer organoid models reveals miR-24 as a candidate regulator of cell survival
Jonathan W. Villanueva, Lawrence Kwong, Teng Han, Salvador Alonso Martinez, Michael T. Shanahan, Matt Kanke, Lukas E. Dow, Charles G. Danko, Praveen Sethupathy
BMC Genomics.2022;[Epub] CrossRef - Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future
Chang Li, Xunzhe Yin, Zuojia Liu, Jin Wang
International Journal of Molecular Sciences.2022; 23(23): 15031. CrossRef - Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research
Xuhui Tong, Rong Tang, Mingming Xiao, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Xianjun Yu, Si Shi
Journal of Hematology & Oncology.2022;[Epub] CrossRef - Ferroptosis: Reviewing CRC with the Third Eye
Xingyu Liu, Halahati Tuerxun, Yawen Li, Yaping Li, Yuanyuan He, Yuguang Zhao
Journal of Inflammation Research.2022; Volume 15: 6801. CrossRef - Low Sulfur Amino Acid, High Polyunsaturated Fatty Acid Diet Inhibits Breast Cancer Growth
Riccardo Turchi, Flavia Tortolici, Monica Benvenuto, Carolina Punziano, Anastasia De Luca, Stefano Rufini, Raffaella Faraonio, Roberto Bei, Daniele Lettieri-Barbato, Katia Aquilano
International Journal of Molecular Sciences.2022; 24(1): 249. CrossRef - Inhibition of SND1 overcomes chemoresistance in bladder cancer cells by promoting ferroptosis
Yu Zhao, Pengpeng Ren, Zhiqin Yang, Lei Wang, Changhua Hu
Oncology Reports.2022;[Epub] CrossRef - Comprehensive Analysis of the Expression and Clinical Significance of a Ferroptosis-Related Genome in Ovarian Serous Cystadenocarcinoma: A Study Based on TCGA Data
Hua Yang
Oncologie.2022; 24(4): 835. CrossRef - Cisplatin Promotes the Efficacy of ICI Therapy by Inducing Ferroptosis and Activating Neutrophils
Ziwei Zhou, Yiming Zhao, Si Chen, Guohui Cui, Wenkui Fu, Shouying Li, Xiaorong Lin, Hai Hu
SSRN Electronic Journal .2022;[Epub] CrossRef - Ferroptosis a Futuristic Roadmap for Cancer and Alzheimer's Disease
Gourav Singh, Prashant Kesharwani, Bhupendra Kumar, Indubhusan Mishra, Saroj Kumar, Gyan Modi
SSRN Electronic Journal .2022;[Epub] CrossRef - Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications
Tianai Sun, Jen-Tsan Chi
Genes & Diseases.2021; 8(3): 241. CrossRef - Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer
Jian-Shu Lou, Li-Ping Zhao, Zhi-Hui Huang, Xia-Yin Chen, Jing-Ting Xu, William Chi-Shing TAI, Karl W.K. Tsim, Yi-Tao Chen, Tian Xie
Phytomedicine.2021; 80: 153370. CrossRef - Lipid Peroxidation, GSH Depletion, and SLC7A11 Inhibition Are Common Causes of EMT and Ferroptosis in A549 Cells, but Different in Specific Mechanisms
Lulu Sun, Hongliang Dong, Weiqun Zhang, Nan Wang, Na Ni, Xuelian Bai, Naiguo Liu
DNA and Cell Biology.2021; 40(2): 172. CrossRef - A Marine Terpenoid, Heteronemin, Induces Both the Apoptosis and Ferroptosis of Hepatocellular Carcinoma Cells and Involves the ROS and MAPK Pathways
Wen-Tsan Chang, Yung-Ding Bow, Pei-Jung Fu, Chia-Yang Li, Chang-Yi Wu, Yi-Hua Chang, Yen-Ni Teng, Ruei-Nian Li, Mei-Chin Lu, Yi-Chang Liu, Chien-Chih Chiu, Cristina Angeloni
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef - Broadening horizons: the role of ferroptosis in cancer
Xin Chen, Rui Kang, Guido Kroemer, Daolin Tang
Nature Reviews Clinical Oncology.2021; 18(5): 280. CrossRef - Elucidating the Roles of Fenton Reactants in Drug‐Treated Cells by Using a Selective Rhodamine‐Thiophenol Fluorogenic Sensor
Zhanlong Wang, Jia Hao Yeo, Elizabeth J. New
Analysis & Sensing.2021; 1(2): 90. CrossRef - Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment
Lesang Shen, Yunxiang Zhou, Haifei He, Wuzhen Chen, Cameron Lenahan, Xiaoyi Li, Yongchuan Deng, Anwen Shao, Jian Huang, Ding Sheng Jiang
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef - Targeting the tumour microenvironment in platinum-resistant ovarian cancer
M. Cummings, C. Freer, N.M. Orsi
Seminars in Cancer Biology.2021; 77: 3. CrossRef - Cell death in head and neck cancer pathogenesis and treatment
Martina Raudenská, Jan Balvan, Michal Masařík
Cell Death & Disease.2021;[Epub] CrossRef - Curcumin induces ferroptosis in non‐small‐cell lung cancer via activating autophagy
Xin Tang, Hui Ding, Maoli Liang, Xing Chen, Yuxia Yan, Nansheng Wan, Qianqian Chen, Jing Zhang, Jie Cao
Thoracic Cancer.2021; 12(8): 1219. CrossRef - Comprehensive Analysis Identifies Potential Ferroptosis-Associated mRNA Therapeutic Targets in Ovarian Cancer
Jiyan Zhang, Jie Xi, Ping Huang, Saitian Zeng
Frontiers in Medicine.2021;[Epub] CrossRef - Effect of Micelle-Incorporated Cisplatin With Sizes Ranging From 8 to 40 nm for the Therapy of Lewis Lung Carcinoma
Zhicheng Wang, Yumin Li, Tong Zhang, Hongxia Li, Zhao Yang, Cheng Wang
Frontiers in Pharmacology.2021;[Epub] CrossRef - PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer
Ting Hong, Guang Lei, Xue Chen, He Li, Xiaoye Zhang, Nayiyuan Wu, Yu Zhao, Yilei Zhang, Jing Wang
Redox Biology.2021; 42: 101928. CrossRef - Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer
Ali Ghoochani, En-Chi Hsu, Merve Aslan, Meghan A. Rice, Holly M. Nguyen, James D. Brooks, Eva Corey, Ramasamy Paulmurugan, Tanya Stoyanova
Cancer Research.2021; 81(6): 1583. CrossRef - The emerging role of ferroptosis in intestinal disease
Shu Xu, Yao He, Lihui Lin, Peng Chen, Minhu Chen, Shenghong Zhang
Cell Death & Disease.2021;[Epub] CrossRef - Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis
Zhiyu Song, Gang Jia, Peizhi Ma, Shundong Cang
Life Sciences.2021; 276: 119399. CrossRef - The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis
Chunhua Rui, Shen-nan Shi, Wenqing Ren, Xia Qin, Chunlin Zhuang, Xiaofei Chen, Gang Chen, Jianqiang Yu, Hong-yang Wang, Zhenyu Cai
Biochemical Pharmacology.2021; 188: 114542. CrossRef - Emerging mechanisms and targeted therapy of ferroptosis in cancer
Haiyan Wang, Yan Cheng, Chao Mao, Shuang Liu, Desheng Xiao, Jun Huang, Yongguang Tao
Molecular Therapy.2021; 29(7): 2185. CrossRef - Dihydroisotanshinone I induced ferroptosis and apoptosis of lung cancer cells
Ching-Yuan Wu, Yao-Hsu Yang, Yu-Shih Lin, Geng-He Chang, Ming-Shao Tsai, Cheng-Ming Hsu, Reming-Albert Yeh, Li-Hsin Shu, Yu-Ching Cheng, Hung-Te Liu
Biomedicine & Pharmacotherapy.2021; 139: 111585. CrossRef - Erastin synergizes with cisplatin via ferroptosis to inhibit ovarian cancer growth in vitro and in vivo
Qi Cheng, Lingjie Bao, Mingqing Li, Kaikai Chang, Xiaofang Yi
Journal of Obstetrics and Gynaecology Research.2021; 47(7): 2481. CrossRef - Ferroptosis, radiotherapy, and combination therapeutic strategies
Guang Lei, Chao Mao, Yuelong Yan, Li Zhuang, Boyi Gan
Protein & Cell.2021; 12(11): 836. CrossRef - Recent progress on targeting ferroptosis for cancer therapy
Guangxiang Xu, Han Wang, Xiaoling Li, Riming Huang, Lianxiang Luo
Biochemical Pharmacology.2021; 190: 114584. CrossRef - Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin
Zheng Tang, Wanli Jiang, Ming Mao, Jinping Zhao, Jiakuan Chen, Nitao Cheng
Clinical and Translational Medicine.2021;[Epub] CrossRef - Nitroimidazoles Part 9. Synthesis, molecular docking, and anticancer evaluations of piperazine-tagged imidazole derivatives
Yaseen A. Al-Soud, Ala’a H. Al-Ahmad, Luay Abu-Qatouseh, Amneh Shtaiwi, Kafa’ A. S. Alhelal, Hossam H. Al-Suod, Sondos O. Alsawakhneh, Raed A. Al-Qawasmeh
Zeitschrift für Naturforschung B.2021; 76(5): 293. CrossRef - Defining a pharmacological inhibitor fingerprint for oxytosis/ferroptosis
David Soriano-Castell, Antonio Currais, Pamela Maher
Free Radical Biology and Medicine.2021; 171: 219. CrossRef - Construction and External Validation of a Ferroptosis-Related Gene Signature of Predictive Value for the Overall Survival in Bladder Cancer
Jingchao Liu, Hong Ma, Lingfeng Meng, Xiaodong Liu, Zhengtong Lv, Yaoguang Zhang, Jianye Wang
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef - Tetrahedral DNA Nanostructures Inhibit Ferroptosis and Apoptosis in Cisplatin-induced Renal Injury
Jiaying Li, Liwen Wei, Yuanqing Zhang, Minhao Wu
ACS Applied Bio Materials.2021; 4(6): 5026. CrossRef - Role of ferroptosis in cisplatin-induced acute nephrotoxicity in mice
Yasumasa Ikeda, Hirofumi Hamano, Yuya Horinouchi, Licht Miyamoto, Tasuku Hirayama, Hideko Nagasawa, Toshiaki Tamaki, Koichiro Tsuchiya
Journal of Trace Elements in Medicine and Biology.2021; 67: 126798. CrossRef - Expression and Prognostic Characteristics of Ferroptosis-Related Genes in Colon Cancer
Jie Zhu, Weikaixin Kong, Zhengwei Xie
International Journal of Molecular Sciences.2021; 22(11): 5652. CrossRef - Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling
Dazhi Fu, Chunxiao Wang, Lei Yu, Rui Yu
Cellular & Molecular Biology Letters.2021;[Epub] CrossRef - A Promising Future of Ferroptosis in Tumor Therapy
Hui Wang, Danfeng Lin, Qianqian Yu, Zhouqi Li, Cameron Lenahan, Ying Dong, Qichun Wei, Anwen Shao
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef - Role of Exosomal Non-coding RNAs in Gastric Cancer: Biological Functions and Potential Clinical Applications
Feng Hu, Jixuan Liu, Huibo Liu, Fan Li, Minjie Wan, Manli Zhang, Yanfang Jiang, Min Rao
Frontiers in Oncology.2021;[Epub] CrossRef - Ferroptosis Holds Novel Promise in Treatment of Cancer Mediated by Non-coding RNAs
Yuan Zhi, Ling Gao, Baisheng Wang, Wenhao Ren, Kristina Xiao Liang, Keqian Zhi
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef - Opportunities for Ferroptosis in Cancer Therapy
Kenji M. Fujihara, Bonnie Z. Zhang, Nicholas J. Clemons
Antioxidants.2021; 10(6): 986. CrossRef - Platinum drugs and taxanes: can we overcome resistance?
Elena V. Sazonova, Gelina S. Kopeina, Evgeny N. Imyanitov, Boris Zhivotovsky
Cell Death Discovery.2021;[Epub] CrossRef - Cisplatin synergizes with PRLX93936 to induce ferroptosis in non-small cell lung cancer cells
Zhigang Liang, Weijun Zhao, Xinjian Li, Longfei Wang, Lifei Meng, Rui Yu
Biochemical and Biophysical Research Communications.2021; 569: 79. CrossRef - Phosphorescent rhenium(I) complexes conjugated with artesunate: Mitochondrial targeting and apoptosis-ferroptosis dual induction
Rui-Rong Ye, Bi-Chun Chen, Jun-Jian Lu, Xiu-Rong Ma, Rong-Tao Li
Journal of Inorganic Biochemistry.2021; 223: 111537. CrossRef - CPEB1 enhances erastin‐induced ferroptosis in gastric cancer cells by suppressing twist1 expression
Jing Wang, Tao Wang, Yang Zhang, Jiaqi Liu, Jie Song, Yanlong Han, Lihong Wang, Shuang Yang, Lili Zhu, Rui Geng, Weimin Li, Xiaoguang Yu
IUBMB Life.2021; 73(9): 1180. CrossRef - DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism
Jing Du, Xu Wang, Yanchun Li, Xueying Ren, Yi Zhou, Wanye Hu, Chaoting Zhou, Qiangan Jing, Chen Yang, Luyang Wang, Huanjuan Li, Lijuan Fang, Yonglie Zhou, Xiangmin Tong, Ying Wang
Cell Death & Disease.2021;[Epub] CrossRef - Role of ferroptosis-related genes in prognostic prediction and tumor immune microenvironment in colorectal carcinoma
Chao Yang, Shuoyang Huang, Fengyu Cao, Yongbin Zheng
PeerJ.2021; 9: e11745. CrossRef - Ferroptosis in the tumor microenvironment: perspectives for immunotherapy
Huanji Xu, Di Ye, Meiling Ren, Hongying Zhang, Feng Bi
Trends in Molecular Medicine.2021; 27(9): 856. CrossRef - Novel Approaches of Dysregulating Lysosome Functions in Cancer Cells by Specific Drugs and Its Nanoformulations: A Smart Approach of Modern Therapeutics
Khaled S Allemailem, Ahmad Almatroudi, Faris Alrumaihi, Saleh A Almatroodi, Mohammad O Alkurbi, Ghaiyda Talal Basfar, Arshad Husain Rahmani, Amjad Ali Khan
International Journal of Nanomedicine.2021; Volume 16: 5065. CrossRef - Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications
Xiao-Huan Tang, Ting Guo, Xiang-Yu Gao, Xiao-Long Wu, Xiao-Fang Xing, Jia-Fu Ji, Zi-Yu Li
Molecular Cancer.2021;[Epub] CrossRef - Redox modulation of vitagenes via plant polyphenols and vitamin D: Novel insights for chemoprevention and therapeutic interventions based on organoid technology
Maria Scuto, Angela Trovato Salinaro, Isabella Caligiuri, Maria Laura Ontario, Valentina Greco, Nello Sciuto, Roberto Crea, Edward J. Calabrese, Flavio Rizzolio, Vincenzo Canzonieri, Vittorio Calabrese
Mechanisms of Ageing and Development.2021; 199: 111551. CrossRef - Establishment of a ferroptosis-related gene signature for prognosis in lung adenocarcinoma patients
Jingjing Cai, Chunyan Li, Hongsheng Li, Xiaoxiong Wang, Yongchun Zhou
PeerJ.2021; 9: e11931. CrossRef - A Novel Ferroptosis-Related Prognostic Signature Reveals Macrophage Infiltration and EMT Status in Bladder Cancer
Yilin Yan, Jinming Cai, Zhengnan Huang, Xiangqian Cao, Pengfei Tang, Zeyi Wang, Fang Zhang, Shujie Xia, Bing Shen
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef - WITHDRAWN: Oroxylin A promotes therapeutic efficacy of cisplatin to suppress bladder cancer progression via inducing ferroptosis
Qiao Tang, Jiahui Jiang, Junyi Sun, Liang Tang, Xiangyang Zhang
Biochemical and Biophysical Research Communications.2021;[Epub] CrossRef - A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer
Yingchun Liang, Fangdie Ye, Chenyang Xu, Lujia Zou, Yun Hu, Jimeng Hu, Haowen Jiang
BMC Cancer.2021;[Epub] CrossRef - Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy
Rui Sha, Yaqian Xu, Chenwei Yuan, Xiaonan Sheng, Ziping Wu, Jing Peng, Yaohui Wang, Yanping Lin, Liheng Zhou, Shuguang Xu, Jie Zhang, Wenjin Yin, Jinsong Lu
eBioMedicine.2021; 71: 103560. CrossRef - Heat Shock Protein Beta 1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma
Shengyi Long, Fang Peng, Baohui Song, Liang Wang, Jun Chen, Bingbing Shang
International Journal of General Medicine.2021; Volume 14: 5483. CrossRef - Current understanding of ferroptosis in the progression and treatment of pancreatic cancer
Shi Dong, Xin Li, Wenkai Jiang, Zhou Chen, Wence Zhou
Cancer Cell International.2021;[Epub] CrossRef - Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis
Shichuan Hu, Jinhu Ma, Chao Su, Yanwei Chen, Yongheng Shu, Zhongbing Qi, Bin Zhang, Gang Shi, Yan Zhang, Yuwei Zhang, Anliang Huang, Yueting Kuang, Ping Cheng
Acta Biomaterialia.2021;[Epub] CrossRef - The Evolving Role of Ferroptosis in Breast Cancer: Translational Implications Present and Future
Hung-Yu Lin, Hui-Wen Ho, Yen-Hsiang Chang, Chun-Jui Wei, Pei-Yi Chu
Cancers.2021; 13(18): 4576. CrossRef - Cashing in on ferroptosis against tumor cells: Usher in the next chapter
Mehdi Rabiee Valashedi, Nima Najafi-Ghalehlou, Amirsadegh Nikoo, Chia Bamshad, Kazuo Tomita, Yoshikazu Kuwahara, Tomoaki Sato, Amaneh Mohammadi Roushandeh, Mehryar Habibi Roudkenar
Life Sciences.2021; 285: 119958. CrossRef - Ferroptosis: A New Promising Target for Lung Cancer Therapy
Rui Xiong, Ruyuan He, Bohao Liu, Wenyang Jiang, Bo Wang, Ning Li, Qing Geng, Manuela Curcio
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef - Glutathione peroxidase 4‐dependent glutathione high‐consumption drives acquired platinum chemoresistance in lung cancer‐derived brain metastasis
Wenwen Liu, Yang Zhou, Wenzhe Duan, Jing Song, Song Wei, Shengkai Xia, Yingyan Wang, Xiaohui Du, Encheng Li, Caixia Ren, Wei Wang, Qimin Zhan, Qi Wang
Clinical and Translational Medicine.2021;[Epub] CrossRef - Targeting Ferroptosis for Lung Diseases: Exploring Novel Strategies in Ferroptosis‐Associated Mechanisms
Tian-Liang Ma, Yong Zhou, Ci Wang, Lu Wang, Jing-Xian Chen, Hui-Hui Yang, Chen-Yu Zhang, Yong Zhou, Cha-Xiang Guan, Laura Bravo
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef - Ferroptosis is involved in the anti‑tumor effect of lycorine in renal cell carcinoma cells
Yang Du, Hong-Chao Zhao, Heng-Cheng Zhu, Yao Jin, Lei Wang
Oncology Letters.2021;[Epub] CrossRef - Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death
Bufu Tang, Wangting Xu, Yajie Wang, Jinyu Zhu, Hailin Wang, Jianfei Tu, Qiaoyou Weng, Chunli Kong, Yang Yang, Rongfang Qiu, Zhongwei Zhao, Min Xu, Jiansong Ji
Clinical Immunology.2021; 232: 108872. CrossRef - Ferritinophagy‐Mediated ROS Production Contributed to Proliferation Inhibition, Apoptosis, and Ferroptosis Induction in Action of Mechanism of 2‐Pyridylhydrazone Dithiocarbamate Acetate
Longlong Li, Hao Li, Yongli Li, Jiankang Feng, Deng Guan, Yalei Zhang, Yun Fu, Shaoshan Li, Changzheng Li, Maria R. Ciriolo
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef - Construction and analysis of a novel ferroptosis‐related gene signature predicting prognosis in lung adenocarcinoma
Jing Zhou, Xinyue Wang, Zhaona Li, Richeng Jiang
FEBS Open Bio.2021; 11(11): 3005. CrossRef - A Ferroptosis-Related Gene Signature for Predicting the Prognosis and Drug Sensitivity of Head and Neck Squamous Cell Carcinoma
Wei Lu, Yihua Wu, Shengyun Huang, Dongsheng Zhang
Frontiers in Genetics.2021;[Epub] CrossRef - Baicalin suppresses autophagy-dependent ferroptosis in early brain injury after subarachnoid hemorrhage
Bao Zheng, Xiwei Zhou, Lujun Pang, Yanjun Che, Xin Qi
Bioengineered.2021; 12(1): 7794. CrossRef - Biological protein mediated ferroptotic tumor nanotherapeutics
Jiaoyang Tao, Chaoqun Li, Yongquan Zheng, Fengmei Wang, Meng Zhang, Xiaodong Wu, Yue Chen, Qingquan Zeng, Fengying Chen, Weidong Fei
Journal of Materials Chemistry B.2021; 9(45): 9262. CrossRef - The role of ferroptosis in lung cancer
Sikai Wu, Chengchu Zhu, Daolin Tang, Q. Ping Dou, Jianfei Shen, Xin Chen
Biomarker Research.2021;[Epub] CrossRef - Downregulation of Cx43 reduces cisplatin-induced acute renal injury by inhibiting ferroptosis
Meiling Yu, Zhuoheng Lin, Xiaoxue Tian, Shiyu Chen, Xinling Liang, Min Qin, Qian Zhu, Yuanyuan Wu, Shilong Zhong
Food and Chemical Toxicology.2021; 158: 112672. CrossRef - Prognostic significance of ferroptosis-related genes and their methylation in AML
Fang Zhou, Baoan Chen
Hematology.2021; 26(1): 919. CrossRef - Research progress on the mechanism of ferroptosis and its clinical application
Jiarui Xia, Huifang Si, Wu Yao, Chao Li, Guo Yang, Yangyang Tian, Changfu Hao
Experimental Cell Research.2021; 409(2): 112932. CrossRef - The mechanisms and therapeutic targets of ferroptosis in cancer
Long Ye, Fengyan Jin, Shaji K. Kumar, Yun Dai
Expert Opinion on Therapeutic Targets.2021; 25(11): 965. CrossRef - Chemotoxicity-induced exosomal lncFERO regulates ferroptosis and stemness in gastric cancer stem cells
Haiyang Zhang, Meng Wang, Yi He, Ting Deng, Rui Liu, Weixue Wang, Kegan Zhu, Ming Bai, Tao Ning, Haiou Yang, Ying Liu, Junyi Wang, Yi Ba
Cell Death & Disease.2021;[Epub] CrossRef - Oxidative Stress and Inflammation Caused by Cisplatin Ototoxicity
Vickram Ramkumar, Debashree Mukherjea, Asmita Dhukhwa, Leonard P. Rybak
Antioxidants.2021; 10(12): 1919. CrossRef - Ferroptosis: The Silver Lining of Cancer Therapy
Zhengming Tang, Zhijie Huang, Yisheng Huang, Yuanxin Chen, Mingshu Huang, Hongyu Liu, Q. Adam Ye, Jianjiang Zhao, Bo Jia
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef - The Regulatory Effects and the Signaling Pathways of Natural Bioactive Compounds on Ferroptosis
Shenshen Zhang, Ruizhe Hu, Yaping Geng, Ke Chen, Ling Wang, Mustapha Umar Imam
Foods.2021; 10(12): 2952. CrossRef - Ferroptosis in Lung Cancer: From Molecular Mechanisms to Prognostic and Therapeutic Opportunities
Peyman Tabnak, Zanyar HajiEsmailPoor, Soroush Soraneh
Frontiers in Oncology.2021;[Epub] CrossRef - Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC
Meng Li, Yanpeng Zhang, Meng Fan, Hui Ren, Mingwei Chen, Puyu Shi
BMC Medical Genomics.2021;[Epub] CrossRef - Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
Jiayu Zou, Li Wang, Hailin Tang, Xiuxiu Liu, Fu Peng, Cheng Peng
International Journal of Molecular Sciences.2021; 22(24): 13335. CrossRef - The Emerging Role of Ferroptosis in Liver Diseases
Si Chen, Jun-yao Zhu, Xin Zang, Yong-zhen Zhai
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef - Roles of ferroptosis in urologic malignancies
Shankun Zhao, Peng Li, Weizhou Wu, Qinzhang Wang, Biao Qian, Xin Li, Maolei Shen
Cancer Cell International.2021;[Epub] CrossRef - Targeting the Interplay between Cancer Metabolic Reprogramming and Cell Death Pathways as a Viable Therapeutic Path
Elisabetta Iessi, Rosa Vona, Camilla Cittadini, Paola Matarrese
Biomedicines.2021; 9(12): 1942. CrossRef - Research Progress on the Mechanism of Tumor Drug Resistance
爱敏 王
Advances in Clinical Medicine.2021; 11(12): 6139. CrossRef - miR-6077 Promotes Cisplatin/Pemetrexed Resistance in Lung Adenocarcinoma by Targeting CDKN1A/Cell Cycle Arrest and KEAP1/Ferroptosis Pathways
Guoshu Bi, Jiaqi Liang, Mengnan Zhao, Huan Zhang, Xing Jin, Tao Lu, Yuansheng Zheng, Yunyi Bian, Zhencong Chen, Yiwei Huang, Valeria Besskaya, Cheng Zhan, Qun Wang, Lijie Tan
SSRN Electronic Journal .2021;[Epub] CrossRef - Ferroptosis and its emerging role in tumor
Xiaoxuan Wang, Zicheng Liu, Lijuan Ma, Haijie Yu
Biophysics Reports.2021; 7(4): 280. CrossRef - Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers
Eikan Mishima, Emiko Sato, Junya Ito, Ken-ichi Yamada, Chitose Suzuki, Yoshitsugu Oikawa, Tetsuro Matsuhashi, Koichi Kikuchi, Takafumi Toyohara, Takehiro Suzuki, Sadayoshi Ito, Kiyotaka Nakagawa, Takaaki Abe
Journal of the American Society of Nephrology.2020; 31(2): 280. CrossRef - CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
Haiyang Zhang, Ting Deng, Rui Liu, Tao Ning, Haiou Yang, Dongying Liu, Qiumo Zhang, Dan Lin, Shaohua Ge, Ming Bai, Xinyi Wang, Le Zhang, Hongli Li, Yuchong Yang, Zhi Ji, Hailong Wang, Guoguang Ying, Yi Ba
Molecular Cancer.2020;[Epub] CrossRef - Systems biology of ferroptosis: A modeling approach
Anna Konstorum, Lia Tesfay, Bibbin T. Paul, Frank M. Torti, Reinhard C. Laubenbacher, Suzy V. Torti
Journal of Theoretical Biology.2020; 493: 110222. CrossRef - Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases
Yunbin Zhang, Jingjing Song, Zhongwei Zhao, Mengxuan Yang, Ming Chen, Chenglong Liu, Jiansong Ji, Di Zhu
Cancer Letters.2020; 470: 84. CrossRef - Ferroptosis: past, present and future
Jie Li, Feng Cao, He-liang Yin, Zi-jian Huang, Zhi-tao Lin, Ning Mao, Bei Sun, Gang Wang
Cell Death & Disease.2020;[Epub] CrossRef - Functional role of ferroptosis on cancers, activation and deactivation by various therapeutic candidates-an update
The Hong Phong Nguyen, B. Mahalakshmi, Bharath Kumar Velmurugan
Chemico-Biological Interactions.2020; 317: 108930. CrossRef - Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs
Yanwei Su, Bin Zhao, Liangfu Zhou, Zheyuan Zhang, Ying Shen, Huanhuan Lv, Luban Hamdy Hameed AlQudsy, Peng Shang
Cancer Letters.2020; 483: 127. CrossRef - Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology
Rikki A. M. Brown, Kirsty L. Richardson, Tasnuva D. Kabir, Debbie Trinder, Ruth Ganss, Peter J. Leedman
Frontiers in Oncology.2020;[Epub] CrossRef - Nonhomologous end-joining repair is likely involved in the repair of double-stranded DNA breaks induced by riluzole in melanoma cells
Robert Cerchio, Christina Marinaro, Tzeh Keong Foo, Bing Xia, Suzie Chen
Melanoma Research.2020; 30(3): 303. CrossRef - The multifaceted role of reactive oxygen species in tumorigenesis
Anuradha Kirtonia, Gautam Sethi, Manoj Garg
Cellular and Molecular Life Sciences.2020; 77(22): 4459. CrossRef - Redox Modulation and Induction of Ferroptosis as a New Therapeutic Strategy in Hepatocellular Carcinoma
Jana Lippmann, Kathrin Petri, Simone Fulda, Juliane Liese
Translational Oncology.2020; 13(8): 100785. CrossRef The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy
Yuechen Zhao, Yanqing Li, Ruifeng Zhang, Feng Wang, Tiejun Wang, Yan Jiao
OncoTargets and Therapy.2020; Volume 13: 5429. CrossRef- Molecular Mechanisms of Ferroptosis and Its Role in Pulmonary Disease
Ningning Tao, Kang Li, Jingjing Liu
Oxidative Medicine and Cellular Longevity.2020; 2020: 1. CrossRef - Ferroptosis and Cancer: Mitochondria Meet the “Iron Maiden” Cell Death
Anna Martina Battaglia, Roberta Chirillo, Ilenia Aversa, Alessandro Sacco, Francesco Costanzo, Flavia Biamonte
Cells.2020; 9(6): 1505. CrossRef - Acquisition of Cisplatin Resistance Shifts Head and Neck Squamous Cell Carcinoma Metabolism toward Neutralization of Oxidative Stress
Wangjie Yu, Yunyun Chen, Nagireddy Putluri, Cristian Coarfa, Matthew J. Robertson, Vasanta Putluri, Fabio Stossi, Julien Dubrulle, Michael A. Mancini, Jonathan C. Pang, Trung Nguyen, Dodge Baluya, Jeffrey N. Myers, Stephen Y. Lai, Vlad C. Sandulache
Cancers.2020; 12(6): 1670. CrossRef - Ferroptosis-Related Gene Signature Predicts Glioma Cell Death and Glioma Patient Progression
Han-jie Liu, Hui-min Hu, Guan-zhang Li, Ying Zhang, Fan Wu, Xiu Liu, Kuan-yu Wang, Chuan-bao Zhang, Tao Jiang
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef - The Mechanism of Ferroptosis and Applications in Tumor Treatment
Xinyue Lin, Jieyi Ping, Yi Wen, Yan Wu
Frontiers in Pharmacology.2020;[Epub] CrossRef - Systematic analysis of the ABC transporter family in hepatocellular carcinoma reveals the importance of ABCB6 in regulating ferroptosis
Junjun Zhang, Xi Zhang, Jie Li, Zewen Song
Life Sciences.2020; 257: 118131. CrossRef - Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Rong Tang, Jin Xu, Bo Zhang, Jiang Liu, Chen Liang, Jie Hua, Qingcai Meng, Xianjun Yu, Si Shi
Journal of Hematology & Oncology.2020;[Epub] CrossRef - Glutathione Synthesis in Cancer Cells
E. V. Kalinina, L. A. Gavriliuk
Biochemistry (Moscow).2020; 85(8): 895. CrossRef - Sestrin2 Expression Has Regulatory Properties and Prognostic Value in Lung Cancer
Hee Sung Chae, Minchan Gil, Subbroto Kumar Saha, Hee Jeung Kwak, Hwan-Woo Park, Balachandar Vellingiri, Ssang-Goo Cho
Journal of Personalized Medicine.2020; 10(3): 109. CrossRef - Near Infrared‐Activatable Platinum‐Decorated Gold Nanostars for Synergistic Photothermal/Ferroptotic Therapy in Combating Cancer Drug Resistance
Andrea C. del Valle, Chih‐Kuang Yeh, Yu‐Fen Huang
Advanced Healthcare Materials.2020;[Epub] CrossRef - Ferroptosis in Cancer Treatment: Another Way to Rome
Yinan Wu, Chengcheng Yu, Meng Luo, Chen Cen, Jili Qiu, Suzhan Zhang, Kaimin Hu
Frontiers in Oncology.2020;[Epub] CrossRef - Emerging roles of ferroptosis in liver pathophysiology
Kyu Min Kim, Sam Seok Cho, Sung Hwan Ki
Archives of Pharmacal Research.2020; 43(10): 985. CrossRef - Ferrostatin-1 protects auditory hair cells from cisplatin-induced ototoxicity in vitro and in vivo
Bing Hu, Yunsheng Liu, Xiaozhu Chen, Jianjun Zhao, Jinghong Han, Hongsong Dong, Qingyin Zheng, Guohui Nie
Biochemical and Biophysical Research Communications.2020; 533(4): 1442. CrossRef - Bioactive metal-containing nanomaterials for ferroptotic cancer therapy
Weidong Fei, Yue Zhang, Yiqing Ye, Chaoqun Li, Yao Yao, Meng Zhang, Fanzhu Li, Caihong Zheng
Journal of Materials Chemistry B.2020; 8(46): 10461. CrossRef - Expression of ATP/GTP Binding Protein 1 Has Prognostic Value for the Clinical Outcomes in Non-Small Cell Lung Carcinoma
Hee Jeong Kwak, Minchan Gil, Hee Sung Chae, Jaekwon Seok, Nagasundarapandian Soundrarajan, Subbroto Kumar Saha, Aram Kim, Kyoung Sik Park, Chankyu Park, Ssang-Goo Cho
Journal of Personalized Medicine.2020; 10(4): 263. CrossRef - The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors
Jinghan Zhu, Yixiao Xiong, Yuxin Zhang, Jingyuan Wen, Ning Cai, Kun Cheng, Huifang Liang, Wanguang Zhang, Xin Yi
Oxidative Medicine and Cellular Longevity.2020; 2020: 1. CrossRef - Regulated Necrotic Cell Death in Alternative Tumor Therapeutic Strategies
Yunseo Woo, Hyo-Ji Lee, Young Mee Jung, Yu-Jin Jung
Cells.2020; 9(12): 2709. CrossRef - Nanomaterial-induced ferroptosis for cancer specific therapy
Mei Liu, Bin Liu, Qianqian Liu, Keke Du, Zhifei Wang, Nongyue He
Coordination Chemistry Reviews.2019; 382: 160. CrossRef - Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Yanhua Mou, Jun Wang, Jinchun Wu, Dan He, Chunfang Zhang, Chaojun Duan, Bin Li
Journal of Hematology & Oncology.2019;[Epub] CrossRef - Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion
José Pedro Friedmann Angeli, Dmitri V. Krysko, Marcus Conrad
Nature Reviews Cancer.2019; 19(7): 405. CrossRef - Molecular mechanisms of ferroptosis and its role in cancer therapy
Tao Xu, Wei Ding, Xiaoyu Ji, Xiang Ao, Ying Liu, Wanpeng Yu, Jianxun Wang
Journal of Cellular and Molecular Medicine.2019; 23(8): 4900. CrossRef - A New Approach in Cancer Treatment: Discovery of Chlorido[N,N′-disalicylidene-1,2-phenylenediamine]iron(III) Complexes as Ferroptosis Inducers
Jessica Sagasser, Benjamin N. Ma, Daniel Baecker, Stefan Salcher, Martin Hermann, Julia Lamprecht, Stefanie Angerer, Petra Obexer, Brigitte Kircher, Ronald Gust
Journal of Medicinal Chemistry.2019; 62(17): 8053. CrossRef - Recent Progress in Ferroptosis Inducers for Cancer Therapy
Chen Liang, Xinglin Zhang, Mengsu Yang, Xiaochen Dong
Advanced Materials.2019;[Epub] CrossRef - Myo-inositol oxygenase expression profile modulates pathogenic ferroptosis in the renal proximal tubule
Fei Deng, Isha Sharma, Yingbo Dai, Ming Yang, Yashpal S. Kanwar
Journal of Clinical Investigation.2019; 129(11): 5033. CrossRef - STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma
Yuanyang Lai, Zhipei Zhang, Jianzhong Li, Weimiao Li, Zhao Huang, Chenxi Zhang, Xiaofei Li, Jinbo Zhao
Biochemical and Biophysical Research Communications.2019; 519(4): 659. CrossRef - Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer
Hai-Hong Zhou, Xu Chen, Lu-Ya Cai, Xing-Wei Nan, Jia-Hua Chen, Xiu-Xiu Chen, Yang Yang, Zi-Hao Xing, Meng-Ning Wei, Yao Li, Sheng-Te Wang, Kun Liu, Zhi Shi, Xiao-Jian Yan
Frontiers in Oncology.2019;[Epub] CrossRef - The role of ferroptosis in digestive system cancer (Review)
Yan Song, Hu Yang, Rui Lin, Kui Jiang, Bang‑Mao Wang
Oncology Letters.2019;[Epub] CrossRef - Potential mechanism of ferroptosis in pancreatic cancer (Review)
Gang Chen, Guangqi Guo, Xiaodong Zhou, Hongxia Chen
Oncology Letters.2019;[Epub] CrossRef - Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death
Lia Tesfay, Bibbin T. Paul, Anna Konstorum, Zhiyong Deng, Anderson O. Cox, Jingyun Lee, Cristina M. Furdui, Poornima Hegde, Frank M. Torti, Suzy V. Torti
Cancer Research.2019; 79(20): 5355. CrossRef - Interactions of Schiff base compounds and their coordination complexes with the drug cisplatin
József Magyari, Berta Barta Holló, Ljiljana S. Vojinović-Ješić, Mirjana M. Radanović, Stevan Armaković, Sanja J. Armaković, Joseph Molnár, Annamária Kincses, Márió Gajdács, Gabriella Spengler, Katalin Mészáros Szécsényi
New Journal of Chemistry.2018; 42(8): 5834. CrossRef - Oxytosis/Ferroptosis—(Re-) Emerging Roles for Oxidative Stress-Dependent Non-apoptotic Cell Death in Diseases of the Central Nervous System
Jan Lewerenz, Gamze Ates, Axel Methner, Marcus Conrad, Pamela Maher
Frontiers in Neuroscience.2018;[Epub] CrossRef - Routes to cell death in animal and plant kingdoms: from classic apoptosis to alternative ways to die—a review
Sonia Emanuele, Elisabetta Oddo, Antonella D’Anneo, Antonietta Notaro, Giuseppe Calvaruso, Marianna Lauricella, Michela Giuliano
Rendiconti Lincei. Scienze Fisiche e Naturali.2018; 29(2): 397. CrossRef - Role of ferroptosis in hepatocellular carcinoma
Jianhua Nie, Binlin Lin, Meng Zhou, Li Wu, Tongsen Zheng
Journal of Cancer Research and Clinical Oncology.2018; 144(12): 2329. CrossRef - Induction of reactive oxygen species: an emerging approach for cancer therapy
Zhengzhi Zou, Haocai Chang, Haolong Li, Songmao Wang
Apoptosis.2017; 22(11): 1321. CrossRef - Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Brent R. Stockwell, José Pedro Friedmann Angeli, Hülya Bayir, Ashley I. Bush, Marcus Conrad, Scott J. Dixon, Simone Fulda, Sergio Gascón, Stavroula K. Hatzios, Valerian E. Kagan, Kay Noel, Xuejun Jiang, Andreas Linkermann, Maureen E. Murphy, Michael Overh
Cell.2017; 171(2): 273. CrossRef
- Illuminating cisplatin-induced ferroptosis in non-small-cell lung cancer with biothiol-activatable fluorescent/photoacoustic bimodal probes
- 23,684 View
- 1,403 Download
- 524 Web of Science
- 505 Crossref
- Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
- Sang Myung Woo, Min Kyeong Kim, Jungnam Joo, Kyong-Ah Yoon, Boram Park, Sang-Jae Park, Sung-Sik Han, Ju Hee Lee, Eun Kyung Hong, Yun-Hee Kim, Hae Moon, Sun-Young Kong, Tae Hyun Kim, Woo Jin Lee
- Cancer Res Treat. 2017;49(4):1022-1032. Published online January 19, 2017
- DOI: https://doi.org/10.4143/crt.2016.495
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
This study assessed the feasibility and compliance of induction chemotherapy with gemcitabine and cisplatin followed by simultaneous integrated boost–intensity modulated radiotherapy (SIB-IMRT) with concurrent gemcitabine in patients with locally advanced unresectable pancreatic cancer.
Materials and Methods
In this trial, patients received induction chemotherapy consisting of gemcitabine (1,000 mg/m2) and cisplatin (25 mg/m2) on days 1, 8, and 15 of each treatment cycle. Patients were subsequently treated with gemcitabine (300 mg/m2/wk) during SIB-IMRT. The patients received total doses of 55 and 44 Gy in 22 fractions to planning target volume 1 and 2, respectively. As an ancillary study, digital polymerase chain reaction was performed to screen for the seven most common mutations in codons 12 and 13 of the KRAS oncogene of circulating cell free DNA (cfDNA).
Results
Forty-four patients were enrolled between 2012 and 2015. Of these, 33 (75%) completed the treatment. The most common toxicities during induction chemotherapy were grades 3 and 4 neutropenia (18.2%), grade 3 nausea (6.8%) and vomiting (6.8%). The most common toxicities during SIB-IMRT were grade 3 neutropenia (24.2%) and grade 3 anemia (12.1%). Ten patients (23%) underwent a curative resection after therapy. Median overall survival was significantly longer in patients who underwent curative resection (16.8 months vs. 11 months, p < 0.01). The median cfDNA concentration was significantly lower after treatment (108.5 ng/mL vs. 18.4 ng/mL, p < 0.001).
Conclusion
Induction chemotherapy with gemcitabine and cisplatin followed by concurrent SIB-IMRT was well tolerated and active. -
Citations
Citations to this article as recorded by- Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma
Krishan R. Jethwa, Ed Kim, Jordan Berlin, Christopher J. Anker, Leila Tchelebi, Gerard Abood, Christopher L. Hallemeier, Salma Jabbour, Timothy Kennedy, Rachit Kumar, Percy Lee, Navesh Sharma, William Small, Vonetta Williams, Suzanne Russo
American Journal of Clinical Oncology.2024; 47(4): 185. CrossRef - Kinetics of plasma cell-free DNA as a prospective biomarker to predict the prognosis and radiotherapy effect of esophageal cancer
Y. Li, J. Wu, Y. Feng, D. Wang, H. Tao, J. Wen, F. Jiang, P. Qian, Y. Liu
Cancer/Radiothérapie.2024; 28(3): 242. CrossRef - Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?
Olivier Caliez, Daniel Pietrasz, Feryel Ksontini, Solène Doat, Jean-Marc Simon, Jean-Christophe Vaillant, Valerie Taly, Pierre Laurent-Puig, Jean-Baptiste Bachet
Digestive and Liver Disease.2022; 54(10): 1428. CrossRef - Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review
Marisol Huerta, Susana Roselló, Luis Sabater, Ana Ferrer, Noelia Tarazona, Desamparados Roda, Valentina Gambardella, Clara Alfaro-Cervelló, Marina Garcés-Albir, Andrés Cervantes, Maider Ibarrola-Villava
Cancers.2021; 13(5): 994. CrossRef - Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Irina Palacín-Aliana, Noemí García-Romero, Adrià Asensi-Puig, Josefa Carrión-Navarro, Víctor González-Rumayor, Ángel Ayuso-Sacido
Biomedicines.2021; 9(8): 906. CrossRef - A review on the efficacy and safety of iodine-125 seed implantation in unresectable pancreatic cancers
Sheng-Nan Jia, Fu-Xing Wen, Ting-Ting Gong, Xin Li, Hui-Jie Wang, Ya-Min Sun, Ze-Cheng Yang
International Journal of Radiation Biology.2020; 96(3): 383. CrossRef - Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer
Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Eun Sang Oh, Sang Hee Youn, Hye Young Jang, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
Scientific Reports.2020;[Epub] CrossRef - Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment
Kyong-Ah Yoon, Sang Myung Woo, Yun-Hee Kim, Sun-Young Kong, Min Kyoung Lee, Sung-Sik Han, Tae Hyun Kim, Woo Jin Lee, Sang-Jae Park
Gut and Liver.2019; 13(6): 683. CrossRef - Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma
Sangjoon Park, Eun Jung Lee, Chai Hong Rim, Jinsil Seong
Yonsei Medical Journal.2018; 59(4): 470. CrossRef - Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer
Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Hyunjung Kim, Eun Sang Oh, Ju Hee Lee, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
Technology in Cancer Research & Treatment.2018;[Epub] CrossRef
- Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma
- 9,947 View
- 254 Download
- 11 Web of Science
- 10 Crossref
- Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
- Keunchil Park, Eun Kyung Cho, Maximino Bello, Myung-Ju Ahn, Sumitra Thongprasert, Eun-Kee Song, Victoria Soldatenkova, Henrik Depenbrock, Tarun Puri, Mauro Orlando
- Cancer Res Treat. 2017;49(4):937-946. Published online January 6, 2017
- DOI: https://doi.org/10.4143/crt.2016.423
-
Abstract
PDFPubReaderePub
- Purpose
The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone (GC) in 1,093 patients with previously untreated advanced squamous non-small cell lung cancer (NSCLC). This post hoc subgroup analysis assessed the efficacy and safety of neci+GC among East Asian (EA) patients enrolled in the study.
Materials and Methods
All patients received up to six 3-week cycles of gemcitabine (days 1 and 8, 1,250 mg/m²) and cisplatin (day 1, 75 mg/m²). Patients in the neci+GC arm also received necitumumab (days 1 and 8, 800 mg) until disease progression or unacceptable toxicity. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from stratified Cox proportional hazards models.
Results
In EA patients, there were improvements for neci+GC (n=43) versus GC (n=41) in OS (HR, 0.805; 95% CI, 0.484 to 1.341) and PFS (HR, 0.720; 95% CI, 0.439 to 1.180), consistent with the results for non-EA patients observed in the present study. The overall safety data were consistent between EA and non-EA patients. A numerically higher proportion of patients experienced serious adverse events (AEs), grade ≥ 3 AEs, and AEs with an outcome of death for neci+GC versus GC in EA patients and EA patients versus non-EA patients for neci+GC.
Conclusion
Although limited by the small sample size and post hoc nature of the analysis, these findings are consistent with those of the overall study and suggest that neci+GC offers a survival advantage and favorable benefit/risk for EA patients with advanced squamous NSCLC. -
Citations
Citations to this article as recorded by- Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
The Hong Phong Nguyen, V. Bharath Kumar, Vinoth Kumar Ponnusamy, Thi Thu Thao Mai, Phuong Tran Nhat, Kathirvel Brindhadevi, Arivalagan Pugazhendhi
Process Biochemistry.2021; 104: 55. CrossRef - Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis
Irena Ilic, Sandra Sipetic, Jovan Grujicic, Milena Ilic
Journal of Oncology Pharmacy Practice.2020; 26(6): 1331. CrossRef - Recent progress in systemic treatment for lung cancer
Jeffrey W. Clark, Dan L. Longo
Current Opinion in Pulmonary Medicine.2018; 24(4): 355. CrossRef - Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies
Vincenzo di Noia, Ettore D’Argento, Sara Pilotto, Giulia Grizzi, Mario Caccese, Roberto Iacovelli, Giampaolo Tortora, Emilio Bria
Expert Opinion on Biological Therapy.2018; 18(9): 937. CrossRef - SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau, Fiona Blackhall, Noor Md Haris, Colin R Lindsay, Raffaele Califano, Mark Voskoboynik, Yvonne Summers, Karen So, Dana Ghiorghiu, Angela W Dymond, Stuart Hossack, Ruth Plummer, Emma Dean
British Journal of Cancer.2017; 117(7): 938. CrossRef
- Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
- 10,912 View
- 402 Download
- 8 Web of Science
- 5 Crossref
- A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
- Keun-Wook Lee, Bum Jun Kim, Mi-Jung Kim, Hye Sook Han, Jin Won Kim, Young Iee Park, Sook Ryun Park
- Cancer Res Treat. 2017;49(3):706-716. Published online October 18, 2016
- DOI: https://doi.org/10.4143/crt.2016.216
-
Abstract
PDFPubReaderePub
- Purpose
This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine regimen.
Materials and Methods
Patients with progressive disease after first-line cisplatin plus S-1 or capecitabine were randomized to receive 3-week cycles of docetaxel 75 mg/m2 intravenously (IV) on D1 (D), docetaxel 60 mg/m2 IV plus cisplatin 60 mg/m² IV on D1 (DC), or docetaxel 60 mg/m2 IV D1 plus oral S-1 30 mg/m2 twice a day on D1-14 (DS).
Results
Seventy-two patients were randomized to the D (n=23), DC (n=24), or DS (n=25) group. The confirmed response rate was 4.3% (95% confidence interval [CI], 0% to 12.6%), 4.3% (95% CI, 0% to 12.6%), and 8.7% (95% CI, 0% to 20.2%) for the D, DC, and DS groups, respectively. Compared to the D arm, the DS arm had a better progression-free survival (2.7 months vs. 1.3 months, p=0.034) without any deterioration in safety or quality of life, whereas the DC arm had a similar progression-free survival (1.8 months vs. 1.3 months, p=0.804) and poorer overall survival (5.6 months vs. 10.0 months, p=0.035).
Conclusion
A re-challenge with S-1, but not cisplatin, in combination with docetaxel has potential anticancer benefits over docetaxel alone in MGC with progression after prior cisplatin plus S-1 or capecitabine. -
Citations
Citations to this article as recorded by- Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab
Yulia D’yachkova, Astra M. Liepa, Rajat Goel, Veronika Earley-Valovic, Abby Paine, Palvi Gupta, Kaisa Taipale
Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef - Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
Frontiers in Pharmacology.2024;[Epub] CrossRef - Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis
Lauren A. Abderhalden, Ping Wu, Mayur M. Amonkar, Brian M. Lang, Sukrut Shah, Fan Jin, Andrew M. Frederickson, Ali Mojebi
Journal of Gastrointestinal Cancer.2023; 54(4): 1031. CrossRef - Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies
J. Hack, S.J. Crabb
Clinical Oncology.2022; 34(8): e329. CrossRef - Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Alison Rowsell, Samantha C. Sodergren, Vassilios Vassiliou, Anne-Sophie Darlington, Marianne G. Guren, Bilal Alkhaffaf, Chantelle Moorbey, Kristopher Dennis, Mitsumi Terada
Gastric Cancer.2022; 25(4): 665. CrossRef - Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology
Elisabeth Coart, Everardo D. Saad
Expert Review of Precision Medicine and Drug Development.2021; 6(4): 271. CrossRef - Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Daniel V. Catenacci, Joseph Chao, Kei Muro, Salah Eddin Al-Batran, Samuel J. Klempner, Zev A. Wainberg, Manish A. Shah, Sun Young Rha, Atsushi Ohtsu, Astra M. Liepa, Holly Knoderer, Anindya Chatterjee, Eric Van Cutsem
The Oncologist.2021; 26(10): e1704. CrossRef - Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef - Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi
Medical Council.2019; (10): 100. CrossRef - Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
Bo Li, Lian Chen, Hong-Liang Luo, Feng-Ming Yi, Yi-Ping Wei, Wen-Xiong Zhang
World Journal of Clinical Cases.2019; 7(5): 600. CrossRef - A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer
Dan Zhang, Jia-Rui Wu, Xiao-Jiao Duan, Kai-Huan Wang, Yi Zhao, Meng-Wei Ni, Shu-Yu Liu, Xiao-Meng Zhang, Bing Zhang
Frontiers in Pharmacology.2019;[Epub] CrossRef - Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis
Ji Cheng, Ming Cai, Xiaoming Shuai, Jinbo Gao, Guobin Wang, Kaixiong Tao
Critical Reviews in Oncology/Hematology.2019; 143: 27. CrossRef - Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis
Jessy Joy van Kleef, Emil ter Veer, Héctor G van den Boorn, Sandor Schokker, Lok Lam Ngai, Mariska J Prins, Nadia Haj Mohammad, Lonneke V van de Poll-Franse, Aeilko H Zwinderman, Martijn G H van Oijen, Mirjam A G Sprangers, Hanneke W M van Laarhoven
JNCI: Journal of the National Cancer Institute.2019;[Epub] CrossRef
- Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab
- 10,721 View
- 358 Download
- 13 Web of Science
- 13 Crossref
- Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
- Miso Kim, Bhumsuk Keam, Tae-Min Kim, Hoon-Gu Kim, Jin-Soo Kim, Sung Sook Lee, Seong Hoon Shin, Min Kyoung Kim, Keon Uk Park, Dong-Wan Kim, Hwan Jung Yun, Jong Seok Lee, Dae Seog Heo
- Cancer Res Treat. 2017;49(2):416-422. Published online July 28, 2016
- DOI: https://doi.org/10.4143/crt.2016.121
-
Abstract
PDFPubReaderePub
- Purpose
The objective of this multicenter phase II study was to evaluate the efficacy and safety of irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancer.
Materials and Methods
Patients were treated with irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 of each 21-day treatment cycle. The primary endpoint was response rate, and secondary endpoints were survival, duration of response, initial metabolic response rate, and toxicity.
Results
A total of 27 patients with squamous cell histology were enrolled in the study. The median age of the patients was 61 years. The objective response rate of the 20 patients in the perprotocol group was 30.0% (90% confidence interval [CI], 13.2 to 46.9). The median follow-up duration was 10.0 months, and the median progression-free survival and overall survival were 4.5 months (95% CI, 1.6 to 6.2) and 8.8 months (95% CI, 4.7 to 10.5), respectively. Four of 13 patients (30.8%) evaluated showed initial metabolic response. The median duration of response for partial responders was 5.0 months (range, 3.4 to 8.0 months). The following grade 3/4 treatment-related hematologic toxicities were reported: neutropenia (40.7%), anaemia (22.2%), and thrombocytopenia (7.4%). Two patients experienced febrile neutropenia. The most common grade 3/4 non-hematologic toxicities were asthenia (14.8%) and diarrhoea (11.1%).
Conclusion
Irinotecan and cisplatin combination chemotherapy showed modest anti-tumour activity and manageable toxicity for patients with metastatic, unresectable esophageal cancer. -
Citations
Citations to this article as recorded by- Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Akira Ooki, Hiroki Osumi, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef - Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study
Xichao Dai, Leilei Tao, Jinqiu Wang, Wenjuan Wu, Weigang Bian, Xichun Dai, Surong Chen
Cancer Medicine.2023; 12(15): 16108. CrossRef - Cisplatin-based combination therapy for cancer
Minerva, Amrita Bhat, Sonali Verma, Gresh Chander, Rajeshwer Singh Jamwal, Bhawani Sharma, Audesh Bhat, Taruna Katyal, Rakesh Kumar, Ruchi Shah
Journal of Cancer Research and Therapeutics.2023; 19(3): 530. CrossRef - The development and progress of nanomedicine for esophageal cancer diagnosis and treatment
Xiaokun Li, Lingmin Chen, Siyuan Luan, Jianfeng Zhou, Xin Xiao, Yushang Yang, Chengyi Mao, Pinhao Fang, Longqi Chen, Xiaoxi Zeng, Huile Gao, Yong Yuan
Seminars in Cancer Biology.2022; 86: 873. CrossRef - Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
Zhihuang Hu, Si Sun, Xinmin Zhao, Hui Yu, Xianghua Wu, Jialei Wang, Jianhua Chang, Huijie Wang
The Oncologist.2022; 27(4): 253. CrossRef - Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
Tianhui Wei, Wenqi Ti, Qingxu Song, Yufeng Cheng
Current Oncology.2022; 29(5): 2920. CrossRef - Combined treatment with niclosamide and camptothecin enhances anticancer effect in U87 MG human glioblastoma cells
Laura Valdez, Benxu Cheng, Daniela Gonzalez, Reanna Rodriguez, Paola Campano, Andrew Tsin, Xiaoqian Fang
Oncotarget.2022; 13(1): 642. CrossRef - Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect
Jiyun Lee, Binnari Kim, Hyun Ae Jung, Yoon La Choi, Jong-Mu Sun
Cancer Immunology, Immunotherapy.2021; 70(5): 1203. CrossRef - Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Paul B Tchounwou, Shaloam Dasari, Felicite K Noubissi, Paresh Ray, Sanjay Kumar
Journal of Experimental Pharmacology.2021; Volume 13: 303. CrossRef - SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
Lan Mu, Yan Song, Kuaile Zhao, Ying Liu, Qingxia Fan, Xi Wang, Qun Li, Xiaopeng Wang, Jing Huang
Thoracic Cancer.2021; 12(9): 1373. CrossRef - Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small cell lung cancer
Mahsa Shahriari, Seyed Mohammad Taghdisi, Khalil Abnous, Mohammad Ramezani, Mona Alibolandi
Journal of Controlled Release.2021; 335: 369. CrossRef - Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
Min Liu, Qingqing Jia, Xiaolin Wang, Changjiang Sun, Jianqi Yang, Yanliang Chen, Ying Li, Lingfeng Min, Xizhi Zhang, Caiyun Zhu, Johannes Artiaga Gubat, Yong Chen
Anti-Cancer Drugs.2020; 31(4): 403. CrossRef - Jiawei Xianglian Decoction (JWXLD), a Traditional Chinese Medicine (TCM), Alleviates CPT‐11‐Induced Diarrhea in Mice
Jinhua Lu, Zechen Lin, Siyu Huang, Yiwei Shen, Jing Jiang, Shengyou Lin, Oliver Micke
Evidence-Based Complementary and Alternative Medicine.2020;[Epub] CrossRef - Treatment of esophageal cancer with multiple liver metastases: a case experience of sustained complete response
Jiangfang Wang, Chaoyang Xu
Journal of International Medical Research.2020;[Epub] CrossRef - Development of chemotherapeutics for unresectable advanced esophageal cancer
Hiroshi Imazeki, Ken Kato
Expert Review of Anticancer Therapy.2020; 20(12): 1083. CrossRef - Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
Bo Zhang, Ling Qi, Xi Wang, Jianping Xu, Yun Liu, Lan Mu, Xingyuan Wang, Lidan Bai, Jing Huang
Cancer Communications.2020; 40(12): 711. CrossRef - Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy
Hidekazu Hirano, Ken Kato
Japanese Journal of Clinical Oncology.2019; 49(5): 412. CrossRef - Carboxylesterase and UDP‐glucuronosyltransferases mediated metabolism of irinotecan: In vitro and in vivo insights from quantitative ultra‐performance liquid chromatography–mass spectrometry analysis
Yifeng Qin, An Kang, Guisheng Zhou, Huan Wang, Wei Wei, Yujie Cao, Yanyan Chen, Jing Wang, Yajun Shi, Yuping Tang, Jianqin Jiang
Biomedical Chromatography.2018;[Epub] CrossRef - A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model
Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kentaro Miyake, Kentaro Igarashi, Kei Kawaguchi, Hiromichi Oshiro, Takashi Higuchi, Masuyo Miyake, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Bartosz Chmielowski, Scott D. N
Biochemical and Biophysical Research Communications.2018; 505(3): 733. CrossRef - Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy
Yi-Han Chiu, Shih-Hsien Hsu, Hsiao-Wei Hsu, Kuo-Chin Huang, Wangta Liu, Chang-Yi Wu, Wei-Pang Huang, Jeff Chen, Bing-Hung Chen, Chien-Chih Chiu
International Journal of Oncology.2018;[Epub] CrossRef - ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PNCA
Xin-Fang Hou, Lin-Ping Xu, Hai-Yan Song, Shuai Li, Chen Wu, Ju-Feng Wang
World Journal of Gastroenterology.2017; 23(10): 1796. CrossRef - Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer
Bin Wei, Jiru Wang, Xiaohui Zhang, Zhaoye Qian, Jingjing Wu, Yuan Sun, Qin Han, Li Wan, Jing Zhu, Yong Gao, Xiaofei Chen
Oncology Letters.2017;[Epub] CrossRef
- Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
- 11,859 View
- 272 Download
- 27 Web of Science
- 22 Crossref
- Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
- Do-Youn Oh, Toshihiko Doi, Kuniaki Shirao, Keun-Wook Lee, Sook Ryun Park, Ying Chen, Liqiang Yang, Olga Valota, Yung-Jue Bang
- Cancer Res Treat. 2015;47(4):687-696. Published online February 12, 2015
- DOI: https://doi.org/10.4143/crt.2014.225
-
Abstract
PDFPubReaderePub
- Purpose
This phase I trial evaluated the question of whether the standard starting dose of axitinib could be administered in combination with therapeutic doses of cisplatin/capecitabine in patients with previously untreated advanced gastric cancer, and assessed overall safety, pharmacokinetics, and preliminary antitumor activity of this combination.
Materials and Methods
Patients in dose level (DL) 1 received axitinib 5 mg twice a day (days 1 to 21) with cisplatin 80 mg/m2 (day 1) and capecitabine 1,000 mg/m2 twice a day (days 1 to 14) in 21-day cycles. Maximum tolerated dose (MTD) was the highest dose at which ≤ 30% of the first 12 patients experienced a dose-limiting toxicity (DLT) during cycle 1. Ten additional patients were enrolled and treated at the MTD in order to obtain additional safety and pharmacokinetic data.
Results
Three DLTs occurred during cycle 1 in three (25%) of the first 12 patients: ruptured abdominal aortic aneurysm, acute renal failure, and > 5 consecutive days of missed axitinib due to thrombocytopenia. DL1 was established as the MTD, since higher DL cohorts were not planned. Common grade 3/4 non-hematologic adverse events in 22 patients treated at DL1 included hypertension (36.4%) and decreased appetite and stomatitis (18.2% each). Cisplatin/capecitabine slightly increased axitinib exposure; axitinib decreased capecitabine and 5-fluorouracil exposure. Eight patients (36.4%) each had partial response or stable disease. Median response duration was 9.1 months; median progression-free survival was 3.8 months.
Conclusion
In patients with advanced gastric cancer, standard doses of axitinib plus therapeutic doses of cisplatin and capecitabine could be administered in combination. Adverse events were manageable. -
Citations
Citations to this article as recorded by- Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review)
Heng Yun, Fangde Dong, Xiaoqin Wei, Xinyong Yan, Ronglong Zhang, Xiuyu Zhang, Yulin Wang
Oncology Reports.2024;[Epub] CrossRef - Construction of a hypoxia-immune-related prognostic panel based on integrated single-cell and bulk RNA sequencing analyses in gastric cancer
Cuncan Deng, Guofei Deng, Hongwu Chu, Songyao Chen, Xiancong Chen, Xing Li, Yulong He, Chunhui Sun, Changhua Zhang
Frontiers in Immunology.2023;[Epub] CrossRef - Early TP53 Alterations Shape Gastric and Esophageal Cancer Development
Pranshu Sahgal, Brandon M. Huffman, Deepa T. Patil, Walid K. Chatila, Rona Yaeger, James M. Cleary, Nilay S. Sethi
Cancers.2021; 13(23): 5915. CrossRef -
High
ELK3
Expression is Associated with the VEGF-C/VEGFR-3 Axis and Gastric Tumorigenesis and Enhances Infiltration of M2 Macrophages
Wang Dazhi, Jiao Zheng, Ren Chunling
Future Medicinal Chemistry.2020; 12(24): 2209. CrossRef - RETRACTED: Long non-coding RNA LINC00978 promotes cell proliferation and tumorigenesis via regulating microRNA-497/NTRK3 axis in gastric cancer
Ju-Yuan Bu, Wei-Ze Lv, Yi-Feng Liao, Xiao-Yu Xiao, Bao-Jun Lv
International Journal of Biological Macromolecules.2019; 123: 1106. CrossRef - RETRACTED ARTICLE: Anti-gastric cancer effect of Salidroside through elevating miR-99a expression
Lin Yang, Yanan Yu, Qi Zhang, Xiaoyu Li, Cuiping Zhang, Tao Mao, Siliang Liu, Zibin Tian
Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 3500. CrossRef - Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa, Lorenzo Lo Muzio
BioMed Research International.2018; 2018: 1. CrossRef - Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang
Cancer Research and Treatment.2017; 49(4): 851. CrossRef - Angiogenesis inhibitors in early development for gastric cancer
Mauricio P. Pinto, Gareth I. Owen, Ignacio Retamal, Marcelo Garrido
Expert Opinion on Investigational Drugs.2017; 26(9): 1007. CrossRef - HER2-induced metastasis is mediated by AKT/JNK/EMT signaling pathway in gastric cancer
Yiseul Choi, Young San Ko, Jin Ju Park, Youngsun Choi, Younghoon Kim, Jung-Soo Pyo, Bo Gun Jang, Douk Ho Hwang, Woo Ho Kim, Byung Lan Lee
World Journal of Gastroenterology.2016; 22(41): 9141. CrossRef
- Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review)
- 15,150 View
- 108 Download
- 12 Web of Science
- 10 Crossref
- Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
- Yun-Gyoo Lee, Eunyoung Lee, Inho Kim, Keun-Wook Lee, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo
- Cancer Res Treat. 2015;47(4):670-675. Published online January 2, 2015
- DOI: https://doi.org/10.4143/crt.2014.045
-
Abstract
PDFPubReaderePub
- Purpose
Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. The aim of this study was to determine the incidence of TEEs in patients with SCLC and to analyze the predictors for TEE occurrence. Materials and Methods We retrospectively analyzed 277 patients who received chemotherapy for SCLC between 2006 and 2012. As the influence of chemotherapy on TEE occurrence developed after its initiation, a time-dependent Cox regression analysis was used to estimate the significant predictors for TEE. Results Among the 277 patients, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of 30 total TEEs, 22 (73%) occurred between the time of initiation and 4 weeks after the last dose of platinum-based chemotherapy. Approximately 218 patients (79%) received cisplatin-based chemotherapy. In multivariate analysis, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (hazard ratio [HR], 4.36; p=0.05). Variables including smoking status (common HR, 2.14; p=0.01) and comorbidity index (common HR, 1.60; p=0.05) also showed significant association with TEE occurrence. Conclusion The 1-year cumulative incidence of TEE is 10.2% in Asian patients with SCLC. Cisplatinbased chemotherapy in SCLC might be a strong predictor for the risk of TEE. -
Citations
Citations to this article as recorded by- Lung cancer, comorbidities, and medication: the infernal trio
Hélène Pluchart, Sébastien Chanoine, Denis Moro-Sibilot, Christos Chouaid, Gil Frey, Julie Villa, Bruno Degano, Matteo Giaj Levra, Pierrick Bedouch, Anne-Claire Toffart
Frontiers in Pharmacology.2024;[Epub] CrossRef - Acute brachial artery occlusion following cisplatin-based chemotherapy: case report
Abenezer Melaku Tafese, Amanuel Yegnanew Adela, Assefa Getachew Kebede, Aklilu Sinte Tegegn, Elsabeth Tizazu Asare, Munir Awol
SAGE Open Medical Case Reports.2024;[Epub] CrossRef - Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis
Theresa Nwagha, Martins Nweke
Clinical Medicine Insights: Oncology.2023;[Epub] CrossRef - Seratrodast platinum(iv) hybrids efficiently inhibit cancer-related thrombosis and metastasis phenotype in vitro and in vivo
Xue-Qing Song, Yi-Xin Ding, Yu-Hang Zhang, Qing Xu, Xiaofeng Xie, Yali Song, Longfei Li
Inorganic Chemistry Frontiers.2023; 10(22): 6596. CrossRef - Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
Hundo Cho, Jin-Hyuk Choi, Seok Yun Kang, Hyun Woo Lee, Yong Won Choi, Tae-Hwan Kim, Mi Sun Ahn, Chul-Ho Kim, Yoo Seob Shin, Jeon Yeob Jang, Young-Taek Oh, Jaesung Heo, Seung Soo Sheen
The Korean Journal of Internal Medicine.2022; 37(3): 653. CrossRef - Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
Tae-Hwan Kim, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Heejun Son, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
Scientific Reports.2022;[Epub] CrossRef - Embolic Stroke Due to a Mural Thrombus in the Ascending Aorta Following Cisplatin-based Chemotherapy
Yukiko Ochiai, Marie Tsunogae, Masayuki Ueda
Internal Medicine.2021; 60(6): 945. CrossRef - Effect of thromboprophylaxis on the incidence of venous thromboembolism in surgical patients with colorectal cancer: a meta-analysis
Yu-Dong Li, Hai-Dong Li, Shu-Xin Zhang
International Angiology.2020;[Epub] CrossRef - Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients
Ruth Maria Schorling, Christian Pfrepper, Thomas Golombek, Chiara Alessandra Cella, Nerea Muñoz-Unceta, Roland Siegemund, Christoph Engel, Sirak Petros, Florian Lordick, Maren Knödler
Oncology Research and Treatment.2020; 43(9): 414. CrossRef - Aortic Mural Thrombus in the Non-atherosclerotic Aorta of Patients with Multiple Hypercoagulable Factors
Takeshi Yagyu, Maiko Naito, Masahiro Kumada, Tsutomu Nakagawa
Internal Medicine.2019; 58(3): 381. CrossRef - Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models
Silvia Riondino, Patrizia Ferroni, Fabio Massimo Zanzotto, Mario Roselli, Fiorella Guadagni
Cancers.2019; 11(1): 95. CrossRef - Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking
Michał Ząbczyk, Grzegorz Królczyk, Grzegorz Czyżewicz, Krzysztof Plens, Shannon Prior, Saulius Butenas, Anetta Undas
Medical Oncology.2019;[Epub] CrossRef - New data for venous thromboembolism in patients with small cell lung cancer: A review
Evangelos Dimakakos, Konstantinos Livanios, Ioannis Gkiozos, Adriani Charpidou, Eleutheria Ntalakou, llias Kainis, Konstantinos Syrigos
Phlebology: The Journal of Venous Disease.2018; 33(8): 517. CrossRef - Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography
Hyungseop Kim, Woo-Baek Chung, Kyoung Im Cho, Bong-Joon Kim, Jeong-Sook Seo, Seong-Mi Park, Hak Jin Kim, Ju-Hee Lee, Eun Kyoung Kim, Ho-Joong Youn
Journal of Cardiovascular Ultrasound.2018; 26(1): 1. CrossRef - Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy
Akihisa Mitani, Taisuke Jo, Hideo Yasunaga, Yukiyo Sakamoto, Wakae Hasegawa, Hirokazu Urushiyama, Yasuhiro Yamauchi, Hiroki Matsui, Kiyohide Fushimi, Takahide Nagase
Anti-Cancer Drugs.2018; 29(6): 560. CrossRef - Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
Arin L. Madenci, Brent R. Weil, Qi Liu, Andrew J. Murphy, Todd M. Gibson, Yutaka Yasui, Wendy M. Leisenring, Rebecca M. Howell, Christopher L. Tinkle, Larissa Nekhlyudov, Lisa R. Diller, Gregory T. Armstrong, Kevin C. Oeffinger, Christopher B. Weldon
Journal of Clinical Oncology.2018; 36(31): 3144. CrossRef - Beneficial effect of additional treatment with�widely�available anticancer agents in advanced small�lung cell carcinoma: A case report
Piotr Kruk
Molecular and Clinical Oncology.2018;[Epub] CrossRef - Cancer-associated venous thromboembolism: Burden, mechanisms, and management
Cihan Ay, Ingrid Pabinger, Alexander T. Cohen
Thrombosis and Haemostasis.2017; 117(02): 219. CrossRef - Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
Elsa Davidsson, Nicola Murgia, Cristian Ortiz-Villalón, Emil Wiklundh, Magnus Sköld, Karl Gustav Kölbeck, Giovanni Ferrara
Multidisciplinary Respiratory Medicine.2017;[Epub] CrossRef - Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology
Patrizia Ferroni, Fabio M. Zanzotto, Noemi Scarpato, Silvia Riondino, Fiorella Guadagni, Mario Roselli
Disease Markers.2017; 2017: 1. CrossRef - Severe Intestinal Ischemia During Chemotherapy for Small Cell Lung Cancer
Barbara Legius, Kristiaan Nackaerts
Lung Cancer Management.2017; 6(3): 87. CrossRef - Epidemiology and risk factors for venous thromboembolism in lung cancer
Cihan Ay, Umut Kaan Ünal
Current Opinion in Oncology.2016; 28(2): 145. CrossRef - A systematic review of biomarkers for the prediction of thromboembolism in lung cancer — Results, practical issues and proposed strategies for future risk prediction models
Marliese Alexander, Kate Burbury
Thrombosis Research.2016; 148: 63. CrossRef
- Lung cancer, comorbidities, and medication: the infernal trio
- 11,690 View
- 138 Download
- 30 Web of Science
- 23 Crossref
- Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
- Myoung Hee Kang, Jung Hun Kang, Haa-Na Song, Bae Kwon Jeong, Gyu Young Chai, Kimun Kang, Seung Hoon Woo, Jung Je Park, Jin Pyeong Kim
- Cancer Res Treat. 2015;47(3):441-447. Published online December 2, 2014
- DOI: https://doi.org/10.4143/crt.2013.219
-
Abstract
PDFPubReaderePub
- Purpose
Concurrent chemoradiation (CRT) with 3-weekly doses of cisplatin is a standard treatment for loco-regionally advanced head and neck squamous cell carcinoma (HNSCC). However, treatment with 3-weekly doses of cisplatin is often associated with several adverse events. Therefore, we conducted this retrospective analysis to determine the efficacy and tolerance of CRT with a low weekly dose of cisplatin in stage IV HNSCC patients.
Materials and Methods
Medical records of patients who were diagnosed with stage IV HNSCC and received concurrent CRT were analyzed. All patients were treated weekly with cisplatin at 20-30 mg/m2 until radiotherapy was completed.
Results
A total of 35 patients were reviewed. Median follow up was 10.7 months (range, 1.7 to 90.5 months), the median radiation dose was 7,040 cGy, and the median dose of cisplatin received was 157 mg/m2. Eleven patients received docetaxel combination chemotherapy. Overall, 25 patients (71.4%) achieved complete response (CR), eight (22.9%) showed partial response. The median overall survival was 42.7 months, the 3-year survival rate was 51.2% and the 3 year disease-free survival rate was 72.8%. Overall survival was improved in patients who achieved CR relative to others (59.7 months vs. 13.4 months; p=0.008). There were significant differences in survival between patients who received docetaxel combination and cisplatin alone (51.8 months vs. 7.9 months; p=0.009). Grade 3-4 adverse events included stomatitis (82.9%), dermatitis (22.9%), infection (11.4%), dysphagia (8.6%), and neutropenia (5.7%).
Conclusion
CRT with low dose weekly cisplatin is likely effective and tolerable, even in patients with locally advanced-stage IV HNSCC. -
Citations
Citations to this article as recorded by- Transcriptomic analysis reveals differential adaptation of colorectal cancer cells to low and acute doses of cisplatin
Heena Saini, Rakshita Dave, Subhashree Chatterjee, Ayushi Mandloi, Harshita Sharma, Ankita Daiya, Sudeshna Mukherjee, Rajdeep Chowdhury, Shibasish Chowdhury
Gene.2023; 864: 147304. CrossRef - A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck
Shruthi Venkateshulu, Kiran Kumar BR
Cureus.2021;[Epub] CrossRef - Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma
Adity Chakraborty, Abhinandan Bhattacharjee, Amlan Jyoti Nath, Shibashis Deb, Aakanksha Rathor
The Egyptian Journal of Otolaryngology.2021;[Epub] CrossRef - Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury
Kranti A. Mapuskar, Emily J. Steinbach, Amira Zaher, Dennis P. Riley, Robert A. Beardsley, Jeffery L. Keene, Jon T. Holmlund, Carryn M. Anderson, Diana Zepeda-Orozco, John M. Buatti, Douglas R. Spitz, Bryan G. Allen
Antioxidants.2021; 10(9): 1329. CrossRef - Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
BMC Cancer.2020;[Epub] CrossRef - Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712. CrossRef - Topical issues of chemoradiotherapy for oropharyngeal squamous cell carcinoma: the efficiency and toxicity of chemotherapy regimens with the goal of radiomodification
A. I. Stukan, R. A. Murashko, V. N. Bodnya, Yu. M. Makarova, I. N. Vasilenko
Onkologiya. Zhurnal imeni P.A.Gertsena.2018; 7(3): 61. CrossRef - Persistent Head and Neck Cancer Following First-Line Treatment
Teresa Bernadette Steinbichler, Madeleine Lichtenecker, Maria Anegg, Daniel Dejaco, Barbara Kofler, Volker Hans Schartinger, Maria-Therese Kasseroler, Britta Forthuber, Andrea Posch, Herbert Riechelmann
Cancers.2018; 10(11): 421. CrossRef - Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
Stuart E. Samuels, Avraham Eisbruch, Jonathan J. Beitler, June Corry, Carol R. Bradford, Nabil F. Saba, Michiel W. M. van den Brekel, Robert Smee, Primož Strojan, Carlos Suárez, William M. Mendenhall, Robert P. Takes, Juan P. Rodrigo, Missak Haigentz, Ale
European Archives of Oto-Rhino-Laryngology.2016; 273(10): 2877. CrossRef
- Transcriptomic analysis reveals differential adaptation of colorectal cancer cells to low and acute doses of cisplatin
- 14,225 View
- 96 Download
- 10 Web of Science
- 9 Crossref
- Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
- Jieun Lee, Tae Ho Hong, In Seok Lee, Young Kyoung You, Myung Ah Lee
- Cancer Res Treat. 2015;47(2):259-265. Published online September 12, 2014
- DOI: https://doi.org/10.4143/crt.2013.230
-
Abstract
PDFPubReaderePub
- Purpose
Gemcitabine-cisplatin combination chemotherapy has been regarded as standard regimen for advanced or metastatic biliary tract cancer (BTC), based on the ABC-02 trial. To date, however, no studies have compared the efficacies of gemcitabine-platinum and fluoropyrimidine- platinum combination chemotherapy, even though fluoropyrimidine has been widely used as a backbone agent for gastrointestinal cancer. This study compared the efficacy and toxicities of gemcitabine-cisplatin (GP) and capecitabine-cisplatin (XP) combination chemotherapy for treatment of advanced BTC. Materials and Methods We examined 49 patients treated with GP and 44 patients treated with XP from October 2009 to July 2012. All patients had unresectable BTC. The GP regimen comprised gemcitabine (1,000 mg/m2, intravenously [IV], days 1 and 8) and cisplatin (75 mg/m2, IV, day 1). The XP regimen comprised capecitabine (1,250 mg/m2 twice a day, peroral, days 1-14) and cisplatin (60 mg/m2, IV, day 1, every three weeks). We analyzed the response rate (RR), time to progression (TTP), overall survival (OS), and toxicity. Results The RRs were 27.3% and 6.1% in the XP and GP arms, respectively. XP resulted in longer TTP (5.2 months vs. 3.6 months, p=0.016), but OS was not statistically different (10.7 months vs. 8.6 months, p=0.365). Both regimens resulted in grade 3-4 hematologic toxicities, but febrile neutropenia was not noted. Grade 3-4 asthenia, stomatitis, and hand-foot syndrome occurred more frequently in the XP arm. Conclusion XP resulted in a superior TTP and RR compared to GP for treatment of advanced BTC, with comparable toxicity. Conduct of prospective large, randomized trials to evaluate the possibility of XP as another standard therapy is warranted. -
Citations
Citations to this article as recorded by-
Pristine B
40
fullerene as a potential gemcitabine drug carrier for anti-lung cancer properties: a DFT and QTAIM study
Abisha Nancy Sukumar, Parimala Devi Duraisamy, Prince Makarios Paul. S, Praveena Gopalan, Abiram Angamuthu
Journal of Biomolecular Structure and Dynamics.2024; : 1. CrossRef - A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada
Ravi Ramjeesingh, Prosanto Chaudhury, Vincent C. Tam, David Roberge, Howard J. Lim, Jennifer J. Knox, Jamil Asselah, Sarah Doucette, Nirlep Chhiber, Rachel Goodwin
Current Oncology.2023; 30(8): 7132. CrossRef - A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
Targeted Oncology.2023; 18(6): 837. CrossRef - Chemotherapy for Biliary Tract Cancer in 2021
Takashi Sasaki, Tsuyoshi Takeda, Takeshi Okamoto, Masato Ozaka, Naoki Sasahira
Journal of Clinical Medicine.2021; 10(14): 3108. CrossRef - Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis
Ting Zheng, Jianjiang Jin, Li Zhou, Yuefeng Zhang
Oncology Research and Treatment.2020; 43(9): 460. CrossRef - The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis
Yan Li, Yaoyao Zhou, Yonglan Hong, Meizhi He, Shuyi Wei, Chen Yang, Dayong Zheng, Feiye Liu
Frontiers in Oncology.2019;[Epub] CrossRef - Gemcitabine-based chemotherapy for advanced biliary tract carcinomas
Omar Abdel-Rahman, Zeinab Elsayed, Hesham Elhalawani
Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef - A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
Yi Zheng, Xiaoxuan Tu, Peng Zhao, Weiqin Jiang, Lulu Liu, Zhou Tong, Hangyu Zhang, Cong Yan, Weijia Fang, Weilin Wang
British Journal of Cancer.2018; 119(3): 291. CrossRef - Cholangiocarcinoma
Michela Squadroni, Luca Tondulli, Gemma Gatta, Stefania Mosconi, Giordano Beretta, Roberto Labianca
Critical Reviews in Oncology/Hematology.2017; 116: 11. CrossRef - CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
Cancer Research and Treatment.2017; 49(3): 807. CrossRef - Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer
Jang Han Jung, Hee Seung Lee, Jung Hyun Jo, In Rae Cho, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park
Chemotherapy.2017; 62(6): 361. CrossRef - The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
Xin-Fang Sun, Zhi-Kuan He, Jin-Ping Sun, Quan-Xing Ge, Er-Dong Shen
Oncotarget.2017; 8(59): 100657. CrossRef
-
Pristine B
40
fullerene as a potential gemcitabine drug carrier for anti-lung cancer properties: a DFT and QTAIM study
- 13,692 View
- 92 Download
- 12 Web of Science
- 12 Crossref
Case Report
- Reversible Cerebellar Ataxia Related to Extrapontine Myelinolysis without Hyponatremia after Cisplatin-Based Chemotherapy for Cholangiocarcinoma
- Jae Heun Chung, Seung Kug Baik, Su-Hee Cho, Seong-Geun Kim
- Cancer Res Treat. 2015;47(2):329-333. Published online September 11, 2014
- DOI: https://doi.org/10.4143/crt.2013.145
-
Abstract
PDFPubReaderePub
- A 60-year-old woman presented with cerebellar signs including dysarthria and ataxia, after intravenous infusion of cisplatin-based chemotherapy. Several blood tests showed mild neutropenia, normocytic normochromic anemia, but no evidence of a marked hyponatremia. Brain magnetic resonance imaging with diffusion-weighted sequences showed hyper-intense signal abnormalities in the extrapontine region, sparing the basis pontis. Here, we report on the case of a patient with reversible cerebellar ataxia related to extrapontine myelinolysis without hyponatremia after treatment with cisplatin-based chemotherapy for cholangiocarcinoma and discuss the literature on cerebellar ataxia in patients who underwent recent chemotherapy for malignancy.
-
Citations
Citations to this article as recorded by- Osmotic demyelination syndrome in cancer patients: Risk even without rapid sodium correction - a scoping review
Youming Wang, Weibing Jia, Minjia Wang, Xiaoli Yang, Xinli Gao, Yao Zhang
Journal of the Neurological Sciences.2024; 467: 123326. CrossRef - Oncologic Emergencies in the Head and Neck
Carlos Zamora, Mauricio Castillo, Paulo Puac-Polanco, Carlos Torres
Radiologic Clinics of North America.2023; 61(1): 71. CrossRef
- Osmotic demyelination syndrome in cancer patients: Risk even without rapid sodium correction - a scoping review
- 11,160 View
- 85 Download
- 3 Web of Science
- 2 Crossref
Original Article
- Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
- Jung Hyun Lee, Sung Gu Kang, Seung Tae Kim, Seok Ho Kang, In Keun Choi, Young Je Park, Sang Chul Oh, Deuk Jae Sung, Jae Hong Seo, Jun Cheon, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Kyong Hwa Park
- Cancer Res Treat. 2014;46(2):172-177. Published online April 15, 2014
- DOI: https://doi.org/10.4143/crt.2014.46.2.172
-
Abstract
PDFPubReaderePub
Purpose There is no established standard second-line chemotherapy for patients with advanced or metastatic urothelial carcinoma (UC) who failed gemcitabine and cisplatin (GC) chemotherapy. This study was conducted in order to investigate the efficacy and toxicity of modified methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in patients with metastatic UC previously treated with GC.
Materials and Methods We retrospectively analyzed 28 patients who received modified MVAC between November 2004 and November 2012. All patients failed prior, first-line GC chemotherapy.
Results The median age of patients was 64.0 years (range, 33.0 to 77.0 years), and 23 (82.1%) patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. The overall response rate and the disease control rate were 36.0% and 64.0%, respectively. After a median follow-up period of 38 weeks (range, 5 to 182 weeks), median progression free survival was 21.0 weeks (95% confidence interval [CI], 6.3 to 35.7 weeks) and median overall survival was 49.0 weeks (95% CI, 18.8 to 79.3 weeks). Grade 3 or 4 hematological toxicities included neutropenia (n=21, 75.0%) and anemia (n=9, 32.1%). Grade 3 or 4 non-hematological toxicities did not occur and there was no treatment-related death.
Conclusion Modified MVAC appears to be a safe and active chemotherapy regimen in patients with stable physical status and adequate renal function after GC treatment.
-
Citations
Citations to this article as recorded by- Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis
Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Satoshi Nozaki, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Nami Tomiyama, Rika Banno, Hiroki Kubota, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, Takahiro Yasui
International Journal of Clinical Oncology.2022; 27(1): 165. CrossRef - SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer
Axel S. Merseburger, Andrea B. Apolo, Simon Chowdhury, Noah M. Hahn, Matthew D. Galsky, Matthew I. Milowsky, Daniel Petrylak, Tom Powles, David I. Quinn, Jonathan E. Rosenberg, Arlene Siefker-Radtke, Guru Sonpavde, Cora N. Sternberg
World Journal of Urology.2019; 37(1): 95. CrossRef - Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma
Lukas Barwitz, Anne Berger, Stefanie Zschaebitz, Max Jenzer, Cathleen Nientiedt, Stefan Duensing, Dirk Jäger, Dogu Teber, Markus Hohenfellner, Carsten Grüllich
The Open Urology & Nephrology Journal.2017; 10(1): 52. CrossRef - Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin
Jennifer A. Locke, Gregory Russell Pond, Guru Sonpavde, Andrea Necchi, Patrizia Giannatempo, Ravi Kumar Paluri, Guenter Niegisch, Peter Albers, Carlo Buonerba, Giuseppe Di Lorenzo, Ulka N. Vaishampayan, Scott A. North, Neeraj Agarwal, Syed A. Hussain, Sum
Clinical Genitourinary Cancer.2016; 14(4): 331. CrossRef - Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
Christoph Oing, Michael Rink, Karin Oechsle, Christoph Seidel, Gunhild von Amsberg, Carsten Bokemeyer
Journal of Urology.2016; 195(2): 254. CrossRef - Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
Ki Hong Kim, Sung Joon Hong, Kyung Seok Han
BMC Cancer.2015;[Epub] CrossRef
- Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis
- 12,458 View
- 90 Download
- 6 Web of Science
- 6 Crossref
Case Report
- A Case of Combined Hepatocellular-Cholangiocarcinoma with Favorable Response to Systemic Chemotherapy
- Gun Min Kim, Hei-Cheul Jeung, Dokyung Kim, Joo Hoon Kim, Sang Hyun Yoon, Eun Suk Jung, Sang Joon Shin
- Cancer Res Treat. 2010;42(4):235-238. Published online December 31, 2010
- DOI: https://doi.org/10.4143/crt.2010.42.4.235
-
Abstract
PDFPubReaderePub
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary liver cancer composed of cells with histopathologic features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of its low incidence, the information on clinical outcomes of cHCC-CC is very limited and there are no published reports describing non-surgical treatment options for cHCC-CC. We report a case of cHCC-CC exhibiting a favorable response to systemic chemotherapy with doxorubicin and cisplatin. A 62-year-old man who recurred after a right lobectomy for cHCC-CC received sorafenib for palliative systemic therapy, but follow up imaging studies showed disease progression. He received 2nd line chemotherapy with doxorubicin at 60 mg/m2 together with cisplatin at 70 mg/m2. After 2 cycles of chemotherapy, a computed tomography scan of the chest showed markedly decreased size and number of the multiple lung metastases. After completing 8 cycles of 2nd line therapy, we changed the regimen to a fluorouracil (5-FU) mono therapy because of the toxicities associated with doxorubicin and cisplatin. To date, the patient has completed his 15th cycle of 5-FU mono therapy with the disease status remaining stable during 18 months of follow-up.
-
Citations
Citations to this article as recorded by- Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
Liangtao Ye, Julia S. Schneider, Najib Ben Khaled, Peter Schirmacher, Carolin Seifert, Lea Frey, Yulong He, Andreas Geier, Enrico N. De Toni, Changhua Zhang, Florian P. Reiter
Liver Cancer.2024; 13(1): 6. CrossRef - A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery
Feng Zhang, Keshu Hu, Bei Tang, Mengxin Tian, Shenxin Lu, Jia Yuan, Miao Li, Rongxin Chen, Zhenggang Ren, Yinghong Shi, Xin Yin
Journal of Gastrointestinal Surgery.2021; 25(4): 971. CrossRef - Treatment of Combined Hepatocellular and Cholangiocarcinoma
Simona Leoni, Vito Sansone, Stefania De Lorenzo, Luca Ielasi, Francesco Tovoli, Matteo Renzulli, Rita Golfieri, Daniele Spinelli, Fabio Piscaglia
Cancers.2020; 12(4): 794. CrossRef - Therapy of Primary Liver Cancer
Mei Feng, Yisheng Pan, Ruirui Kong, Shaokun Shu
The Innovation.2020; 1(2): 100032. CrossRef - Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature
Yuka Futsukaichi, Kazuto Tajiri, Saito Kobayashi, Kohei Nagata, Satoshi Yasumura, Terumi Takahara, Masami Minemura, Ichiro Yasuda
Clinical Journal of Gastroenterology.2019; 12(2): 128. CrossRef - Clinical and pathological features of combined hepatocellular–cholangiocarcinoma compared with other liver cancers
Kazuki Wakizaka, Hideki Yokoo, Toshiya Kamiyama, Masafumi Ohira, Koichi Kato, Yuki Fujii, Ko Sugiyama, Naoki Okada, Takanori Ohata, Akihisa Nagatsu, Shingo Shimada, Tatsuya Orimo, Hirofumi Kamachi, Akinobu Taketomi
Journal of Gastroenterology and Hepatology.2019; 34(6): 1074. CrossRef - Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score–Matched Study
Yu-Hui Huang, Benjamin V. Park, Yi-Fan Chen, Ron C. Gaba, Grace Guzman, R. Peter Lokken
Journal of Vascular and Interventional Radiology.2019; 30(9): 1317. CrossRef - Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
Satoshi Kobayashi, Takeshi Terashima, Satoshi Shiba, Yukio Yoshida, Ikuhiro Yamada, Shouta Iwadou, Shigeru Horiguchi, Hideaki Takahashi, Eiichiro Suzuki, Michihisa Moriguchi, Kunihiro Tsuji, Taiga Otsuka, Akinori Asagi, Yasushi Kojima, Ryoji Takada, Chigu
Cancer Science.2018; 109(8): 2549. CrossRef - Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma
Lauren S. Chan, Daniel Y. Sze, George A. Poultsides, John D. Louie, Mohammed A. Abdelrazek Mohammed, David S. Wang
CardioVascular and Interventional Radiology.2017; 40(9): 1383. CrossRef - A Case of Curative Resection of Advanced Combined Hepatocellular-cholangiocarcinoma after Neoadjuvant Chemotherapy
Jee Eun Choi, Kyung Hee Kim, Seon A Kim, Jung Hwan Lee, Sang Myung Woo, Sang-Jae Park, Eun Kyung Hong, Woo Jin Lee
Korean Journal of Pancreas and Biliary Tract.2016; 21(2): 101. CrossRef - Combined hepatocellular cholangiocarcinoma: Controversies to be addressed
An-Qiang Wang
World Journal of Gastroenterology.2016; 22(18): 4459. CrossRef - Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy
Kathryn Fowler, Nael E. Saad, Elizabeth Brunt, M. B. Majella Doyle, Manik Amin, Neeta Vachharajani, Benjamin Tan, William C. Chapman
Annals of Surgical Oncology.2015; 22(13): 4130. CrossRef - Combined hepatocellular-cholangiocarcinoma (cHCC-CC): a distinct entity
Kate O’Connor, Joanna C. Walsh, David F. Schaeffer
Annals of Hepatology.2014; 13(3): 317. CrossRef - Transplantation versus resection for patients with combined hepatocellular carcinoma–cholangiocarcinoma
Ryan T. Groeschl, Kiran K. Turaga, T. Clark Gamblin
Journal of Surgical Oncology.2013; 107(6): 608. CrossRef
- Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
- 11,131 View
- 83 Download
- 14 Crossref
Original Article
- Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
- Jina Yun, Kyoung-Mee Kim, Seung Tae Kim, Jung-Hoon Kim, Jung A Kim, Jee Hyun Kong, Soo Hyeon Lee, Young-Woong Won, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
- Cancer Res Treat. 2010;42(2):101-106. Published online June 30, 2010
- DOI: https://doi.org/10.4143/crt.2010.42.2.101
-
Abstract
PDFPubReaderePub
Purpose The aim of this study was to determine whether the ERCC1 expression is effective to predict the clinical outcomes of patients with advanced gastric cancer (AGC) and who were treated with cisplatin-based first-line chemotherapy.
Materials and Methods A total of 89 measurable AGC patients received cisplatin and capecitabine, with or without epirubicin, as a part of a randomized phase II study. Patients were included for the current molecular analysis if they had received two or more cycles of chemotherapy, their objective tumor responses were measured and if their paraffin-embedded tumor samples were available. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and the patients were divided into two groups (positive or negative) according to the presence of IHC staining of the tumor cell nuclei.
Results Of the 32 eligible patients, 21 patients (66%) had tumor with a positive expression of ERCC1 and the remaining 11 patients had tumor with a negative ERCC1-expression. The ERCC1-negative patients achieved a higher response rate than that of the ERCC1-positive patients (44% vs. 28%, respectively), although the difference was not statistically significant (p=0.42). The median survival time for the all patients was 14.6 months (95% CI: 13.6 to 15.6 months). The one-year survival rate was similar for the ERCC1-negative patients (61%) and the ERCC1-positive patients (70%).
Conclusion In the current study, the tumor ERCC1 expression by IHC staining could not predict the clinical response or survival of AGC patients who were treated with cisplatin-based first-line chemotherapy. The ERCC1 protein expression does not appear to be a useful tool for the selection of tailored chemotherapy for these patients.
-
Citations
Citations to this article as recorded by- Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review
Eduardo Henrique Cunha Neves Filho, Rosane Oliveira de Sant'Ana, Luiz Vianney Saldanha Cidrão Nunes, Adriana Pinheiro Bezerra Pires, Maria do Perpétuo Socorro Saldanha da Cunha
APMIS.2017; 125(2): 79. CrossRef - Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine
Shalong Wang, Lianwen Yuan
BioScience Trends.2016; 10(3): 171. CrossRef - Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke, Jian-wei Bi
Tumor Biology.2014; 35(4): 2941. CrossRef - The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
Tumor Biology.2014; 35(9): 8721. CrossRef - Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107. CrossRef - Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term
Liqi Chen, Guoli Li, Jieshou Li, Chaogang Fan, Jian Xu, Bo Wu, Kun Liu, Caihua Zhang
Cancer Chemotherapy and Pharmacology.2013; 71(4): 921. CrossRef - ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean women
Seung‐Su HAN, Jae Weon KIM, Sang Hoon LEE, Dong Ho KIM, Noh‐Hyun PARK, Yong‐Sang SONG, Soon‐Beom KANG
Asia-Pacific Journal of Clinical Oncology.2012;[Epub] CrossRef - Gastric Cancer
Joshua D. Lawson, Jason K. Sicklick, Paul T. Fanta
Current Problems in Cancer.2011; 35(3): 97. CrossRef
- Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review
- 10,077 View
- 42 Download
- 8 Crossref
Case Report
- A Case of Gemcitabine and Cisplatin Associated Posterior Reversible Encephalopathy Syndrome
- Eun Jin Kwon, Se Won Kim, Kwang Ki Kim, Hyung Suk Seo, Do Yeun Kim
- Cancer Res Treat. 2009;41(1):53-55. Published online March 31, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.1.53
-
Abstract
PDFPubReaderePub
A 58-year-old female receiving gemcitabine and cisplatin chemotherapy for stage IV gallbladder cancer developed the clinicoradiologic syndrome, posterior reversible encephalopathy syndrome (PRES). Just before the 4th gemcitabine chemotherapy cycle, she was admitted to the hospital with complaints of headache, dizziness, and generalized tonic-clonic seizures. A MRI was performed on the day when the seizure developed, and the findings showed patchy cortical and subcortical T2 hyperintensity without enhancement that involved both occipital and parietal lobes. Phenytoin loading and maintenance was started for prevention of recurrent seizures, which was successful. The follow-up brain MRI obtained 10 days after the seizure attack showed completely resolved radiologic findings. After the MRI findings revealed complete resolution, phenytoin maintenance was stopped. Even with discontinuation of phenytoin, she had no seizures or other clinical manifestations.
-
Citations
Citations to this article as recorded by- Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System
Wei Zhang, Yuhong Wang, Xin Jiang, Hu Zhao, Xinli Jia, Qiye Wang, Yue Chen, Yuanfang Jiang, Zhifang Ma, Lina Chang, Xin Wang
Expert Opinion on Drug Safety.2024; 23(7): 917. CrossRef - Posterior reversible encephalopathy syndrome in pregnancy
Vaibhavi Birle, Pradnya Dongargaonkar, Sunil Sharma, Aditi Sandip Gaiwal
MGM Journal of Medical Sciences.2022; 9(2): 246. CrossRef - Delayed Gemcitabine-Induced Posterior Reversible Encephalopathy Syndrome
John R. Schaub, Shou-Ching Tang
The American Journal of the Medical Sciences.2021; 361(6): 795. CrossRef - Delayed Posterior Reversible Leukoencephalopathy Syndrome Triggered by FLOT Chemotherapy
Jordi Gandini, Mario Manto, Nicolas Charette
Frontiers in Neurology.2020;[Epub] CrossRef - First line Immunotherapy for Non-Small Cell Lung Cancer
Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya
Pharmaceuticals.2020; 13(11): 373. CrossRef - Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study
Pavlína Danhofer, Michaela Tomečková, Dáša Černá, Danica Zapletalová, Ondřej Horák, Štefánia Aulická, Lenka Juříková, Jiří Domanský, Petra Kovalčíková, Tomáš Pavlík, Jaroslav Štěrba, Hana Ošlejšková
Seizure.2019; 72: 1. CrossRef - PRES in the course of hemato-oncological treatment in children
Katarzyna Musioł, Sylwia Waz, Michał Boroń, Magdalena Kwiatek, Magdalena Machnikowska-Sokołowska, Katarzyna Gruszczyńska, Grażyna Sobol-Milejska
Child's Nervous System.2018; 34(4): 691. CrossRef - Posterior reversible encephalopathy syndrome (PRES) in mesenteric leiomyosarcoma: A case report
Ramy Schoucair, Gregory Nicolas, Rechdi Ahdab, Noha Bejjani, Eddie K. Abdalla
International Journal of Surgery Case Reports.2018; 49: 96. CrossRef - Posterior Reversible Encephalopathy Syndrome in a Patient with Spinal Metastasis
Jin Wook Kim, Ju Ho Jeong
Journal of Neurointensive Care.2018; 1(1): 47. CrossRef - Electrographic patterns in patients with posterior reversible encephalopathy syndrome and seizures
Carlos Kamiya-Matsuoka, Sudhakar Tummala
Journal of the Neurological Sciences.2017; 375: 294. CrossRef - A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin
Hannah Cherniawsky, Neesha Merchant, Micheal Sawyer, Maria Ho
Medicine.2017; 96(8): e5850. CrossRef - Neurological PRESentations in Sickle Cell Patients Are Not Always Stroke: A Review of Posterior Reversible Encephalopathy Syndrome in Sickle Cell Disease
Ziad Solh, Michael S. Taccone, Samantha Marin, Uma Athale, Vicky R. Breakey
Pediatric Blood & Cancer.2016; 63(6): 983. CrossRef - Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study
Carlos Kamiya-Matsuoka, Asif M. Paker, Linda Chi, Ayda Youssef, Sudhakar Tummala, Monica E. Loghin
Journal of Neuro-Oncology.2016; 128(1): 75. CrossRef - Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome
Joan How, Margaret Blattner, Susan Fowler, Andrea Wang-Gillam, Suzanne E. Schindler
The Neurologist.2016; 21(6): 112. CrossRef - Reversible posterior leukoencephalopathy syndrome following combinatorial cisplatin and pemetrexed therapy for lung cancer in a normotensive patient: A case report and literature review
CHANGQING XIE, VOVANTI T. JONES
Oncology Letters.2016; 11(2): 1512. CrossRef - A Unique Case of Rituximab-Related Posterior Reversible Encephalopathy Syndrome in a Heart Transplant Recipient With Posttransplant Lymphoproliferative Disorder
A. Jaiswal, I. Sabnani, D.A. Baran, M.J. Zucker
American Journal of Transplantation.2015; 15(3): 823. CrossRef - Posterior Reversible Encephalopathy Syndrome: A Neurologic Phenomenon in Cancer Patients
Eileen M. Le, Monica E. Loghin
Current Oncology Reports.2014;[Epub] CrossRef - Acute neurological disorders following intraperitoneal administration of cisplatin
Geert A.A.M. Simkens, Monique C.J. Hanse, Ignace H.J.T. de Hingh
International Journal of Gynecology & Obstetrics.2013; 120(3): 291. CrossRef - Gemcitabine-induced posterior reversible encephalopathy syndrome: A case report
Pasquale Cioffi, Lucio Laudadio, Antonio Nuzzo, Maurizio Belfiglio, Fabio Petrelli, Iolanda Grappasonni
Journal of Oncology Pharmacy Practice.2012; 18(2): 299. CrossRef - Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
Michela Maur, Chiara Tomasello, Antonio Frassoldati, Maria Vittoria Dieci, Elena Barbieri, PierFranco Conte
Journal of Clinical Oncology.2012; 30(6): e76. CrossRef - Reversible Posterior Leukoencephalopathy Syndrome following Sunitinib Therapy: A Case Report and Review of the Literature
Khurum H Khan, Audrey Fenton, Eimer Murtagh, James JA McAleer, Alison Clayton
Tumori Journal.2012; 98(5): e139. CrossRef - Des pathologies encéphaliques à connaître — Syndrome d’encéphalopathie postérieure réversible
S. Legriel, F. Pico, F. Bruneel, G. Troché, J. -P. Bedos
Réanimation.2011; 20(S2): 368. CrossRef - Acute Transverse Myelopathy Probably Related to Intravenous Gemcitabine Plus Cisplatin
Meizuo Zhong, Bin Li, Jing Li
Annals of Pharmacotherapy.2011; 45(4): 544. CrossRef - Case Files of the New York City Poison Control Center: Paradichlorobenzene-Induced Leukoencephalopathy
Stephanie H. Hernandez, Sage W. Wiener, Silas W. Smith
Journal of Medical Toxicology.2010; 6(2): 217. CrossRef
- Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System
- 9,625 View
- 91 Download
- 24 Crossref
Original Articles
- Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
- Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
- Cancer Res Treat. 2008;40(4):155-163. Published online December 31, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.4.155
-
Abstract
PDFPubReaderePub
Purpose This retrospective study was carried out to evaluate the efficacy and toxicity of radiation therapy (RT) with/without cisplatin-based chemotherapy in nasopharyngeal cancer (NPC).
Materials and Methods One hundred forty six patients with NPC received curative RT and/or cisplatin-based chemotherapy. Thirty-nine patients were treated with induction chemotherapy (IC), including cisplatin and 5-fluorouracil followed by RT. Another 63 patients were treated with concurrent chemoradiotherapy (CCRT) using cisplatin, and 22 patients were treated with IC followed by CCRT. The remaining 22 patients were treated with RT alone.
Results One hundred four (80.0%) patients achieved complete response (CR), and 23 (17.7%) patients achieved partial response (PR). The patterns of failure were: locoregional recurrences in 21.2% and distant metastases in 17.1%. Five-year overall survival (OS) and progression free survival (PFS) were 50.7% and 45.0%, respectively. Multivariate Cox stepwise regression analysis revealed CR to chemoradiotherapy to be a powerful prognostic factor for OS. CR to chemoradiotherapy and completion of radiation according to the time schedule were favorable prognostic factors for PFS. A comparison of each treatment group (IC → RT vs. CCRT vs. IC → CCRT vs. RT alone) revealed no significant differences in the OS or PFS. However, subgroup analysis showed significant differences in both OS and DFS in favor of the combined chemoradiotherapy group compared with RT alone, for stage IV and T3-4 tumors. Grade 3-4 toxicities were more common in the combined chemoradiotherapy arm, particularly in the CCRT group.
Conclusions This study was limited in that it was a retrospective study, much time was required to collect patients, and there were imbalances in the number of patients in each treatment group. Combined chemoradiotherapy remarkably prolonged the OS and PFS in subgroup patients with stage IV or T3-4 NPC.
-
Citations
Citations to this article as recorded by- Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma
Jun Zhang, Guo-lin Tan, Ming Jiang, Tian-sheng Wang, Guo-hui Liu, Shan-shan Xiong, Xiang Qing
Cellular Signalling.2023; 101: 110530. CrossRef - SEPT9, H4C6, and RASSF1A methylation in nasopharyngeal swabs: A reflection of potential minimally invasive biomarkers for early screening of nasopharyngeal cancer
Tai Qian, Zhiwei Zhou, Qiongxia Zhang, Yu-Light Liou, Honghao Zhou
Medicine.2023; 102(50): e36583. CrossRef - MicroRNA-145-5p modulates Krüppel-like factor 5 and inhibits cell proliferation, migration, and invasion in nasopharyngeal carcinoma
Chien-Han Yuan, Wei-Chi Hsu, A.-Mei Huang, Ben-Chih Yuan, I.-Hung Chen, Chia-An Hsu, Rong-Feng Chen, Yih-Min Chu, Hui-Hui Lin, Hung-Lung Ke
BMC Molecular and Cell Biology.2022;[Epub] CrossRef - Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma
Fen Xue, Dan Ou, Xiaomin Ou, Xin Zhou, Chaosu Hu, Xiayun He
Oral Oncology.2022; 134: 106139. CrossRef -
Transcription Factor STAT1 Promotes the Proliferation, Migration and Invasion of Nasopharyngeal Carcinoma Cells by Upregulating
LINC01160
Jingang Ai, Guolin Tan, Tiansheng Wang, Wei Li, Ru Gao, Yexun Song, Shanshan Xiong, Xiang Qing
Future Oncology.2021; 17(1): 57. CrossRef - RETRACTED ARTICLE: Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells
Hao Chen, Min Luo, Xiangping Wang, Ting Liang, Chaoyuan Huang, Changjie Huang, Lining Wei
Cellular & Molecular Biology Letters.2021;[Epub] CrossRef - DNA methylation biomarkers for nasopharyngeal carcinoma
Baoai Han, Xiuping Yang, Po Zhang, Ya Zhang, Yaqin Tu, Zuhong He, Yongqin Li, Jie Yuan, Yaodong Dong, Davood K. Hosseini, Tao Zhou, Haiying Sun, Edwin Wang
PLOS ONE.2020; 15(4): e0230524. CrossRef - Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Nasopharyngeal Carcinoma Patients after Comprehensive Therapy
Yueli Tian, Khamis Hassan Bakari, Shanshan Liao, Xiaotian Xia, Xun Sun, Chunxia Qin, Yongxue Zhang, Xiaoli Lan
Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef - MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells
Guanhong Huang, Ming-yu Du, Hongming Zhu, Nan Zhang, Zhi-Wei Lu, Lu-Xi Qian, Wenjun Zhang, Xiaokang Tian, Xia He, Li Yin
Biomedicine & Pharmacotherapy.2018; 106: 217. CrossRef - Long non-coding RNA n326322 promotes the proliferation and invasion in nasopharyngeal carcinoma
Mingyu Du, Teng Huang, Jing Wu, Jia-Jia Gu, Nan Zhang, Kai Ding, Lu-Xi Qian, Zhi-Wei Lu, Wen-Jun Zhang, Xiao-Kang Tian, Xia He, Li Yin
Oncotarget.2018; 9(2): 1843. CrossRef - GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma
Guo-Hui Nie, Liang Luo, Hong-Fang Duan, Xiao-Qing Li, Mei-Jun Yin, Zhao Li, Wei Zhang
Tumor Biology.2016; 37(4): 4559. CrossRef - The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Ch
Cancer Research and Treatment.2016; 48(3): 917. CrossRef - MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 Nasopharyngeal Carcinoma Cells
Kang Zhu, Ying He, Cui Xia, Jing Yan, Jin Hou, Demin Kong, Yeye Yang, Guoxi Zheng
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2016; 24(3): 145. CrossRef - Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma
Hong-Fang Duan, Xiao-Qing Li, Hong-Yi Hu, Yu-Chi Li, Zhi Cai, Xue-Shuang Mei, Peng Yu, Li-Ping Nie, Wei Zhang, Zhen-Dong Yu, Guo-Hui Nie
Tumor Biology.2015; 36(9): 6679. CrossRef - Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
Seung Hwan Moon, Joon Young Choi, Hwan Joo Lee, Young-Ik Son, Chung-Hwan Baek, Yong Chan Ahn, Myung-Ju Ahn, Keunchil Park, Byung-Tae Kim
Clinical and Experimental Otorhinolaryngology.2015; 8(2): 142. CrossRef - MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells
Jing Wu, Li Yin, Ning Jiang, Wen-jie Guo, Jia-jia Gu, Meng Chen, You-you Xia, Jian-zhong Wu, Dan Chen, Jian-feng Wu, De-jun Wang, Dan Zong, Nan Zhang, Kai Ding, Teng Huang, Xia He
Experimental Cell Research.2015;[Epub] CrossRef - miR‐539 induces cell cycle arrest in nasopharyngeal carcinoma by targeting cyclin‐dependent kinase 4
Ling‐yan Lv, Yu‐zhi Wang, Qian Zhang, Hong‐rui Zang, Xing‐jie Wang
Cell Biochemistry and Function.2015; 33(8): 534. CrossRef - Chemotherapy of Head and Neck Cancer
Chang Ki Yeo
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 291. CrossRef - MicroRNA‐320a inhibits cell proliferation, migration and invasion by targeting BMI‐1 in nasopharyngeal carcinoma
Xiaoming Qi, Jianqiang Li, Changbo Zhou, Chunlei Lv, Min Tian
FEBS Letters.2014; 588(20): 3732. CrossRef - IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Nasopharyngeal Cancer: Plan Evaluation and Treatment Outcome
J. W. Kim, J. H. Cho, K. C. Keum, J. H. Kim, G. E. Kim, J. Y. Lee, S. K. Kim, C. G. Lee
Japanese Journal of Clinical Oncology.2012; 42(12): 1152. CrossRef - Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions?
Senem Demirci, Serra Kamer, Gulsen Kara, Ozgur Yildirim, Mustafa Esassolak
Acta Oto-Laryngologica.2011; 131(8): 852. CrossRef - miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion
Hongping Xia, Samuel S. Ng, Songshan Jiang, William K.C. Cheung, Johnny Sze, Xiu-Wu Bian, Hsiang-fu Kung, Marie C. Lin
Biochemical and Biophysical Research Communications.2010; 391(1): 535. CrossRef
- Effects of SENP1-induced deSUMOylation of STAT1 on proliferation and invasion in nasopharyngeal carcinoma
- 10,593 View
- 66 Download
- 22 Crossref
- A Phase II Trial of Paclitaxel, 5-fluorouracil (5-FU) and Cisplatin in Patients with Metastatic or Recurrent Gastric Cancer
- Gun Hi Kang, Gwang Sil Kim, Hyo Rak Lee, Young Jin Yuh, Sung Rok Kim
- Cancer Res Treat. 2008;40(3):106-110. Published online September 30, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.3.106
-
Abstract
PDFPubReaderePub
Purpose We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer.
Materials and Methods Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m2 on day 1, 5-FU 1 g/m2/day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m2 on day 1 were administered. This regimen was repeated every 3 weeks.
Results A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0~77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed.
Conclusions The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and accepatable toxicity for treating metastatic gastric cancer.
-
Citations
Citations to this article as recorded by- Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosis
Jia Luo, ZhouXue Wu, Yun Lu, Kang Xiong, Qian Wen, Ling Zhao, BiQiong Wang, Yan Gui, ShaoZhi Fu
International Journal of Biological Macromolecules.2020; 152: 718. CrossRef - A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells
Gaetano Marverti, Gaia Gozzi, Eleonora Maretti, Angela Lauriola, Leda Severi, Francesca Sacchetti, Lorena Losi, Salvatore Pacifico, Stefania Ferrari, Glauco Ponterini, Eliana Leo, Maria Paola Costi, Domenico D’Arca
International Journal of Molecular Sciences.2020; 21(12): 4452. CrossRef - Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma
Cui Chen, Feng-hua Wang, Xin An, Hui-yan Luo, Zhi-qiang Wang, Ying Liang, Le Zhang, Yu-hong Li
Cancer Chemotherapy and Pharmacology.2013; 71(2): 371. CrossRef - Targeted therapy for gastric cancer—current status
Jan Kulig, Piotr Kołodziejczyk, Piotr Kulig, Janusz Legutko
Journal of Oncology Pharmacy Practice.2013; 19(1): 75. CrossRef - Targeted Therapies for Gastric Cancer
Jaclyn Yoong, Michael Michael, Trevor Leong
Drugs.2011; 71(11): 1367. CrossRef - Down-Regulation of Human Epidermal Growth Factor Receptor 2/neu Oncogene by Corosolic Acid Induces Cell Cycle Arrest and Apoptosis in NCI-N87 Human Gastric Cancer Cells
Myung Sun Lee, Eun Young Cha, Phuong Thien Thuong, Ji Yeon Kim, Moon Sang Ahn, Ji Young Sul
Biological and Pharmaceutical Bulletin.2010; 33(6): 931. CrossRef - Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma
Hye Ryun Kim, Seong Ha Cheon, Kwang-Hun Lee, Jung Ryun Ahn, Hei-Cheul Jeung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
International Journal of Hyperthermia.2010; 26(4): 305. CrossRef
- Intraperitoneal administration of biocompatible hyaluronic acid hydrogel containing multi-chemotherapeutic agents for treatment of colorectal peritoneal carcinomatosis
- 9,581 View
- 63 Download
- 7 Crossref
- Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer
- Jung Hwan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Suee Lee, Sung-Hyun Kim, Dae-Cheol Kim, Jin-Hwa Lee, Hyung-Sik Lee, Se-Heun Cho, Hyo-Jin Kim
- Cancer Res Treat. 2008;40(3):101-105. Published online September 30, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.3.101
-
Abstract
PDFPubReaderePub
Purpose Metastatic breast cancer patients are usually exposed to taxane and anthracycline as neoadjuvant, adjuvant and palliative chemotherapeutic agents. This study was designed to determine the efficacy and safety of the use of a gemcitabine and cisplatin (GP) combination treatment in patients with metastatic breast cancer that were pretreated with anthracycline and taxane.
Materials and Methods We evaluated the use of a GP regimen (1,000 mg/m2 gemcitabine administered on days 1 and 8 plus 60 mg/m2 cisplatin administered on day 1 every 3 weeks) in 38 breast cancer patients who had received prior chemotherapy with anthracycline and taxane as an adjuvant or neoadjuvant therapy, or as a palliative therapy.
Results The median patient age was 49 years (age range, 35~69 years). The overall response rate was 28.9% in 11 patients (95% confidence interval [CI], 14~44%). The median time to progression was 5.2 months (95% CI, 3.6~6.8 months). Median survival was 19.5 months (95% CI, 11.2~27.8 months). Major grade 3/4 hematological toxicity was due to leukopenia (36 of 157 cycles, 23.1%). Non-hematological toxicity was rarely severe; grade1/2 nausea and vomiting were observed in 37.8% of the patients. There were no treatment related deaths.
Conclusions Our results suggest that the use of gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in patients with advanced breast cancer that have been pretreated with anthracycline and taxane.
-
Citations
Citations to this article as recorded by- Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
Eun Kyo Joung, Ji Hyun Yang, Sooeun Oh, Se Jun Park, Jieun Lee
The Korean Journal of Internal Medicine.2021; 36(1): 182. CrossRef - Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
Jinfeng Zhang, Mingxi Lin, Yizi Jin, Linhan Gu, Ting Li, Baoying Yuan, Biyun Wang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Jian Zhang, Xichun Hu
Breast Cancer Research and Treatment.2020; 182(3): 719. CrossRef - Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
Jung Sun Kim, In Hae Park, Keun Seok Lee, Jungsil Ro
Journal of Breast Cancer.2014; 17(4): 339. CrossRef - A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up
Pramod K. Julka, Raju T. Chacko, Shona Nag, Rajinder Parshad, Aravindan Nair, Chaitanyanand B. Koppiker, Fen Chao Richard Xue, Helen Barraclough, Navreet Dhindsa, Anil Seth, Anurita Majumdar, Tarun Puri
Breast Cancer.2013; 20(4): 357. CrossRef - Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer
Tao Wang, Shaohua Zhang, Min Zeng, Xinyou Lu, Ge Shen, Shikai Wu, Santai Song, Zefei Jiang
Medical Oncology.2012; 29(1): 56. CrossRef - Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
H J Stemmler, D diGioia, W Freier, H W Tessen, G Gitsch, W Jonat, W Brugger, E Kettner, W Abenhardt, H Tesch, H J Hurtz, S Rösel, O Brudler, V Heinemann
British Journal of Cancer.2011; 104(7): 1071. CrossRef - Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
Ali I. Shamseddine, Fadi S. Farhat
Chemotherapy.2011; 57(6): 468. CrossRef - Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
Binghe Xu, Zefei Jiang, Sung-Bae Kim, Shiying Yu, Jifeng Feng, Artur Malzyner, Auro del Giglio, Hyun C. Chung, Li Jun Shen, Daniel Lee Kay Pen
Breast Cancer.2011; 18(3): 203. CrossRef
- Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
- 10,655 View
- 67 Download
- 8 Crossref
- Treatment Outcome of Cisplatin-based Concurrent Chemoradiotherapy in the Patients with Locally Advanced Nasopharyngeal Cancer
- Tae Hee Kim, Yoon Ho Ko, Myung Ah Lee, Bum-soo Kim, So Ryoung Chung, Ie Ryung Yoo, Chan-Kwon Jung, Yeon-Sil Kim, Min Sik Kim, Dong-Il Sun, Young Seon Hong, Kyung Shik Lee, Jin-Hyoung Kang
- Cancer Res Treat. 2008;40(2):62-70. Published online June 30, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.2.62
-
Abstract
PDFPubReaderePub
Purpose The standard treatment of locally advanced nasopharyngeal cancer is a concurrent chemoradiotherapy (CCRT), and cisplatin has been used as the most popular chemotherapeutic agent. But many different doses and schedules for cisplatin administration such as daily, weekly and 3 week cycles have been proposed. We compared and analyzed the tumor response, the overall survival, the toxicity and the chemotherapy dose intensity in the patients with locally advanced nasopharyngeal cancer who were treated with CCRT.
Materials and Methods We performed a retrospective study on 55 patients with locally advanced nasopharyngeal cancer, and they were treated with CCRT as a front-line treatment from Jan 1996 to Jun 2007 at Kangnam Saint Mary's Hospital.
Results The patients had a median age of 53 years (range: 19~75 years). Of the total 55 patients, a 3-week cycle of 100mg cisplatin was administered in 31 patients and 30 mg weekly cisplatin was administered in 24 patients combined with radiotherapy. Twenty one patients had a complete response and four patients had a partial response for a response rate of 71.4% (95% CI: 59.5~83.3) after CCRT and followed by adjuvant chemotherapy. The complete response rates for the 30 mg and 100 mg cisplatin groups were 72.7% (95% CI: 54.9~90.5) and 54.2% (95% CI: 36.7~71.7), respectively (p=0.23). The duration of CCRT in the 100mg cisplatin group was significantly longer than that of the 30mg cisplatin group (11.1±2.9 weeks vs. 9.0±1.2 weeks, p=0.003). The major deviation group, which was defined as prolongation of the radiotherapy duration for more than 2 weeks, had a significantly lower objective response rate than did the non-deviation group (56.3% vs 84.2%, respectively, p=0.002). The major severe toxicities were leucopenia (49.1%), pharyngoesophagitis (49.1%), anorexia (43.6%), nausea (41.8%) and vomiting (40%).
Conclusions Weekly 30mg cisplatin-based CCRT is a practical, feasible cisplatin schedule for the patients with locally advanced nasopharyngeal cancer in regard to decreasing the interruption of radiation treatment and decreasing the treatment-related acute toxicities.
-
Citations
Citations to this article as recorded by- A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study
Jiong-Lin Liang, Yue-Feng Wen, Ying-Ping Huang, Jia Guo, Yun He, Hong-Wei Xing, Ling Guo, Hai-Qiang Mai, Qi Yang
Radiotherapy and Oncology.2025; 203: 110660. CrossRef - The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma
Yi-Jun Hua, Yan-Feng Ou-Yang, Xiong Zou, Le Xia, Dong-Hua Luo, Ming-Yuan Chen
Frontiers in Oncology.2021;[Epub] CrossRef - Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort
S. Ghosh-Laskar, A. Pilar, K. Prabhash, A. Joshi, J.P. Agarwal, T. Gupta, A. Budrukkar, V. Murthy, M. Swain, V. Noronha, V.M. Patil, P. Pai, D. Nair, D.A. Chaukar, S. Thiagarajan, G. Pantvaidya, A. Deshmukh, P. Chaturvedi, S. Nair, A. D‘Cruz
Clinical Oncology.2019; 31(12): 850. CrossRef - Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study
Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie
Tumor Biology.2016; 37(4): 4429. CrossRef - Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials
Cheng-run Du, Hong-mei Ying, Fang-fang Kong, Rui-ping Zhai, Chao-su Hu
Radiation Oncology.2015;[Epub] CrossRef - Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
Cai-neng Cao, Jing-wei Luo, Li Gao, Jun-lin Yi, Xiao-dong Huang, Kai Wang, Shi-ping Zhang, Yuan Qu, Su-yan Li, Jian-ping Xiao, Zhong Zhang, Guo-zhen Xu, Riccardo Dolcetti
PLOS ONE.2015; 10(3): e0119101. CrossRef - Controversies in the systemic treatment of Nasopharyngeal carcinoma
Herbert H. Loong, Anthony T.C. Chan
Oral Oncology.2014; 50(9): 785. CrossRef - Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma
Junlin Yi, Xiaodong Huang, Li Gao, Jingwei Luo, Shiping Zhang, Kai Wang, Yuan Qu, Jianping Xiao, Guozhen Xu
Radiation Oncology.2014;[Epub] CrossRef - Factors Predict Prolonged Wait Time and Longer Duration of Radiotherapy in Patients with Nasopharyngeal Carcinoma: A Multilevel Analysis
Po-Chun Chen, Ching-Chieh Yang, Cheng-Jung Wu, Wen-Shan Liu, Wei-Lun Huang, Ching-Chih Lee, Bart O. Williams
PLoS ONE.2014; 9(10): e109930. CrossRef - Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area
Weihong Wei, Zeli Huang, Shaoen Li, Hemei Chen, Guoyi Zhang, Shuxia Li, Weihan Hu, Tao Xu
Oncology Research and Treatment.2014; 37(3): 88. CrossRef - Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
Qiu-Yan Chen, Yue-Feng Wen, Ling Guo, Huai Liu, Pei-Yu Huang, Hao-Yuan Mo, Ning-Wei Li, Yan-Qun Xiang, Dong-Hua Luo, Fang Qiu, Rui Sun, Man-Quan Deng, Ming-Yuan Chen, Yi-Jun Hua, Xiang Guo, Ka-Jia Cao, Ming-Huang Hong, Chao-Nan Qian, Hai-Qiang Mai
JNCI: Journal of the National Cancer Institute.2011; 103(23): 1761. CrossRef - Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
Cancer Research and Treatment.2008; 40(4): 155. CrossRef
- A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study
- 12,364 View
- 70 Download
- 12 Crossref
- Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis
- Jae-Hyuk Choi, Sung Yong Oh, Hyuk-Chan Kwon, Jung Hwan Kim, Jae Hoon Lee, Suee Lee, Dong Mee Lee, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Hyo-Jin Kim
- Cancer Res Treat. 2008;40(1):22-26. Published online March 31, 2008
- DOI: https://doi.org/10.4143/crt.2008.40.1.22
-
Abstract
PDFPubReaderePub
Purpose Gemcitabine is the most active agent to treat unresectable pancreatic cancer. The superiority of combining other drugs with cisplatin is still controversial; therefore, we performed a retrospective analysis of gemcitabine versus gemcitabine combined with cisplatin to determine the treatment outcomes for patients with locally advanced or metastatic pancreatic cancer.
Materials and Methods From 2001 to 2007, we enrolled 60 patients who were treated with gemcitabine or gemcitabine combined with cisplatin for locally advanced or metastatic pancreatic cancer. Gemcitabine 1, 000 mg/m2 (G) was administrated at day 1 and day 8 every 3 weeks. Cisplatin 60 mg/m2 was added at day 1 every 3 weeks to the gemcitabine schedule (GP).
Results Number of G: GP was 34: 26, locally advanced to metastatic ratio was 35% to 65% in group G and 46% to 54% in group GP. Median follow up duration was 29 months. The median number of chemotherapy cycles was 4 (range: 2~11) for the G group, and 4 (range: 1~11) for the GP group. The response rate of the G and GP groups was 17% and 11%, respectively. The progression free survival (PFS) was 4.5 months and 2.8 months, respectively, for the G and GP groups. The overall survival (OS) was 10.7 and 8.7 months respectively, for the G and GP groups, but there is no statistically significant difference of the PFS (p=0.2396) and OS (p=0.4643) between the 2 groups. The hematological toxicity profile was similar (the grade III neutropenia and thrombocytopenia was 4.4% and 3.1%, respectively, in G group, and 7.5% and 2.8%, respectively, in the GP group). But non-hematological toxicities such as skin rash, abnormal liver function and nausea/vomiting were observed in 3 patients of the GP group. On the prognostic factor analysis, no factors predicted a longer PFS and OS for both the G and GP groups.
Conclusions Gemcitabine single treatment might be more tolerable and it had the same efficacy compared to cisplatin combination treatment in this retrospective study.
-
Citations
Citations to this article as recorded by- Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
David J. Kuter
Haematologica.2022; 107(6): 1243. CrossRef - Treatment of drug-induced immune thrombocytopenias
Irene Marini, Gunalp Uzun, Kinan Jamal, Tamam Bakchoul
Haematologica.2022; 107(6): 1264. CrossRef - Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer
Giuseppe Belfiore, Maria Paola Belfiore, Alfonso Reginelli, Raffaella Capasso, Francesco Romano, Giovanni Pietro Ianniello, Salvatore Cappabianca, Luca Brunese
Medical Oncology.2017;[Epub] CrossRef - Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Steffen Doerfel, Paul Burgess, Stacey Kalambakas, Yasser Mostafa Kamel, Frederic Forget
International Journal of Hematology.2017; 106(6): 765. CrossRef - Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramlau, Kirushna Kumar, Bhabita Mayer, Brendan M. Johnson, Conrad A. Messam, Yasser Mostafa Kamel
Cancer Medicine.2015; 4(1): 16. CrossRef - Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer
Qin Li, Zhenyan Yuan, Han Yan, Zhaoyang Wen, Ruixue Zhang, Bangwei Cao
Clinical Therapeutics.2014; 36(7): 1054. CrossRef - Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
PLoS ONE.2014; 9(8): e104346. CrossRef - Oncolytic Activity of Avian Influenza Virus in Human Pancreatic Ductal Adenocarcinoma Cell Lines
Samantha B. Kasloff, Matteo S. Pizzuto, Micol Silic-Benussi, Silvia Pavone, Vincenzo Ciminale, Ilaria Capua, K. L. Beemon
Journal of Virology.2014; 88(16): 9321. CrossRef - Triptolide Cooperates With Cisplatin to Induce Apoptosis in Gemcitabine-Resistant Pancreatic Cancer
Wenbo Zhu, Jingjie Li, Sihan Wu, Shifeng Li, Liang Le, Xingwen Su, Pengxin Qiu, Haiyan Hu, Guangmei Yan
Pancreas.2012; 41(7): 1029. CrossRef
- Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
- 11,378 View
- 57 Download
- 9 Crossref
- Phase II Study of Docetaxel and Cisplatin as First-line Chemotherapy in Patients with Recurrent or Metastatic Gastric Cance
- Kyung-Ha Kim, Ki-Ju Jeung, Hyun-Jung Kim, Sang-Byung Bae, Chan-Kyu Kim, Nam-Su Lee, Kyu-Taek Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park
- Cancer Res Treat. 2007;39(2):49-53. Published online June 30, 2007
- DOI: https://doi.org/10.4143/crt.2007.39.2.49
-
Abstract
PDFPubReaderePub
Purpose Palliative chemotherapy for patients with recurrent or metastatic gastric cancer has been shown to have a survival benefit. Docetaxel monotherapy has achieved appreciable results for treating gastric cancer. We investigated the clinical efficacy and feasibility of a docetaxel and cisplatin combination regimen for patients suffering with recurrent or metastatic gastric cancer.
Materials and Methods Patients with histologically proven, bidimensionally measurable lesions of recurrent or metastatic gastric cancer, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and no prior palliative chemotherapy were eligible for this study. The combination chemotherapy regimen consisted of docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 on day 1, and this was repeated every 3 weeks until disease progression.
Results 32 patients were enrolled from 2002 to 2005. The objective response rate was 31.3% (95% confidence interval (CI): 14.2~48.2%) with no CR. The disease control rate was 59.4%. At a median follow up of 38.9 months, the median overall survival was 7.4 months (95% CI: 6.3~8.5). The median time to progression was 4.7 months (95% CI: 3.1~6.3). During a total of 106 cycles, grade 3 or 4 hematological toxicities were observed as follows: neutropenia (39 of 106 cycles) and anemia (3 of 106 cycles). The grade 3 or 4 non-hematological toxicities included anorexia (18.9%) and nausea/vomiting (21.7%).
Conclusion Docetaxel and cisplatin combination chemotherapy showed promising anti-tumor activity and this was well tolerated as a first-line treatment for patients with recurrent or metastatic gastric cancer. Further large, randomized phase III studies are warranted.
-
Citations
Citations to this article as recorded by- CYTOTOXIC EFFECTS OF ARIPIPRAZOLE ON MKN45 AND NIH3T3 CELL LINES AND GENOTOXIC EFFECTS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES
Mohammad SHOKRZADEH, Abbas MOHAMMADPOUR, Mona MODANLOO, Melika HASSANI, Nasrin Ghassemi BARGHI, Parisa NIROOMAND
Arquivos de Gastroenterologia.2019; 56(2): 155. CrossRef - Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma
Ilkay Tugba Unek, Tulay Akman, Ilhan Oztop, Olcun Umit Unal, Tarik Salman, Ugur Yilmaz
Gastric Cancer.2013; 16(3): 428. CrossRef - A randomized phase 2 study of docetaxel and S‐1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
Hei‐Cheul Jeung, Sun Young Rha, Chong Kun Im, Sang Joon Shin, Joong Bae Ahn, Woo Ick Yang, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung
Cancer.2011; 117(10): 2050. CrossRef - Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer
F. Tugba Kos, Dogan Uncu, Nuriye Özdemir, Burcin Budakoglu, Hatice Odabaş, Hüseyin Abali, Berna Oksuzoglu, Sercan Aksoy, Nurullah Zengin
Chemotherapy.2011; 57(3): 230. CrossRef
- CYTOTOXIC EFFECTS OF ARIPIPRAZOLE ON MKN45 AND NIH3T3 CELL LINES AND GENOTOXIC EFFECTS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES
- 8,792 View
- 52 Download
- 4 Crossref
- A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
- Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
- Cancer Res Treat. 2007;39(1):6-9. Published online March 31, 2007
- DOI: https://doi.org/10.4143/crt.2007.39.1.6
-
Abstract
PDFPubReaderePub
Purpose To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy.
Materials and Methods Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m2 by 3-hour infusion on day 1, and cisplatin, 60 mg/m2 by 1 hour infusion on day 1, with the treatment repeated every 3 weeks.
Results 37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%).
Conclusion The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.
-
Citations
Citations to this article as recorded by- Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
Cancer Management and Research.2022; Volume 14: 2825. CrossRef - Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
Japanese Journal of Clinical Oncology.2009; 39(4): 237. CrossRef
- Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
- 9,182 View
- 45 Download
- 2 Crossref
First
Prev
